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INTRODUCTION 
1 INTRODUCTION 
1.1 Posttranslational modifications 
The deciphering of the human genome in 2001 constitutes a milestone in the history of 
biological research. Unexpectedly, it revealed that it contains just 30.000 genes; this is only 
twice as many as in lower eukaryotes such as worm or fly1, 2. Since the size of the human 
proteome, defined as the number of different protein molecules in humans, exceeds that of 
the genome, defined as the number of genes, by at least two orders of magnitude3, 4, human 
complexity cannot be a direct consequence of the number of encoding genes. Instead, 
diversification of the coding capacity of the genome is achieved by two major mechanisms, 
first of all at the transcriptional level by mRNA splicing5, 6, and secondly at the protein level by 
posttranslational modifications (PTMs)3.  
PTMs refer to covalent alterations that are usually added after a protein is expressed. They 
are mediated by specific enzymes which account for about 5 % of the genome of higher 
eukaryotes3. PTMs also occur in prokaryotes, but tend to be less common and less diverse 
compared to nucleated cells. They range from generic, widespread alterations (e.g. 
glycosylation) to highly specific and rare modifications (e.g. SUMOylation). Depending on the 
action of demodifying enzymes, PTMs can either occur transiently (e.g. phosphorylation, 
palmitoylation) or permanently (e.g. prenylation).  
PTMs are important because they can add a vast array of different functionalities to their 
target proteins. By that, they are able to turn the 20 naturally occurring codon-encoded amino 
acids into a variety of amino acids with new characteristics, which cannot be achieved by 
mRNA splicing. Proteins can be modified by the same PTM at multiple sites or by different 
modifications within the same protein. This can create a dynamic library of properties, which 
is tightly controlled by protein modifying and demodifying enzymes in response to systemic 
stimuli7.  
A good example for the dynamic utilization of PTMs is the information retrieval system from 
chromatin8, 9. Histones are the chief protein component of chromatin. Their primary role is to 
condense DNA by acting as spools around which DNA winds. In addition, their tails can be 
modified at multiple sites by different PTMs e.g. methylations, acetylations, phosphorylations, 
ubiquitinations, SUMOylations, or ADP-ribosylations. This creates a large combinatorial 
library of histone PTMs which defines whether DNA is in a transcriptionally active or inactive 
state.  
1 
INTRODUCTION 
1.2 Protein prenylation 
Posttranslational modification of proteins with isoprene lipids is a widespread PTM that affects 
up to 2% of the mammalian proteome10. The first reports on prenylated proteins and peptides 
were secreted pheromone peptides found in jelly fungi11, 12. Their structure resembles the 
α-factor mating pheromone from baker´s yeast and contains a farnesylated cysteine 
methylester at the C-terminus13. During the course of the discovery of the cholesterol 
biosynthesis pathway (see section 1.3.4), several groups reported that (i) one of the crucial 
steps in cholesterol biosynthesis was at the early step of mevalonic acid synthesis catalyzed 
by 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase14 and that (ii) a compound 
derived from mevalonic acid other than the final product cholesterol was specifically 
incorporated into proteins15, 16. Later, it became clear that protein prenylation is characterized 
by the attachment of a farnesyl or a geranylgeranyl moiety to one or two C-terminal cysteine 
residues of target proteins via a thioether linkage.  
 
Table 1-1 Biochemistry of the protein prenyltransferases.  
 FTase GGTase-I RabGGTase 
Subunit composition 
(mammalian) 
α 44 kDa 
β 48 kDa 
α 44 kDa 
β 43 kDa 
α 65 kDa 
β 37 kDa 
Protein recognition motif 
-CA1A2X 
X = Ala, Gln, Ser, Met, Phe 
A1: flexible 
A2: Ile, Val preferred 
-CA1A2X 
X = Leu, Phe, rare: Met 
A1: flexible 
A2: Ile, Leu preferred 
common:  
-CC, -CXC, -CCX,  
-CCXX, -CCXXX 
rare: -CXXX 
Isoprenoid substrate farnesyl pyrophosphate (FPP) geranylgeranyl pyrophosphate (GGPP) 
   
Metal requirements: Zn2+, Mg2+ Zn2+ Zn2+ 
 
Schematic representation of the reaction catalyzed by the two CAAX prenyltransferases FTase (n = 1) and 
GGTase-I (n = 2) A or RabGGTase in concert with REP (Rab Escort Protein) B. The enzymes catalyze the 
formation of a thioether linkage between the prenyl group and one or two C-terminal cysteines of the protein 
substrate. 
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The prenylation reactions are catalyzed by three different protein prenyltransferases: protein 
farnesyltransferase (FTase), protein geranylgeranyltransferase-I (GGTase-I), and Rab 
geranylgeranyltransferase (RabGGTase)17, 18. FTase and GGTase-I recognize their 
substrates via a short C-terminal recognition sequence, referred to as the CAAX box, where 
C is a cysteine, A is variable, and X is commonly Ala, Gln, Ser, Met, or Phe for FTase and 
Leu or Phe for GGTase-I. In contrast, protein substrate recognition by RabGGTase is more 
complex since it requires an additional protein, the Rab Escort Protein (REP), to recruit its 
substrates (Table 1-1). 
 
1.2.1 Structural features of the protein prenyltransferases 
All three protein prenyltransferases are α, β heterodimeric enzymes. FTase and GGTase-I 
share the same α subunit with a molecular mass of 48 kDa19. The α subunit consists of 14 α 
helices folded into 7 successive pairs to form a series of right-handed antiparallel coiled 
coils20, 21, also known as “helical hairpins”. These helices are arranged in a crescent-shaped 
superhelix that wraps around the β subunit (Figure 1-1 A)22. The first 50 amino acids on the 
N-terminus of the α subunit form a proline-rich disordered domain, which is not involved in 
catalysis and does not influence the structure of the rest of the enzymes23, 24.  
 
 
Figure 1-1 Overall structures of FTase A and RabGGTase B. Red: α-subunit, blue: β-subunit, gray: Ig-like 
domain, green: LRR-domain, purple: Zn2+ ion. 
 
In contrast, the α subunit of RabGGTase contains an Ig-like and a leucine-rich repeat (LRR) 
domain in addition to the helical domain, which is highly similar to that of FTase/GGTase-I 
despite only 22 % sequence identity (Figure 1-1 B)25. Since these domains are absent in the 
structures found in lower eukaryotes, they are believed not to be involved in catalysis26, 27, but 
their specific function is as yet unknown.  
The β subunits of all three protein prenyltransferases share only 25 % sequence identity, but 
are also similar in their structure (Figure 1-1 A and B). They consist of 14, 13, or 12 α helices 
in FTase, GGTase-I, or RabGGTase, respectively. The helices fold into an α-α barrel forming 
3 
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a funnel-shaped hydrophobic cavity with a diameter of 15 Å, which consists of several 
conserved aromatic residues. This cavity represents the active site of the enzymes and 
contains the lipid and protein substrate binding sites. The α and β subunits form an extensive 
interface burying about 20 % of accessible surface area of each subunit20, 21.  
 
Zn2+ binding site. All three protein prenyltransferases are zinc 
metalloenzymes with one Zn2+ located near the α, β subunit 
interface (Figure 1-1)20, 21, 25, 28-33. Zn2+ is coordinated by three 
strictly conserved residues: D297β, C299β, and H362β in FTase; 
D269β, C271β, and H321β in GGTase-I; and D238β, C240β, and 
H290β in RabGGTase. All three crystal structures reveal a 
stabilizing hydrogen bond between the Zn2+-coordinated histidine 
residue and an aspartic acid residue (D359β, D318β, and D287β 
for FTase, GGTase-I, and RabGGTase, respectively; Figure 1-2). 
High-resolution substrate and product complexes indicate that the cysteine thiol of the CAAX 
motif interacts with Zn2+ at 2.3 Å distance in the substrate-bound and 2.6 Å distance in the 
product-bound state, resulting in a tetravalent coordination of the Zn2+ ion.  
 
Figure 1-2 Zn2+ coordination. 
Black: FTase, red: GGTase-I, 
and blue: RabGGTase. 
 
Lipid substrate binding. The lipid substrates of the 
CAAX prenyltransferases are buried next to the peptide 
binding site in the hydrophobic cavity of the β subunit20, 
34. The pyrophosphate moieties of FTase and GGTase-I 
are sequestered within the diphosphate binding pocket. 
In FTase, this is mainly formed by R291β, K294β, both of 
which interact with the β-phosphate of FPP, and by 
Y300β, which forms a hydrogen bond with the α-
phosphate of FPP35 (corresponding residues in GGTase-
I: R263β, K266β, and Y272β) (Figure 1-3). Both the pyrophosphate and the first three 
isoprene units of FPP and GGPP bind to FTase and GGTase-I in a similar conformation, 
which is mediated by analogous hydrophobic interactions with aromatic residues in their 
active sites. The additional fourth isoprene unit of GGPP is turned with an angle of 90° 
compared to the rest of the molecule (Figure 1-4). The active site of RabGGTase is 
structurally similar, but the exact conformation of the bound GGPP had not been determined 
until recently♣. 
 
Figure 1-3 Pyrophosphate coordination. 
Black: FTase, red: GGTase-I. 
                                                                  
 
♣ During the course of this work, our group published the RabGGTase structure in complex with its 
native substrate GGPP36. 
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Isoprenoid substrate specificity. Both FPP and 
GGPP are tightly bound to all protein prenyltrans-
ferases in the nanomolar range, yet the enzymes 
display distinct lipid substrate specificities in vivo. This 
can be explained by the amino acids that occupy the 
bottom of their lipid binding site. In GGTase-I and 
RabGGTase, residues 49β and 48β, respectively, are 
always small amino acids like Thr or Ser, whereas the 
corresponding residue is a Trp in FTase (W102β). This 
bulky amino acid fills the space which is occupied by the 
additional fourth isoprene unit in the GGTase-I:GGPP 
complex (Figure 1-4).  
Beese and co-workers showed that this amino acid 
determines whether the CAAX prenyltransferase 
accepts FPP or GGPP as a substrate. A single mutation 
W102Tβ was shown to interconvert the lipid substrate preference of both enzymes, 
surprisingly without changing the peptide substrate selectivity20.  
 
Figure 1-4 Bottom of the lipid binding 
pocket of the protein prenyltransferases. 
Blue: FTase:FPP; red: GGTase:GGPP; 
green: RabGGTase; light red or blue: 
pyrophosphate moieties of the respective 
isoprenoid. For further details, see text. 
In RabGGTase, the bottom of the lipid binding site is further enlarged since Y154β (FTase) 
and Y126β (GGTase-I) are replaced by a much less bulky amino acid (L99β) at the 
corresponding position (Figure 1-4)37.  
To explain the lipid substrate discrimination of FTase and GGTase-I, Beese and co-workers 
have postulated the “molecular ruler hypothesis”, in which the depth of the lipid binding cavity 
of the two enzymes functions as a simple length-discriminating molecular ruler. In this 
hypothesis, larger non-cognate isoprenoids fill up the lipid binding pocket such that the 
diphosphate and C1 of the isoprenoid are mispositioned for efficient catalysis (Figure 1-5 
C)34. 
Distefano and co-workers solved the structure of FTase in complex with GGPP and several 
other lipid analogs. From these data, they suggest a different explanation for the failure of 
FTase to transfer longer lipids than FPP, which they refer to as the “second site exclusion 
model”38. The pyrophosphate and the C1 atom of both GGPP and the benzophenone-
functionalized GGPP 3 are correctly located at corresponding positions in the FTase:FPP 
complex (Figure 1-5 D and E). Interestingly, the isoprene conformation is perturbed in both 
cases, which stands in stark contrast to what the molecular ruler hypothesis had predicted. 
The crystal structure of FTase in complex with 3 revealed that the terminal benzophenone 
group bulges into the CAAX substrate binding pocket and prevents proper CAAX peptide 
binding. In contrast, the first two isoprene units of GGPP in the FTase:GGPP complex are 
perturbed and prevent the essential C1 move to produce a product complex due to steric 
5 
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clashes with the peptide substrate (see section 1.2.2). The study indicated that the isoprenoid 
substrate specificity of FTase is not mediated by misalignment of the pyrophosphate group 
but by the inhibition of ternary complex formation (Figure 1-5 D) or by failure of the ternary 
complex to convert into product (Figure 1-5 B).  
 
 
 
 
 
Figure 1-5 Schematic juxtaposition of the “molecular ruler hypothesis” and the “second site exclusion model” to 
explain the lipid substrate discrimination of FTase between FPP, GGPP, and other isoprenoid analogs. The β 
subunit of FTase (purple) contains the active site with the binding sites of the pyrophosphate, isoprene lipid, and 
the peptide substrate. The CAAX protein/peptide is shown in black and comprises the nucleophilic Zn2+-
coordinated thiol(ate). A Schematic representation of FTase lipid and peptide substrate binding based on the x-ray 
structure of FTase:FPP. B X-Ray structure of farnesylated peptide product (black) bound to FTase. Superimposed 
in red is the lipid conformation prior to product formation, which clashes with peptide binding. C “Molecular ruler 
model” proposed by Long et al.34. D X-ray structure of 3 bound to FTase. Superimposed is a putatively bound 
CAAX peptide, which leads to steric problems and prevents the formation of the ternary complex38. E X-ray 
structure of GGPP bound to FTase. Adapted from38. 
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Peptide binding and substrate specificity. Bound next to the lipid substrate in the active 
site, the CA1A2X peptide forms direct van der Waals interactions with the second and third 
isoprene units of the lipid39, 40. Beese and co-workers have extensively investigated the CAAX 
requirements for FTase and GGTase-I. A1 is solvent-exposed, therefore, any amino acid is 
tolerated at this position20, 41, 42. A2 is buried in the “A2 
binding pocket” and forms a hydrophobic interaction 
with the pocket (Figure 1-6). The selection of amino 
acids at the A2 position is constrained (A2 can be Ile, 
Val, Leu, Phe, Tyr, Pro, Thr, or Met), yet it has little 
effect on CAAX specificity. X binds to the “specificity 
pocket” at the bottom of the peptide substrate 
binding site and represents the primary determinant 
of peptide substrate selectivity. The FTase specificity 
pocket is more polar and accepts Met (hydrophobic 
AA), Ser (small AA), and Glu (polar AA)- and to a 
lesser extent Ala, Thr, and Cys (small AA)- through a 
specific network of electrostatic interactions. 
Interestingly, Phe is too bulky for the specificity 
pocket, but is still tolerated by binding in an adjacent 
hydrophobic cavity42.  
Figure 1-6 CAAX binding in active site. 
Black: FTase, red: GGTase-I. 
In GGTase-I, the crystal structure revealed only one X-binding site that discriminates against 
polar, charged, and small amino acids. X is occupied by hydrophobic amino acids such as 
Leu or Phe and occasionally by Ile or Val.  
The studies by Beese and co-workers suggest that the CAAX peptide is anchored to 
FTase/GGTase-I through the coordination of the cysteine thiol by Zn2+ and through water-
mediated hydrogen bondings of the C-terminal carboxyl group. As a result, the enzymes are 
capable of discriminating against peptides that are too long or too short, or that lack a 
cysteine residue.  
RabGGTase does not recognize its substrates via direct interaction, but needs REP to recruit 
its substrates43, 44. In line with this, Rab proteins (in most cases) do not carry a peptide 
recognition sequence such as the CAAX motif found in FTase and GGTase-I substrates. 
Usually, they are doubly prenylated at -CC, -CXC, -CCX, -CCXX, or -CCXXX upon formation 
of the quarternary complex that is composed of Rab, REP, RabGGTase, and GGPP. Some 
RabGTPases, however, have only one prenylatable C-terminal cysteine in a CXXX sequence. 
While most of them do not fulfill the classical CAAX motif requirements, Rab8 contains a 
CVLL motif, which was shown to serve as a substrate for GGTase-I in vitro. Nevertheless, the 
role of Rab8 geranylgeranylation by GGTase-I in vivo seems to play only a minor role45.  
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1.2.2 Mechanism of the protein prenylation reaction 
Due to the importance of prenylated proteins in many signaling pathways, the mechanisms of 
the prenylation reactions of the three protein prenyltransferases have been intensively 
investigated. FTase and GGTase-I display similar reaction mechanisms, whereas that of 
RabGGTase is fundamentally different.  
Based on structural and metal substitution studies29, 46, mutational analyses35, 47, 
stereochemical48, 49, kinetic isoptope effects50, 51, and kinetic examinations39, 52, as well as 
studies with non-natural substrates53, an ordered substrate binding reaction pathway featuring 
a mainly associative mechanism with an “exploded” transition state has been proposed 
(Scheme 1-1)54-56.  
 
 
Scheme 1-1 Transition state model of the farnesylation reaction catalyzed by FTase. Adapted from50. 
 
According to this model, FPP first binds to the apo form of FTase in the hydrophobic funnel of 
the active site, followed by CAAX peptide association. The coordination of the reactive thiol 
by Zn2+ is essential for catalysis since it lowers the pKa of the thiol and thereby activates it for 
the nucleophilic attack28-30, 57, 58.  
Comparison of the structures of the CAAX protein prenyltransferases in complex with 
isoprenoids and CAAX peptides to the structures of the enzymes bound to the prenylated 
CAAX peptide products revealed that the conformation and the peptide backbone is 
practically identical prior to and after the chemical step. It is believed that the lipid substrate 
rotates at the third isoprene unit to move the C1 atom closer to the activated CAAX thiolate 
(Figure 1-5 B)59. In GGTase-I, the rotation takes place at the fourth isoprene unit in GGPP20.  
Under release of pyrophosphate, the reaction of the CAAX peptide with FPP and GGPP 
irreversibly forms a stable thioether bond. The negative charges of the diphosphate leaving 
group are stabilized by L164α (both in FTase and GGTase-I) and Y300β or Y272β in FTase 
or GGTase-I, respectively.  
Interestingly, only FTase is dependent on Mg2+ for efficient catalysis31, 60. The  Mg2+-
coordinating property of D352β in FTase is replaced by a Lys residue in GGTase-I (L311β), 
8 
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which stabilizes the developing negative charge of the diphosphate group of GGPP and 
thereby renders GGTase-I independent of Mg2+47, 61.  
Kinetic studies suggest that the rate-limiting step of the prenylation reaction is product 
release. This occurs upon competitive binding of lipid substrate to the enzyme by expelling 
the attached lipid chain of the prenylated product to an “exit groove” on the β subunit20, 59. 
Initially, it was believed that this is mainly stimulated through isoprenoid binding, but recently, 
Spielmann and colleagues postulate a more complex reaction mechanism which includes a 
CAAX peptide-stimulated product release62.  
The prenylation reaction catalyzed by RabGGTase is substantially different from the CAAX 
prenyltransferases since it (i) requires the additional protein REP to recruit its substrates and 
(ii) in most cases performs double geranylgeranylation. How the assembly of the ternary 
complex necessary for catalysis takes place is still debated63-67. In the “classical pathway”, the 
unprenylated Rab interacts with REP first, which is then followed by RabGGTase binding. 
The observation that the affinity of REP for RabGGTase is increased upon binding of either 
Rab or GGPP led to the proposal of an alternative pathway: REP binds to GGPP-bound 
RabGGTase first, followed by the association of the RabGTPase26, 68.   
The mechanism of RabGGTase-mediated prenylation was studied using biochemical and 
structural methods27, 36, 69, 70. The crystal structure of the Rab:REP complex revealed two 
binding interfaces between (i) the Rab binding platform (RBP) of REP and the effector loops 
of Rab and (ii) the C-terminal binding region (CBR) of REP and the CBR interacting motif 
(CIM) of Rab64, 69. The binding between RabGGTase and REP is largely mediated through the 
interaction of two critical residues of REP-1 (F279 and R290) with the α-subunit of 
RabGGTase27. The CIM is a conserved motif among all RabGTPases and consists of two 
hydrophobic residues near the C-terminus of Rab proteins36.  
A structure of the ternary complex has not been solved to date, but modeling and biophysical 
studies indicate that the flexible C-terminus of Rab weakly associates with RabGGTase upon 
formation of the ternary complex. In doing so, it presents the cysteine residue to the reactive 
center with Zn2+. The lipid binding site, which is formed by five helices, is located in domain II 
of REP-1. Upon prenyl transfer and the binding of a new isoprenoid, the conjugated isoprenes 
move from the hydrophobic funnel in the active site of the enzyme to the lipid binding site in 
domain II of REP-1. This results in the expansion of the cavity and in conformational changes 
of F279 and R290 of REP-1, leading to a decreased affinity of RabGGTase towards the 
prenylated Rab:REP complex and finally to product release from the enzyme. 
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1.3 Protein substrates of the protein prenyltransferases 
Since the initial discovery of farnesylated fungal proteins, a broad variety of protein 
prenyltransferase substrates have been identified. The best studied ones belong to the Ras 
superfamily comprising the small GTPases Ras71-73, Rho and Cdc4274-79, Rac80, Rap81, 82, and 
Rab83, 84, but also include the γ subunits of heterotrimeric G proteins85-88, centromeric 
proteins89, proteins involved in the regulation of cell cycle and apoptosis90, 91, cellular 
framework92-94, glycogen metabolism95, as well as visual signal transduction96-98.  
 
1.3.1 The small GTPases of the Ras superfamily 
The largest group of prenylated proteins belongs to the Ras superfamily of small GTPases. 
These display molecular weights ranging from 20 to 30 kDa99, 100 and are also called G 
proteins due to their ability to bind guanine nucleotides. The Ras superfamily comprises more 
than 150 members and is divided into 5 subgroups based on homology studies of their amino 
acid sequence: Ras, Ran, Rho/Rac/Cdc42, Rab, and Arf/Sar1. All these proteins function as 
key regulators in a variety of important cellular processes: the Ras family regulates gene 
expression and proliferation, the Ran family nucleocytoplasmic transport and microtubule 
organization, the Rho/Rac/Cdc42 family the organization of the cytoskeleton as well as gene 
expression, and the Rab and the Arf/Sar family vesicular transport. Except for the Arfs, which 
are N-terminally myristoylated, and the Rans, which are not posttranslationally lipidated at all, 
all members of the Ras superfamily are posttranslationally prenylated at one or two cysteines 
within their C-terminal region. 
Like all G proteins, the small GTPases from the Ras superfamily contain a conserved 
GTPase domain and specifically bind one molecule of guanine nucleotide. They function as 
molecular switches and cycle between a GDP-bound “off” and a GTP-bound “on” state 
(Figure 1-7)101. In the GDP-bound state, they are in an inactive conformation. Upon GTP 
binding, they are transformed into an active conformation, which allows them to interact with 
effector proteins and to initiate downstream signaling events.  
The GTPase cycle of the Ras superfamily is highly regulated by accessory proteins. Most of 
the small GTPases exist in the cytosol in the inactive GDP-bound form due to their intrinsic 
GTPase activity. GDP release is the rate-determining step in the GTPase cycle with a half-life 
in the range of hours. Additional factors are needed to speed up this process in a regulated, 
i.e. signal-dependent manner. The release of GDP is catalyzed by guanine nucleotide 
exchange factors (GEFs)102. GTP readily binds to the nucleotide-free GTPase due to a 10-
fold excess of GTP in comparison to GDP in the cell (1 mM compared to 100 µM). 
Remarkably, the additional phosphate group switches the GTPase from the inactive to the 
active state by causing conformational changes of the so-called switch I and switch II 
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regions103. These regions are part of the effector-binding domain that engage downstream 
signaling only upon GTP binding.  
Without external regulation, the active GTP-bound state is defined by the intrinsic GTPase 
activity of the protein, which hydrolyzes GTP to GDP under release of an inorganic 
phosphate. Since the intrinsic GTPase hydrolysis rate is low (e.g. 0.028 min-1 for Ras104) 
additional proteins are needed to efficiently inactivate the GTPases and thus to prevent 
permanent activation of the proteins, which could lead to misregulation. The intrinsic GTPase 
activity is dramatically enhanced by up to 5 orders of magnitudes by GTPase activating 
proteins (GAPs)105, 106. 
 
 
Figure 1-7 Schematic representation of the GTPase cycle. Upon an external stimuli, the GTPase switches from an 
inactive GDP-bound to an active GTP-bound state, which is tighly controlled by its GEFs. Once activated, it can 
recruit its effectors and enables downstream signaling processes. Inactivation is achieved through GTP hydrolysis, 
which is catalyzed by GAPs. *For Rab- and RhoGTPases, an additional level of regulation through GDIs is 
present, which keep the prenylated GDP-bound protein in the cytosol. GEF: guanine nucleotide exchange factor; 
GAP: GTPase activating protein; GDI: GDP dissociation inhibitor. 
 
For Rabs and Rhos, GDP dissociation inhibitors (GDIs) bind to the GDP-bound GTPases and 
inhibit GDP release, preventing the GTPases from activation, and thus acting as an additional 
control mechanism to keep the proteins in the inactive state79, 107. More significantly, the GDP 
form of the proteins can be extracted from membranes by GDIs. 
 
1.3.2 Ras and Rho/Rac/Cdc42 families: post-prenylation processing, localiza-
tion, and signaling 
The GTPases from the Ras superfamily share common structural, biochemical, and 
regulatory features, but still are involved in a variety of different signaling and trafficking 
pathways. 
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Ras family. The interest in small GTPases and in particular Ras stems from the discovery 
that Ras genes encoded by rat sarcoma viruses (v-H-ras, v-N-Ras, and v-K-Ras) are heavily 
associated with cancer (see section 1.3.4)108-112. Since then, Ras has been intensively 
investigated and has become the prototype of a small monomeric GTPase with (both 
structural and functional) characteristics which can be generally applied to the rest of the 
members of the Ras superfamily. There are four types of Ras proteins, N-, H-, K-Ras4A, and 
K-Ras4B (the two latter are splice variants of the kras gene), which are ubiquitously 
expressed in eukaryotic cells. These Ras isoforms are structurally surprisingly very similar 
and differ virtually only in the hypervariable C-terminal region, also called the target domain. 
Upstream of the CAAX motif, N-, H-, and K-Ras4A possess additional cysteine(s) (C181; 
C181 and C184; and C180, respectively) that can undergo posttranslational palmitoylation113. 
In contrast, a polybasic domain with 11 lysines, forming a net charge of +9 and lacking a 
palmitoylation site, can be found at the C-terminus of K-Ras4B114.  
 
 
Scheme 1-2 Schematic representation of the posttranslational processing of N-Ras or K-Ras4B, RhoA, and Rab7. 
A N-Ras is farnesylated on one cysteine (red) by FTase, which is followed by -AAX removal by Rce1, carboxy-
methylation by Icmt, and palmitoylation on one cysteine by DHHC9/GCP16 (green). K-Ras4B is similarly 
posttranslationally processed, but does not contain any palmitoylation site. Instead, it contains a hexalysine repeat 
in the target domain (blue). B RhoA is geranylgeranylated by GGTase-I on one cysteine (red), -AAX cleaved, and 
carboxymethylated. C Rab7 undergoes double geranylgeranylation on two cysteines (red), followed by 
carboxymethylation. Rab proteins with two cysteines as the terminal residues are not carboxymethylated.   
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Ras proteins are synthesized as soluble proteins on free polysomes in the cytosol and are 
subsequently targeted to cellular membranes by several PTMs (Scheme 1-2)115. After 
farnesylation on the C-terminal cysteine by FTase, the S-isoprenyl CAAX moiety becomes a 
substrate of Ras converting enzyme 1 (Rce1)115-117, which is a protease located in the ER 
membrane that cleaves off the -AAX group adjacent to the prenylated cysteine. 
Subsequently, a second ER membrane protein, Isoprenylcysteine carboxymethyltransferase 
(Icmt), methylates the carboxyl group118. The transfer of Ras proteins from the endogenous 
membrane to the inner leaflet of the plasma membrane requires a second signal found in the 
above mentioned target domain. For N-, H-, and K-Ras4A, palmitoylation, which is catalyzed 
by DHHC9/ GCP16, occurs on the cysteine(s) found in this C-terminal hypervariable region at 
the Golgi. This significantly increases the affinity for membranes and precedes the 
translocation of N- and H-Ras via vesicular transport mechanisms to the plasma 
membrane119, 120. In contrast, K-Ras4B does not contain additional cysteine lipidation sites. 
Instead, the polybasic sequence is thought to ensure complete plasma membrane localization 
via electrostatic interactions (Scheme 1-2). 
Initially, it was believed that the inner cytoplasmic side of the plasma membrane is the 
predominant location of Ras action in a variety of signal transduction pathways. The best 
characterized one is the MAPK pathway (Figure 1-8). An external stimulus activates this 
pathway by the binding of growth factors at the extracellular domain of protein tyrosine kinase 
receptors (PTKRs)121. This leads to receptor dimerization, which is followed by 
autophosphorylation by the intrinsic kinase activity in trans within the cytoplasmic regions of 
the receptor. These phosphorylated tyrosine residues represent docking sites for adaptor 
proteins such as Grb2 (Growth factor receptor-bound protein 2), which recruits Sos (Son of 
sevenless) through its SH3 (Src homology domain 3) domain. Sos is a Ras GEF which, once 
recruited to a location near the membrane-anchored Ras protein, switches Ras to the active 
GTP-bound conformation. Following activation, Ras recruits one of its effectors, the 
serine/threonine kinase Raf-1. Raf-1 becomes activated by the association with membranes 
and in turn activates MEK (MAPK/Erk kinase, a dual specificity tyrosine/threonine kinase) by 
phosphorylation. MEK then phosphorylates and activates the serine/threonine kinases Erk1 
and Erk2. Phosphorylated Erks form dimers and are translocalized into the nucleus. There, 
they phosphorylate the Ets family of transcription factors such as Elk-1 to activate 
transcription. Although the MAPK pathway is the best characterized one, it is only one of 
many that are regulated by Ras.  
The MAPK pathway has for a long time served as a model for the prototypical unidirectional 
pathway that relays a signal from the extracellular space to the nucleus. Later, it became 
obvious that the situation is not so simple. First, the MAPK pathway cannot be regarded as an 
isolated pathway, but is rather embedded in a complex network of cellular processes with 
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many crosstalks between the GTPases of the Ras superfamily122, 123. Second, Ras has 
emerged as an important model system of compartmentalized signaling, which can be found 
both between different and within one membrane compartment124, 125. For example, the PTMs 
of Ras proteins are not static, but have been shown to be highly dynamic: the activation of N- 
and H-Ras at the plasma membrane triggers depalmitoylation and back-trafficking to the 
Golgi, where a set of effectors is recruited. Repalmitoylation redirects the proteins to the 
plasma membrane (the so-called “Ras acylation cycle”)126, 127. K-Ras4B is dynamically 
regulated by either the binding of calmodulin128-130 or protein kinase C, which phosphorylates 
the GTPase on S181131.  
 
 
Figure 1-8 Overview of CAAX prenyltransferase-mediated protein prenylation, post-prenylation modifications, 
membrane targeting, and the function of the prenylated proteins. A Ras or Rho protein (light green) is prenylated 
by FTase or GGTase-I with FPP or GGPP, respectively 1. -AAX removal by Rce1 2 and carboxymethylation by 
Icmt 3 take place at the ER. In the case of Rho proteins (red), the protein is chaperoned by a Rho-specific GDI, 
which targets the Rho protein to the correct membrane 4a. K-Ras4A, N-Ras, and K-Ras are targeted to the Golgi 
4b, where they are further palmitoylated on one or two cysteines 5. Once palmitoylated, the mature protein 
trafficks to the plasma membrane. There, it recruits its GEF, which activates the protein 6 and engages 
downstream signaling, including the MAPK signaling pathway. Through depalmitoylation-repalmitoylation, it is 
subjected to a dynamic acylation cycle. K-Ras4B is targeted to the plasma membrane without additional 
palmitoylation through its hexalysine motif within its targeting domain 4c. Membrane attachment is dynamically 
regulated by protein kinase C and/or calmodulin. For details, see text. 
 
14 
Protein substrates of the protein prenyltransferases 
In addition to compartmentalization to different organelles, compartmentalization also takes 
place within an organelle. The best studied case is the plasma membrane, which can no 
longer be regarded as a homogenous platform of cell signaling. Instead, it consists of 
microdomains, which concentrate proteins and lipids to facilitate processes such as signal 
transduction events.  
The most prominent, albeit still debated, concept of membrane microdomains are the lipid 
rafts132. These domains are rich in cholesterol and sphingolipids and are believed to contain 
liquid-ordered phases, partitioning into patches within the disordered glycerophospholipids of 
the membrane. The various mature Ras isoforms are thought to insert into lipid rafts with 
different distributions, depending on their PTM and the activation state of the GTPase.  
Thus, both organelle-specific signaling and the heterogeinity of the plasma membrane play a 
role in the complexity of signaling outputs124, 125.  
 
Rho/Rac/Cdc42 family. Like Ras, Ras homologous (Rho) proteins also play important roles 
within signaling networks that are extracellularly stimulated and lead to cell cycle progression, 
gene expression, and, most prominently, to actin reorganization (Figure 1-8)133, 134.  
The actin cytoskeleton is composed of actin filaments and many specialized actin binding 
proteins. It is essential in many cellular functions such as cell shape change, cell motility, cell 
adhesion, and cytokinesis135, 136. In most cases, filamentous actin is organized into a number 
of distinct structures, whose formation is regulated by the GTPases of the Rho family through 
the control of their GEFs and GAPs.  
In particular, Rho proteins regulate the formation of actin stress fibers, which are bundles of 
actin filaments that span the cell and are linked to the extracellular matrix through focal 
adhesions. Rac proteins regulate the formation of (i) lamellipodia, which are thin protrusive 
actin sheets found on the edges of many migrating cells, and (ii) membrane ruffles, observed 
as lamellipodia at the leading edge of the cell that lift up and fold backwards. Cdc42 is a 
regulator of the formation of filopodia, which are finger-like protrusions with long actin 
filaments in the direction of the protrusion and are often found in motile cells.  
Until now, 20 members of this Rho/Rac/Cdc42 subfamily have been identified, with RhoA, 
Rac1, and Cdc42 being the best characterized. RhoGTPases undergo post-prenylation 
processing as described for the RasGTPases. However, they do not contain polybasic 
patches or palmitoylation sites within their C-terminal hypervariable domain to target them to 
the plasma membrane. Instead, they are regulated by guanine nucleotide dissociation 
inhibitors (GDIs), which act as chaperones to mask the prenyl group, block spontaneous 
activation by maintaining them in the inactive GDP-bound form137, and promote their 
membrane delivery.  
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1.3.3 The vesicular transport controlled by RabGTPases 
 
 
 
 
 
Figure 1-9 Overview of intracellular localization of specific Rab proteins in mammalian cells, which correlates to 
their compartment-related function in vesicular transport. The key Rab proteins regulating the main hubs of 
endocytosis, biosynthetic pathways, and secretion are shown in bold. Some proteins are cell-specific (e.g. Rab3A 
in neurons) or tissue-specific (e.g. Rab17 in epithelia) or show cell-type-specific localization (e.g. Rab13 in tight 
junctions). The large white arrows represent exocytosis and endocytosis. Endocytosis Cargo is packed in 
clathrin-coated vesicles (CCVs) and trafficked to the early endosome, mediated by Rab5, and subsequently to 
recycling endosomes or late endosomes. The back-transport to the plasma membrane (directly or via recycling 
endosomes) is regulated by Rab4. Cargo trafficking from the recycling endosomes to the plasma membrane is 
mediated by Rab11. Rab7 regulates the transport from early to late endosomes as well as to the lysosome, while 
receptor recycling from late endosomes to the TGN is mediated by Rab9. Exocytosis COPII-coated vesicles are 
transported from the ER to the Golgi apparatus, which is facilitated by Rab1 and in part by Rab33B. Rab6 controls 
the retrograde Golgi-ER as well as the intra-Golgi transport of COPI-coated vesicles. Subsequently, the vesicles 
are passaged through the Golgi to the TGN, which serves as the major distribution center along the biosynthetic 
pathway to different destinations. Rab3A mediates the secretion of transmitters from synaptic vesicles in neurons. 
Rab8 is involved in the TGN-plasma membrane transport. Abbreviations: CCV, clathrin-coated vesicle; CCP, 
clathrin-coated pit; EC, epithelial cells; IC, ER–Golgi intermediate compartment; M, melanosomes; MTOC, 
microtubule-organizing centre; SG, secretory granules; SV, synaptic vesicles; T, T-cell granules; TGN, trans-Golgi 
nextwork. Adapted from138. 
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Intracellular vesicular transport. One of the characteristic features of eukaryotic cells are 
intracellular organelles, which are separated from the rest of the cell by membranes. They 
can be regarded as autonomous units that have to sustain their specific structural, functional, 
and biochemical properties such as pH, redox potential, viscosity, or membrane composition. 
Continuous flow of biomaterial takes place in a highly regulated fashion between these 
organelles. 
The study of membrane traffic was hallmarked by discoveries of Palade139, Schekman140, and 
Rothman141 and colleagues. Using electron microscopy audiography, genetic manipulation of 
yeast, and in vitro reconstitution, respectively, these pioneering studies established the 
hypothesis that the transfer of cargo molecules between organelles is mediated by shuttling 
transport vesicles, both in endocytotic (which serves for the uptake of nutrients and signaling 
molecules as well as for the internalization of receptors) and exocytotic pathways (secretory 
export of proteins and lipids).  
Exocytosis is initiated by the translocation of newly synthesized proteins into the ER. After 
correct protein folding, the proteins exit the ER and are transported through the Golgi 
apparatus, which is accompanied by maturation and often by PTMs of the cargo. 
Subsequently, the mature proteins are trafficked to their final destination at the lysosome, the 
plasma membrane, or the extracellular space.  
Conversely, in endocytosis, newly internalized material is transported to the early endosome, 
which functions as a central sorting station. Then, the cargo is “sorted”, either to early and 
recycling endosomes for the recycling of the material to the plasma membrane (e.g. 
membrane receptors), or to late endosomes and the lysosome for degradation.  
Vesicular trafficking processes can be divided into four essential steps: (i) vesicle formation 
and budding at the donor membrane, (ii) transport, (iii) tethering, and (iv) fusion with the 
acceptor membrane, all of which have to be tightly regulated to ensure the correct transport 
processes142-144.  
Rab proteins have been implicated in the control of each of these steps (Figure 1-9)138, 145, 146.  
Upon synthesis and posttranslational prenylation of the RabGTPase by RabGGTase in 
concert with REP, the enzyme dissociates from the ternary complex, and REP delivers the 
prenylated Rab to the membrane. The membrane represents the site where the RabGTPase 
is subjected to the GTPase cycle, switches from the inactive to the active state, and functions 
as a regulator of vesicular trafficking (Figure 1-10). 
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Figure 1-10 Schematic representation of the Rab-mediated vesicular transport. After (usually) double prenylation 
1, the GDP-bound proteins are delivered to the membrane by REP 2. Following membrane insertion, GEF binding 
releases the bound nucleotide 3. Due to a 10-fold excess of GTP over GDP, GTP binds to Rab 4. The active 
GTPase initiates specific vesicle-mediated transport processes (budding 6, transport 7, tethering, and fusion 8) 
through the recruitment and binding of specific effector proteins 5. The active GTP-bound Rab is turned off by the 
action of GAPs 9, and the GDP-bound Rab is recycled back to the acceptor membrane by Rab-specific GDIs and 
GDF(s) 10, 11. GDI is relased and can undergo another Rab extraction cycle 12, 13. For details, see text. 
 
Budding. The first step of a typical vesicle trafficking event 
is budding, which can be considered as a process of 
simultaneous cargo selection and vesicle formation. 
Budding is mediated by protein coats, which are highly 
dynamic supramolecular assemblies that cycle on and off 
membranes (Figure 1-11)147-149. There are three main 
classes of coated vesicles: (i) clathrin-coated vesicles 
(CCV), (ii) vesicles covered with either the coat protein 
complex-I (COPI) or (iii) the coat protein complex-II (COPII). 
CCVs are mainly derived from the plasma membrane or the trans-Golgi network (TGN) and 
are transported to endosomes150, whereas COPI and COPII mediate the vesicular trafficking 
in the early secretory pathway. COPI predominantly regulates the vesicle transport from the 
Figure 1-11 Vesicle budding. 
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Golgi to the ER as well as within the Golgi cisternae, while COPII mediates the traffic from the 
ER to the Golgi (Figure 1-9)151, 152.  
Coat assembly and disassembly is believed to be regulated by Arf and Sar1 for COPI/CCVs 
and COPII, respectively153. The small GTPases are in turn tightly controlled by their specific 
GAPs and GEFs. The majority of cargo material is actively concentrated in the coated buds 
and vesicles prior to export to the acceptor membrane. Coat proteins recognize sorting 
signals found in the cytosolic domains of transmembrane cargo proteins.  
In addition, the GTPases of the Rab family have been associated with cargo selection154, 155 
and vesicle formation156, 157 as well. In particular, TIP47, an effector of Rab9, has been shown 
to be intimately involved in the formation of vesicles containing mannose 6-phosphate 
receptors (MPRs) that are recycled from late endosomes to the Golgi. Activated Rab9 
increases both the association of TIP47 with late endosomes and its affinity for MPRs.  
Once the cargo is concentrated at the site of vesicle budding, the flat membrane patches are 
deformed into round buds. After vesicle fission, which is mediated by Arf/Sar1 (COPI and 
COPII) or dynamin (CCV), the coated vesicles are released. 
 
Transport. After budding, the vesicles are transported 
through the cytoplasm toward their final destination at the 
acceptor membrane. This is often mediated by active 
trafficking processes using either actin-dependent motors 
(slow, short-range/local transport using myosins) or 
microtubule-dependent motors (high-speed, long-range 
transport using kinesins or dyneins; Figure 1-12). During the 
last decade, the emerging role of Rab proteins in vesicle transport through the recruitment 
and the control of motor proteins has been demonstrated in multiple studies158-163 
(summarized in164-167). One interesting example for Rab-dependent recruitment of 
microtubule-based dynein/dynactin as well as myosin motors is the involvement of Rab7 and 
Rab27 in melanosome trafficking. Melanosomes are lysosome-related organelles which 
synthesize, store, and transport melanin and undergo rapid microtubule-dependent transport 
towards the melanocyte periphery. Subsequently, they are captured to actin filaments and 
slow actin-dependent retention at the cell periphery before they are transferred to 
neighbouring keratinocytes168. Rab7 has been shown to regulate microtubule-dependent 
melanosome transport through the recruitment of its effectors Rab-7 interacting lysosomal 
protein (RILP) and oxysterol-binding protein-related protein 1 L (ORP1L)169, 170. After transport 
to the cell periphery, the melanosomes are attached to the peripheral actin through the 
myosin motor Va171. The myosin Va, on the other hand, is recruited by active Rab27 through 
 
Figure 1-12 Vesicle transport.  
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its effector melanophilin/Slac2a172. Thus in this process, the melanosome is shifted from 
microtubule- to actin-based transport.  
 
Tethering. Once the vesicle reaches the target membrane, a 
specific group of proteins, so-called tethering factors, functions in 
the initial recognition between the incoming vesicle and the target 
membrane and brings them in close proximity (Figure 1-13).  
The membrane tethers identified so far can be grouped into two 
classes: long coiled-coil single protein-based tethers and large 
multi-subunit complexes173, 174. Characteristic for coiled-coil 
tethers are long stretches of heptad repeats with every seventh 
residue showing propensity to form an α-helix. These long, extended rod-like molecules 
(usually) form dimers and have been observed between vesicles and Golgi membranes and 
between Golgi cisternae175. Until now, 12 members of this class of tethers have been 
characterized, with p115, Uso1p, GM130, and Giantin being the best studied ones174.  
 
Figure 1-13 Vesicle tethering. 
The second class of tethers are formed by the multi-subunit complexes, which include COG 
(8 subunits), Dsl1 (3 subunits), GARP (4 subunits), TRAPP I (7 subunits), TRAPP II (19 
subunits), and the Exocyst (8 subunits).  
The GTPases of the Rab family have been implicated in the regulation of tethering factors on 
the vesicle due to their compartment-specific localization along with their ability to specifically 
interact with their effectors. The tethers can function as both Rab effectors and Rab exchange 
factors. For example, active Rab1 promotes the binding of p115, a Rab effector, to 
membranes176 (yeast homologs: Ypt1p binding to Uso1p177), whereas the HOPS complex 
acts as an effector of a RabGTPase (Ypt7p) and as its GEF at the same time178, 179. 
 
Fusion. The actual fusion event between an incoming vesicle and the acceptor membrane is 
mainly mediated by SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein 
receptors, Figure 1-14)180, 181. They have a simple domain structure with a characteristic 
SNARE motif, a region of 60-70 amino acids arranged in heptad repeats, which has been 
evolutionarily conserved and can undergo coiled-coil formation182. Most SNAREs are 
transmembrane proteins, with their functional N-terminal domains facing the cytosol and the 
C-terminus anchored in the membrane. Even though the mechanism of the SNARE-promoted 
fusion event is not fully understood, the prevailing “SNARE hypothesis” assumes that each 
vesicle carries a specific “v-SNARE” that pairs with a corresponding “t-SNARE” on the target 
membrane183. This trans-SNARE complex forms a very stable four-helix bundle, with one α-
helix being contributed by the monomeric v-SNARE and the other three by the oligomeric 
t-SNARE182, 184. Careful analysis of trans-SNARE complex formation revealed that the 
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elongated coiled coils of four interwined parallel α-helices contain 16 stacked layers of 
interacting side chains, which are hydrophobic except for the central ´0´ layer that contains 
three highly conserved glutamine (Q) residues on the t-SNAREs and one arginine (R) residue 
on the v-SNARE185. As a consequence, an alternative nomenclature classifies them as Qa-, 
Qb-, Qc-, and R-SNAREs (Figure 1-14)184.  
According to the “zippering hypothesis”, the SNARE motifs “zip” from the N-terminal ends 
towards their C-terminal membrane anchors, which clamps the membranes together. The 
trans-complexes transform from a loose state (in which the N-terminal parts of the SNARE 
motifs are “zipped up”) into a tight state. Thereby, mechanical force is excerted on the 
membranes, which initiates the opening of a fusion pore and leads to vesicle fusion186.  
During the fusion event, the trans-complex relaxes into a cis-complex. The ATPase NSF 
(N-ethylmaleimide-sensitive factor), along with SNAPs (soluble NSF association protein), 
functions as a cofactor to disassemble the trans-complex and thus recycles the SNAREs for 
other rounds of catalyses (Figure 1-14)187, 188.  
The GTPases of the Rab family have been implicated to participate in driving the fusion 
process. Acting in “Rab microdomains”, they are believed to concentrate SNAREs, accessory 
proteins, and key lipids and to recruit their effectors at the fusion site189, partly due to their 
specific intracellular compartmentalization190, as shown earlier for the GTPases from the Ras 
and Rho family. 
 
Figure 1-14 SNARE-mediated vesicle fusion. For details, see text. 
 
Once the active GTP-bound Rab reaches the acceptor membrane, its function in the 
regulation of the four steps of vesicle trafficking is fulfilled. GAPs subsequently catalyze GTP 
hydrolysis and switch the GTPase to the inactive state. The Rab protein is then recycled back 
to the donor membrane for another round of catalysis. This process is mediated through GDP 
dissociation inhibitors (GDIs)107, 191-193. GDIs are structurally related to REP and extract the 
lipidated Rab from the acceptor membrane. The reinsertion of the prenylated protein into the 
donor membrane is thought to be mediated by GDI displacement factors (GDFs), which 
release the Rab protein from the Rab:GDI complex (Figure 1-10)194.  
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1.3.4 Protein Prenyltransferases as therapeutic targets 
As described in the previous sections the GTPases of the Ras superfamily are key players in 
many signaling and trafficking pathways. Consequently, it is not surprising that expression 
defects, mutations, or misregulation of the GTPases themselves, their effectors, their 
regulators, or their posttranslationally modifying enzymes affect this highly sophisticated 
network, which can lead to abnormalities in human beings.  
Ras proteins have been heavily linked to tumor formation in cancer due to their regulatory 
function in the control of cell proliferation195. 20 % of all human cancers harbor mutant ras 
genes, but the isoforms involved and the incidence of mutations differ for various cancers. 
Point mutations in Ras can be most frequently found in KRAS (~ 85 %), followed by NRAS (~ 
15 %) and HRAS (< 1%). One type of mutation in the Ras genes renders Ras oncogenic and 
makes it insensitive to the action of GAPs. Thereby, Ras is locked in the GTP-bound, active 
state and constantly activates downstream signaling, including the described MAPK 
pathway109, 196. Another class of mutation leads to proteins with abnormally high GDP 
dissociation rates, again leading to increased population of the GTP state even in the 
absence of an input signal. 
Rho proteins have been implicated to be associated with vascular diseases due to their role 
in the reorganization of the actin cytoskeleton and other important cellular processes197.  
RabGTPases and their regulatory molecules and effectors have also been demonstrated to 
be altered in human diseases198. Loss of function mutations in the Rab genes, for example in 
the Rab27A gene, leads to Griscelli syndrome type 2. This autosomal recessive disorder is 
characterized by immune impairment, increased susceptibility to infections, and partial 
albinism as a result from defects in Rab27-mediated melanosome trafficking199. Genetic 
defects in Rab regulatory molecules are associated with retinal degeneration in 
choroideremia (point mutation(s) in REP, leading to an accumulation of unprenylated Rab27 
incapable of regulating melanosome trafficking200), X-linked mental retardation (genetic 
defects in GDI201), and kidney disease in tuberous sclerosis (mutations in the tuberous 
sclerosis (TCS1) protein, which functions as a Rab GAP202).  
Central to the action of the small GTPases of the Ras superfamily as regulators in the 
described signaling and vesicular trafficking pathways is their organelle-specific 
compartmentalization, which is in turn mediated by their PTM status. Interest in the 
therapeutic targeting of their PTM-mediating enzymes stems from the seminal observation 
that membrane detachment of Ras through inhibition of FTase can reverse the transformed 
phenotypes of cancer cells. Consequently, a variety of small-molecule inhibitors of FTase 
(FTIs), competing with the CAAX peptide, the lipid substrate, or both, have been developed 
(Figure 1-15)203, 204. Among these, three compounds, tipifarnib, lonafarnib, and BMS214662, 
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are currently being evaluated in anticancer clinical trials. Although FTIs have been shown to 
be effective in the treatment of hematologic malignancies205, 206, their effects on solid tumors 
are limited207, 208.  
 
 
Figure 1-15 The cholesterol synthesis pathway and protein prenylation. Protein prenylation can be specifically 
inhibited by FTIs (green) and GGTIs (blue), which target the prenylation enzymes. Without isoprene modification, 
the protein substrates of FTase and GGTase are incapable of associating to membranes and thus cannot excert 
their role in signaling pathways. Alternatively, prenylation can be modulated by statins that inhibit the conversion of 
HMG-CoA to L-mevalonate through competitive inhibition of the rate-limiting enzyme HMG-CoA reductase. As 
prenyltransferase-unspecific drugs, their action leads to a decrease in the downstream biosynthesis of cholesterol 
and other intermediate metabolites including FPP and GGPP (orange). Consequently, the prenylation machinery 
of all three enzymes is shut down due to a lack of lipid substrates. Adapted from209. 
 
Surprisingly, the efficacy of FTIs in preclinical testing was not strictly associated with the 
presence or absence of activating mutations of Ras210, probably because they do not inhibit 
the function of K-Ras4B (which is the Ras isoform most involved in human solid tumors), 
K-Ras4A, and N-Ras. The main reason for this is believed to be the alternative prenylation 
(cross-prenylation) of K- and N-Ras by GGTase-I in FTI-treated cells. This led to the 
recognition of GGTase-I as an additional therapeutic target in cancer and to the development 
of GGTase-I inhibitors (GGTIs). These attempts were supported by the observation that 
several geranylgeranylated CAAX proteins, including RalA and RhoC, are critical for 
oncogenesis downstream of Ras211-216. GGTIs have been shown to be able to impair tumor 
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growth in vivo and, in contrast to FTIs, cause inhibition of Rho signaling, cell cycle arrest at 
G0 and G1, and apoptosis217.  
Recently, the GTPases of the Rab family have been shown to be involved in cancer as well. 
RNA microarray analyses revealed that about half of the Rab genes are overexpressed in 
ovarian cancer. In prostate and transitional cell bladder cancer, upregulation of Rab25 was 
found218. Rab5A and Rab7 were demonstrated to be overexpressed in thyroid adenomas, 
wheras overexpression of Rab1B, Rab4B, Rab10, Rab22A, Rab24, and Rab25 has been well 
documented in hepatocellular carcinomas and cholangiohepatomas219.  
However, the effects of FTIs and GGTIs on the prenylation across the entire proteome have 
not been studied due to a lack of appropriate analytical methods. Despite the fact that some 
of these compounds are in clinical trials, the identity of the targets that mediate the 
therapeutic effects of those inhibitors is still debated; for example, compounds BMS1-4, 
initially developed by Bristol-Myers Squibb pharmaceuticals as specific FTase inhibitors, have 
reached clinics without a complete analysis of potential cross-inhibition of GGTase-I and/or 
RabGGTase. Ross-MacDonald and co-workers demonstrated that these compounds induced 
apoptosis by inhibiting RabGGTase and not FTase220. Yet the true in vivo potency towards 
both enzymes or other potential causes for the clinical outcome are not fully understood.  
The second group of compounds that modulate prenylation are the cholesterol-lowering drugs 
known as statins (Figure 1-15). Statins are first-line therapeutics for the prevention of 
coronary heart disease and atherosclerosis221. They prevent the formation of FPP, which 
serves as a precursor for GGPP and cholesterol synthesis, by inhibiting the synthesis of 
mevalonate. Initially, the clinical use of statins was limited to the treatment of high cholesterol 
levels for cardiovascular indications. However, statins are currently being evaluated in the 
therapy of cancer as well as neurodegenerative and autoimmune diseases209, 222, 223. The 
therapeutic effects of statins in these disorders are believed to be due to their ability to 
suppress protein prenylation, but of which targets and to what extent is largely unknown, 
similar to the effects of FTIs and GGTIs described before. 
1.4 Tools to investigate protein prenylation 
Since the discovery that prenylated proteins act as key regulators in many signaling and 
trafficking processes protein prenylation has been thoroughly investigated. Yet many 
questions regarding the in vivo function of the three protein prenyltransferases remain 
unanswered, including the size and composition of the eukaryotic prenylome (the prenylated 
proteome), potential cell type-specific variations in the abundance and type of prenylation, 
cross-specificities among the enzymes, rates and order of prenylation, or the true therapeutic 
effects and toxicities of protein prenyltransferase inhibitors and statins. To address these 
questions, efforts have been made to develop methods to investigate protein prenylation. 
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There are several strategies to approach this task (Figure 1-16). First, one can utilize the 
changes in the physical or biochemical properties of the protein substrate upon the addition of 
the lipid group (Figure 1-16 B). Second, one can tag the peptide or protein substrate with 
reporter groups (C) or third, derivatize the isoprenoid with fluorophores or affinity tags (D).  
 
 
Figure 1-16 Schematic representation of the prenylation reaction and possibilities of its investigation. A Upon 
transfer of a prenyl group, the hydrophobicity of the protein/peptide is increased, and one molecule of 
pyrophosphate is released. B Pyrophosphate release can be measured to investigate the kinetics of the reaction 
(CA or HTS) in vitro224. C The increase in hydrophobicity can be sensed by a dansyl fluorophore coupled to a 
peptide substrate (CA or HTS) in vitro225. D For in vitro, in lysate, or in vivo applications, the isoprenoid moiety can 
be functionalized with either a fluorophore226, 227 or, ideally, an affinity tag for subsequent Western blot or MS/MS 
analysis. Potential applications in lysate and/or in vivo are marked in red. HTS: high throughput screen; CA: 
cuvette assay; FL: fluorescence; WB: Western blot; MS: mass spectrometry; PD: pulldown. 
 
Fierke and colleagues developed a coupled assay that reports on the prenylation reaction by 
monitoring the dissociation of the diphosphate upon attachment of a farnesyl group224. In an 
alternative approach, Pompliano and later Poulter and co-workers developed a prenylation 
assay which exploits the change in fluorescence of a dansylated peptide substrate due to a 
presumed increased hydrophobicity of the environment of the dansyl fluorophore upon 
prenylation225, 228. Despite wide successes of these approaches, particularly of the latter 
method, these technologies are prone to artefacts and, importantly, are limited to in vitro 
investigations.  
Synthetic analogs of isoprenoid pyrophosphates have proven to be well suited as probes to 
investigate the features of protein prenyltransferase-mediated lipidation reactions. These 
include mechanistic probes to study the stereochemistry, the transition state, or kinetic 
isoptope effects; photoaffinity-labeled or other biophysical probes to investigate binding 
modes of the lipid and protein substrates; or stereospecific isomers to probe the lipid 
substrate tolerance of the enzymes229.  
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One of the primary advantages of incorporating the reporter group within the lipid substrate is 
the direct read-out of the prenylated protein, even in complex mixtures such as cellular 
lysates or living cells.  
Soon after the discovery of protein prenylation, radioactive labeling of the lipid substrates 
either via metabolic conversion of tritiated mevalonate into isoprenoids or by direct addition of 
radioactive isoprenoids as pyrophosphates or alcohols to cells or cell lysates was 
developed230-232. Using an excess of synthetic isoprenoids these analogs successfully 
competed with endogenous pools of isoprenoids. Alternatively, they were added in vivo using 
available pharmacological and biochemical tools that allow efficient manipulation of the pool 
of intracellular phosphoisoprenoids and prenylation protein substrates233. The prenylated 
products were detected by radio-audiography of samples separated by SDS-PAGE or affinity 
precipitates. In spite of high detection sensitivity, these procedures, however, are very 
laborious and poorly scalable. 
To overcome these problems, efforts in incorporating chemical reporters into the isoprene 
chain have been undertaken. As in all cases of altering enzyme substrates, it is common 
experience that not every modification in the lipid substrate is tolerated. In the last two 
decades, many studies examined the effect of modifications within the farnesyl chain of FPP 
on FTase binding and/or catalysis.  
 
 
Figure 1-17 Synthetic analogs of FPP and GGPP. Red and blue indicate different constitutional isomers. For 
further details, see text. 
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The work of Das and Allen has paved the way for the design of functionalized farnesyl 
analogs234. The photo-affinity group diazotrifluoropropionyl (DATFP) was incorporated into the 
terminal isoprene moiety for cross-linking applications. They showed that the photoactive 
reagent was a good mimic of FPP for FTase binding, which gave insight into the tolerance for 
substitutions in the FPP analogs (4, Figure 1-17). The study revealed that the terminal 
isoprene unit was amenable to alterations, indicating the importance of size rather than 
hydrophobicity of the lipid substrate for successful competition with FPP. This analog, 
however, was shown not to be transferred by FTase onto peptide substrates.  
Distefano and co-workers pursued a similar approach and designed a photo-affinity-tagged 
analog based on benzophenone as a photoactive core. This analog exhibited better chemical, 
thermal, and photochemical stability as well as a better tolerated wavelength for activation (5, 
6, Figure 1-17)235. In contrast to the DATFP-based probe, the resulting analog was similar in 
polarity to FPP, but somewhat larger and also not a FTase substrate either.  
The first studies on structural alterations in the lipid chain that were still tolerated by FTase for 
successful transfer were reported by Poulter, Gibbs and co-workers53, 236. These studies 
revealed that the incorporation of fluorines, a vinylic, or a cyclopropyl moiety (7/8, 9, and 10, 
respectively) at the C3 position resulted in alternate substrates for FTase, albeit often with 
lower transfer efficiency. 
While these studies demonstrated that FTase displays flexibility in recognizing its lipid 
substrates, modification at the C3 position is not optimal when designing probes that contain 
reporter groups. The terminal position, in contrast, is much more suitable for derivatization. 
However, not every modification made here is tolerated by FTase, as shown for the cross-
linking probes 5 and 6. One of the reasons was anticipated to be the overall length of the 
isoprenoid analog. Therefore, Distefano and co-workers sought to design benzophenone-
based probes with shorter spacers (11, 12)237-240. These were accepted as lipid substrates in 
FTase-mediated catalysis and allowed two interesting conclusions to be drawn: firstly, the 
overall length should mimic the native substrate as closely as possible and secondly, the 
terminal isoprene substitution should not be too bulky.  
Spielmann and co-workers developed isoprenoid analogs with alterations at the terminal 
isoprene unit, but kept the geranyl core structure (13)241. The C8 position was substituted with 
an aniline group, resulting in an analog that was an excellent substrate for FTase.  
The first isoprenoid analog that contained a reporter group, enabling a direct readout of the 
prenylated product, was reported by Waldmann and co-workers226. A geranyl or a farnesyl 
chain was augmented with a N-methylanthraniloyl (mant) moiety at the C8 position (14, 15). 
These analogs were used for the preparation of fluorescently prenylated Rab7 using 
RabGGTase. In further work, they developed 3,7,11-trimethyl-12-(7-nitro-benzo[1,2,5]oxa-
diazo-4-ylamino (NBD)-tagged FPP and GGPP mimics (16, 17), which have turned out to be 
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functional substrates of FTase, GGTase-I, and RabGGTase227, 242. Their application in cell 
lysate or in vivo, however, has been limited due to a generally low abundance of protein 
prenyltransferase substrates in mammalian lysate in combination with a moderate sensitivity 
of the developed methodology.   
 
1.5 Strategies for site-specific protein labeling 
The elucidation of the distribution, dynamics, and functions of proteins in vivo is essential for 
the understanding of their cellular functions. The site-specific labeling of proteins addresses 
these questions by introducing reporter groups that can be employed to monitor their physical 
or biochemical properties. One of the major challenges in this field is to develop a method 
that, ideally, is site- and chemoselective and can be applied to virtually any protein. One 
approach is to incorporate reporter groups into the substrates of PTM enzymes, which are 
posttranslationally transferred to their targets243, as shown for prenylatable proteins in section 
1.4. Since not all proteins are subjected to PTMs or substrate alterations may not be tolerated 
by the PTM-mediating enzyme, a more generic approach for site-specific protein derivati-
zation is needed. 
For in vitro applications, the reactive groups of proteins have been exploited by targeting 
small molecules that carry the desired functionality to the thiol(s) of solvent-exposed cysteine 
residues, amines of lysines or the N-terminus, as well as carboxylates of aspartate, 
glutamate, and the C-terminus. While these techniques are simple and display fast reaction 
kinetics, they do not provide any specificity, given that these groups are often found at 
multiple sites on the protein surface. Thus, efforts have been undertaken to develop protein 
labeling strategies with higher site-specificity244, 245.  
The easiest approach for targeting a small molecule to a protein sequence in a specific 
manner is to use a high-affinity binding interaction, where the protein tag capable of 
associating to the compound is fused to the protein of interest. This has been demonstrated 
with many examples including antibody tags fused to localization signal sequences to target 
various haptene-fluophores to specific cellular compartments246. In an alternative approach, 
the dihydrofolate reductase (DHFR) and the F36V mutant of FK506-binding protein 12 
(FKBP12(F36V)) bind to the small molecules methotrexate and SLF´, a synthetic ligand for 
FKBP12247.  
One of the major concerns of the strategies mentioned is the large tag size (108-157 AAs, 
Table 1-2), which can significantly influence the native structure or function of the protein. In 
contrast to the fusion of a large protein tag, the introduction of a short peptide sequence 
presents a much less invasive approach. Similar to proteins, there are high-affinity 
interactions found between small molecules and peptides. Nolan and colleages evolved a 
28 
Strategies for site-specific protein labeling 
peptide tag of 38 amino acids, which binds to a Texas fluorophore248. In a different approach, 
Vogel and co-workers have used a hexa- or decahistidine tag that can be labeled with nickel-
nitrilotriacetic acid (Ni-NTA) derivatives249.  
The most promising approach in non-covalent peptide-small molecule labeling was developed 
by Tsien and co-workers250, 251. In this system, fluorogenic biarsenical compounds (FlAsH) 
display intense fluorescence with varying colors upon binding to a tetracysteine peptide in 
vitro and in vivo252. Except for the FlAsH technology, whose drawbacks, however, are 
background labeling, residual arsenic toxicity, and long labeling times, protein-ligand 
dissociation followed by signal deterioration remains a concern in all non-covalent labeling 
strategies mentioned.  
To circumvent signal loss through ligand dissociation, covalent labeling has emerged as the 
preferred approach for protein derivatization. The most prominent method in which the 
reporter group, in this case the fluorophore, is covalently attached to the target protein is to 
express it in fusion with the genetically encoded green fluorescent protein (GFP) or one of its 
variants253, 254. Despite enormous successes in the in vivo studies of protein function and 
localization, the utility of this strategy is limited because it is restricted to a defined 
(fluorescence) read-out. In line with the described non-covalent strategies, the need for 
chemically diverse protein labels has led to the development of covalent labeling strategies of 
fusion proteins with small molecules.  
To guarantee specificity, researchers have exploited the specificity of enzymes for these 
purposes. Johnsson and co-workers fused the protein of interest with mutant forms of human 
O6-alkylguanine transferase (hAGT), which can be alkylated on C145 with different O6-
benzylguanine suicide substrates255-257. In a different approach, the self-splicing proteins 
known as inteins were adapted to meet the needs for a selective labeling of proteins in vitro 
as well as in living cells258-260. The advantage of this approach is its “traceless” labeling since 
the intein splices itself out of the protein in an autocatalytic manner.  
Again, despite many reported successful applications of hAGT- and intein-mediated labeling 
strategies, the protein tags are large (207 and 150 AA, respectively) and- even if temporary 
(intein)- prone to influence the structural or biochemical properties of the target proteins. 
Instead of fusing the enzyme itself to the protein to ensure specificity, a different approach 
emerged that included the fusion of peptidic substrates of suitable enzymes. One class of 
enzyme that perfectly fulfills these needs are PTM-mediating enzymes. These enzymes show 
high fidelity in protein substrate recognition, bringing excellent specificity into the labeling 
approach. Depending on the type of PTM, these enzymes display moderately or significantly 
shortened recognition sequences, but are often tolerant to modifications made to the small 
molecule to be attached (Table 1-2).  
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Table 1-2 Different methods for the site-specific labeling of proteins. 
 Method Tag size1 Specificity restrictions 
Non-covalent tagging 
DHFR 
157  
(ProTS) 
labels 
endogenous 
DHFR 
protein-ligand dissociation 
 FKBP12 (F36V) 
108  
(ProTS) 
excellent protein-ligand dissociation 
Tetracysteine 
biarsenicals 
6-10  
(PepTS) 
background 
due to affinity 
to monothiols 
reducing environment; 
fluorogenic; possible 
residual arsenic toxicity; 
long labeling times 
His6/Ni-NTA 
6  
(PepTS) 
unclear fast off-rate, Ni quenches fluorescence  
Texas-red-
binding peptide 
23-38  
(PepTS) 
excellent Texas-red only, ligand dissociation 
Covalent tagging 
 
GFP et al. 238 excellent 
restricted to fluorescence 
large tag size 
hAGT 207 (ProTS) 
labels 
endogenous 
AGT 
large tag size 
limited scope of 
modification 
 intein/NCL 150→1
2 
(ProTS) 
competition 
with 
endogenous 
cys 
reducing environment 
slow rate 
ACP(PCP)/ 
PPTase 
77  
(ProTS) 
excellent cell surface proteins 
 biotin ligase/ hydrazide 
15 
 (PepTS) 
excellent 
one natural substrate in 
E.coli, cell surface 
proteins, 2-step labeling 
1Tag size is given in number of amino acids; 2Tag is temporary and cleaved-off inside the cell; PepTS: peptide 
target sequence; ProTS: protein target sequence; FG: functional group; X: amino acid; SM: small molecule; 
adapted from245. 
 
In one approach, the PTM-mediating enzyme phosphopantetheine transferase (PPTase) was 
exploited to label a 77 AA protein sequence derived from either peptide carrier protein 
(PCP)261 or acyl carrier protein (ACP)262 with 2´-phosphopantetheine-linked probes from 
coenzyme A (CoA). In spite of reduction of the length of the recognition sequence by a factor 
of two, the tag size is still large. Recently, Ting and co-workers developed a strategy in which 
the PTM-mediating enzyme E.coli biotin ligase (BirA) is capable of labeling a peptide 
sequence of 15 amino acids with either its natural substrate biotin or a synthetic ketone 
analog. In a second step, the ketone moiety was derivatized with hydrazide- or 
hydroxylamine-functionalized probes263, 264 (summarized in Table 1-2).  
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Some considerations concerning the chemical entity to be incorporated into the small 
molecule have to be taken into account as well. In one approach, one can directly incorporate 
the reporter group (such as affinity tags, fluorophores, or any other biophysical probes). This 
has the advantage that the labeling is performed in one step and prevents loss in read-out 
signal. However, it bears the disadvantage that not all modifications may be tolerated by the 
enzyme, if the synthetic substrate significantly differs in size, polarity and/or chemical 
reactivity from the native substrate. Additionally, the synthetic efforts of preparing the 
functionalized probes for each application are high.  
Alternatively, one can incorporate a chemical group into the small molecule that can be 
chemoselectively modified after being attached to the protein243. A potentially suitable 
chemical group and the reaction involved have to fulfill several criteria: (i) the functional group 
should be small to mimic the native substrate as closely as possible; (ii) the chemical reaction 
should be biocompatible, that means should be tolerated for protein or cellular functions 
(depending on the in vitro or in vivo application); (iii) the reaction should be orthogonal, that 
means the incorporated functionality should be absent in biological systems; and (iv) the 
reaction should tolerate water as a solvent and display sufficiently rapid kinetics.  
So far, only a few chemical moieties have been reported that possess the required qualities of 
biocompatibility and selective reactivity (Table 1-3). Ketones and aldehydes are mild 
electrophiles and attractive scaffolds to be incorporated into biomolecules such as proteins263, 
lipids, or glycans265, since they can be derivatized with amine-bearing compounds. They are, 
however, limited to cultured cells due to a constraining pH optimum of the reaction as well as 
lack of “true” bioorthogonality in more complex physiological settings, since metabolites such 
as sugars often carry ketones and/or aldehydes.  
The Diels-Alder cycloaddition is a reaction between a diene and dienophile that is known to 
proceed very well in water and has been used for protein labeling purposes. However, this 
reaction displays restricted chemoselectivity due to one of its reactants, the dienophile, which 
can undergo undesired side reactions with side chains of amino acids266.  
In contrast, azides have been shown to be excellent bioorthogonal chemical groups for 
labeling all classes of biomolecules. Azides are small, absent in animals, do not readily react 
either with water or with amine-bearing functionalities, and are not prone to decomposition or 
to reduction under physiological conditions. In recent years, azides have been incorporated in 
a vast array of biomolecules243 upon the development of three distinct bioorthogonal 
reactions: the [3+2] cycloaddition of azides with activated alkynes (termed as the “Click 
reaction”)267, 268, the Staudinger ligation of azides with functionalized triarylphosphines269, 270, 
and the strain-promoted cycloaddition (Table 1-3)271. The three types of reactions display 
excellent chemoselectivities, but the suitability of their application might vary on a case by 
case basis272.  
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Table 1-3 Commonly used chemical reactions for in vitro and in vivo labeling of biomolecules. 
Chemical reporter Reactive partner Ligation product Target (R) 
imine ligation 
   
 
ketone/aldehyde oxime ligation 
  
protein 
glycan 
Staudinger ligation 
  
“Click” chemistry 
 
 
 
 
azide 
Strain-promoted 
cycloaddition 
 
 
protein 
glycan 
lipid 
 
 
terminal alkyne 
“Click” chemistry 
 
 
protein 
Adapted from243. 
 
Similar to the azide, the phosphine employed in the Staudinger ligation is bioorthogonal as 
well, but can undergo oxidation by air or metabolic enzymes during the course of the ligation. 
However, the Staudinger ligation is a very mild reaction that is well tolerated by biological 
systems without showing toxicities. As a result, it has been applied to study many biological 
processes including tagging of recombinant proteins273, glycan labeling on cell surfaces274, or 
immobilization of small molecules and proteins on glass slides275, 276.   
The primary advantage of the copper-catalyzed click reaction over the Staudinger ligation is 
its faster rate (around 25 faster than the Staudinger ligation in lysates). Consequently, click 
chemistry is preferred when very small quantities of azide-labeled biomolecules need to be 
detected277. The big drawback, however, is the cellular toxicity of the metal catalyst, which 
often limits its application in vivo278.  
In an attempt to combine the advantages of the two approaches, an alternative azide-
employing bioorthogonal reaction was developed. The strain-promoted cycloaddition exploits 
the ring strain of an alkyne embedded in a cycloctyne compound for its activation without the 
need of accessory catalysts. This reaction has been used to label biomolecules both in vitro 
and on cell surfaces without observable toxic effects271. Despite slow reaction kinetics, this 
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reaction is considered to represent the next generation of azide-mediated protein labeling 
which compromises between the advantages of click chemistry and the Staudinger ligation♣. 
                                                                  
 
♣In 2007, Bertozzi and co-workers reported on a strain-promoted click reaction with enhanced reaction 
kinetics279. 
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Protein prenylation is a widespread PTM in eukaryotes which is mediated by three distinct 
protein prenyltransferases: FTase, GGTase-I, and RabGGTase. Among their protein 
substrates, the small GTPases from the Ras superfamily represent the largest group and are 
involved in a variety of signaling and trafficking pathways. Interest in the analysis of 
prenylation and its associated enzymes stems from the observation that changes in the 
prenylation status of the target proteins can lead to abnormalities in human beings. While the 
prenylation mechanisms have been thoroughly investigated, most studies were carried out in 
vitro. Therefore, many questions regarding the in vivo function and regulation of the three 
protein prenyltransferases have not been elucidated to date.  
Recent advances in the field of chemical biology paved the way for the application of organic 
synthesis to introduce specific modifications into proteins. Such approaches are highly useful 
since they enable the investigation of various aspects of protein biochemistry in vitro and in 
vivo; this would not be possible using molecular biological techniques alone.  
In particular, the combination of chemical and biochemical tools may also be valuable for the 
investigation of the posttranslational prenylation reactions catalyzed by FTase, GGTase-I, 
and RabGGTase. Generating isoprenoid analogs that contain reporter groups by classical 
organic synthesis could be suitable for tracking protein prenyltransferase substrates upon 
prenylation. These reporter groups can either be (i) fluorescence or affinity tags for a direct 
read-out or (ii) a chemical entity capable of further derivatization by an adequate site- and 
chemoselective reaction. Ideally, these functionalized analogs should be accepted as 
substrates by all three protein prenyltransferases.  
As part of this study, different protocols were to be developed that would permit the tagging of 
all prenylatable protein substrates in mammalian cells with suitable reporter groups. This 
would allow researchers to track, isolate, and identify protein prenyltransferase substrates 
upon lipid attachment. In the first instance, this should be achieved by means of organic 
synthesis of lipid substrates modified with a suitable reporter group. If lipid analogs turned out 
to constitute poor substrates for wild-type protein prenyltransferases, the plan was to enhance 
their activity by protein engineering. If successful, the approach could address many 
unanswered questions: For instance, what is the size and composition of the cellular 
prenylome? What is the abundance of the different prenylation types and what is their tissue-
specific distribution? At what rate and in which order do prenylation reactions occur in vivo? 
What are the therapeutic effects and toxicities of protein prenyltransferase inhibitors and 
statins?  
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Figure 2-1 Schematic representation of the strategy for the incorporation of functional groups into the isoprene 
chain for (i) the investigation of the cellular prenylome or (ii) for a generic site- and chemoselective protein labeling 
technique. STR: streptavidin, HRP: horse-radish peroxidase. 
 
In addition to being a useful tool to investigate protein prenylation, the strategy could also 
meet a long-standing demand in the field of site-specific protein labeling. A generic labeling 
strategy should be highly site- and chemoselective, but at the same time influence the target 
protein as little as possible. Enzymes that mediate PTM reactions have turned out to be 
suitable for these purposes because (i) they often recognize short protein or peptide 
sequences that can be genetically fused to the target protein and (ii) their small-molecule 
substrates are often amenable to modifications. PTM enzymes such as biotin ligase or 
phosphopantetheine transferase partly fulfill these requirements. However, they are either 
limited by insufficient enzyme specificity or, if higher specificity is required, a large protein tag. 
In contrast, the CAAX prenyltransferases FTase and GGTase-I recognize a peptide motif that 
is four amino acids short; this consitutes the smallest enzyme recognition sequence reported 
to date and can in theory be fused to the C-terminus of any protein. Additionally, it has been 
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established that the CAAX prenyltransferases tolerate modifications within the isoprenyl 
chain.  
Hence, part of this work was aimed at the development of a generic protein labeling strategy 
that exploits the posttranslational prenylation reaction by (i) equipping the target protein with a 
genetically encoded CAAX sequence that is recognized by the prenyltransferase(s) and by 
(ii) synthesizing functionalized isoprenoid analogs that contain reporter groups.  
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3 RESULTS AND DISCUSSION 
3.1 Exploiting the substrate tolerance of FTase for site-specific protein 
labeling 
Central to the outlined objectives was the development of a generally applicable procedure 
for the site- and chemoselective derivatization of proteins carrying a short genetically 
encoded microtag. The posttranslational modification reactions catalyzed by FTase and 
GGTase-I fulfill these requirements. Their recognition sequences are four amino acids short 
and can be fused to the C-terminus of virtually any protein242. Previous studies have indicated 
that despite a rigid specificity for their protein substrate, variations in the lipid chain are 
tolerated by these enzymes (section 1.4).  
This chapter describes the use of FTase for the site-specific derivatization of proteins with 
functionalized isoprenoids. The properties of the semi-synthetic proteins will be biochemically 
characterized. Finally, the advantages and disadvantages of the incorporated azide and diene 
groups used for subsequent chemical labeling by Staudinger ligation and Diels-Alder 
cycloaddition, respectively, will be discussed.  
 
3.1.1 Strategy for the design of the genetically encodable microtag and the 
chemically functionalized isoprenoid analogs 
FTase and GGTase-I are structurally and mechanistically similar enzymes that could both be 
suitable for the purposes pursued (Table 1-1). However, several lines of evidence suggest 
that FTase meets the different experimental needs and the general applicability of the method 
better than GGTase-I.  
First of all, the catalytic prenylation efficiency among both CAAX prenyltransferases has been 
shown to be best in the case when FTase is used in combination with the CAAX box derived 
from the C-terminus of K-Ras4B, CVIM242. Secondly, since proteins produced by enzymatic 
lipidation reactions display a decrease in solubility, attachment of the shortest lipid chain, 
farnesyl, is desirable. Third, since Ras represents the best studied GTPase among the 
members of the Ras superfamily, its PTM-mediating enzymes, particularly FTase, have been 
studied extensively. A large amount of information on the mechanism of the farnesylation 
process and, most importantly for our studies, on the influence of modifications on both the 
lipid chain and the protein substrate are available.  
In order to meet the experimental requirements, some criteria regarding the equipment of the 
isoprenoid analogs with functional groups have to be evaluated. As described in section 1.5, 
there are generally two different strategies for protein labeling.  
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A direct incorporation of the reporter group into the isoprene chain represents the ideal 
situation, since it enables a one-step labeling process. The most widely used labeling-
detection system in medical research and diagnostics is the biotin-streptavidin system. 
Streptavidin is a bacterial protein from Streptomyces avidinii that consists of four subunits, 
each of which can bind one biotin molecule with KD values in femtomolar range (KD ~ 1014–
1015 M-1)280. Often referred to as the strongest non-covalent bond in biology, this system has 
been extensively used since (i) the biotin group can be attached to any small molecule (for 
example to a substrate of a PTM reaction) and (ii) streptavidin can be fused to reporter 
enzymes. Most prominently, horse-radish peroxidase (HRP) is very often utilized in 
immunhistochemistry and produces chemiluminescence upon cleavage of its substrate. Here, 
the read-out is coupled to an enzymatic reaction, which leads to a significant signal 
amplification. Thus, we envisaged an isoprenoid analog which is equipped with a biotin 
functionality at the terminal isoprene units.  
Since we were concerned that a bulky and hydrophilic biotin-tagged analog might not be 
tolerated as a substrate by FTase, we sought to design an alternatively functionalized 
isoprenoid that contains a smaller chemical functionality in the terminal isoprene unit suitable 
for further chemoselective transformation (see section 1.5). Since it was not clear at this point 
to which extent the overall length, the bulkiness, and/or the hydrophobicity of the resulting 
isoprenoid would influence the FTase substrate recognition, two paths were followed in 
parallel. In the first, we made use of the observation that alterations in the hydrophobicity of 
the analogs by adding or removing unsaturated bonds were well tolerated (see section 1.4). 
Additionally, designing probes that mimic the lipid chain in structure, but not in polarity, might 
help to develop probes with reduced aggregation and/or precipitation potential of the target 
protein after prenylation. For reasons discussed in section 1.5, we designed FPP analogs that 
contain an azide group for further Staudinger ligation, click chemistry, or strain-promoted 
cycloaddition.  
In the second approach, the development of a FPP analog that better mimicked the native 
structure in hydrophobicity was attempted. The Diels-Alder cycloaddition has been intensively 
studied, shown to proceed in water without any additives, and to be biocompatible in protein 
biochemistry266. We expected that one of the reactants in this reaction, the diene, would 
mimic the lipid chain in polarity better than the hydrophilic azide group♣.  
                                                                  
 
♣ During the course of this PhD thesis, several other groups reported on similar strategies to 
incorporate azides into the isoprenyl chain. These synthetic analogs were efficiently transferred to 
CAAX peptides and proteins and used for peptide and protein labeling281-285, protein immobilization286, 
287, proteomics applications288, and the preparation of protein-DNA conjugates289 by means of click 
chemistry and Staudinger ligation. 
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Dr. Joaquín Gomis (Prof. Waldmann, Department of Chemical Biology, Max-Planck-Institut 
für molekulare Physiologie, Dortmund) synthesized two azide-, one diene-, and one biotin-
functionalized isoprenoid analog. The developed probes are shown in Figure 3-1 in 
comparison with the native substrates FPP and GGPP290. 
 
 
Figure 3-1 Chemical structure of the functionalized isoprenoid analogs in comparison with the native substrates 
FPP and GGPP290. The analogs were synthesized by Dr. Joaquín Gomis. 
 
3.1.2 Prior work 
Previous studies have shown that FTase is flexible in its substrate recognition; it can transfer 
isoprenoids with lengths of up to 15 atoms that also contain additional ether groups291. The 
developed analogs can be regarded as hybrid molecules compared to the typical protein 
prenyltransferase substrate. Containing GPP as a core structure, the isoprenyl chain was 
then augmented with the respective functional groups. In order to fulfill certain synthetic 
needs, such as the prevention of thermal interconversion or ester hydrolysis290, the resulting 
analogs differ in the overall lengths of the linear chain. The length of the diene-functionalized 
isoprenoid HOM-GPP (15 atoms) is closer to that of GGPP than that of FPP since the lipid 
contains only one carbon fewer than GGPP. Additionally, it bears an ether group at position 
C9, while instead of an additional geranyl unit at position C10 it has a conjugated diene 
functionality at carbons C11 to C14. The chain length of the azide-functionalized analog AAA-
GPP is comparable to that of FPP, but the terminal methyl group is substituted by an azide 
moiety. APO-GPP has one additional terminal azide group relative to FPP and comprises an 
ether functionality at the same position as in HOM-GPP. The hydrophobicity of the three 
analogs is expected to be significantly lowered due to the presence of less unsaturated 
carbon-carbon bonds as well as the incorporation of azide, amide, and/or ether moieties.  
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To analyze the interactions of the designed FPP analogs with FTase, Dr. Janina Cramer 
(Prof. Roger S. Goody, Department of Physical Biochemistry, Max-Planck-Institut für 
molekulare Physiologie, Dortmund) made use of a previously established fluorescent 
prenylation assay227. In this assay, the affinity of the non-fluorescent phosphoisoprenoid is 
estimated by its influence on the interaction between the enzyme and the fluorescent 
isoprenoids NBD-GPP or NBD-FPP. In competitive titration experiments the preformed 
complex of NBD-FPP and FTase was titrated with the respective isoprenoid. The resulting 
dequenching of the NBD-FPP fluorescence indicated that the analogs were displaced from 
FTase. The titration data were fitted numerically by a previously described approach and 
resulted in the KD values summarized in Table 3-1.  
 
Table 3-1  KD values of the analogs towards FTase binding and mode of competition. 
Isoprenoid analog Kd / nM competition 
NBD-FPP 5290  
FPP 2.8292  
HOM-GPP 16.4 ± 0.9 full displacement 
AAA-GPP 26.5 ± 1.8 partial displacement 
APO-GPP 2.3 ± 0.3 partial displacement 
BGPP 32.3 ± 2.7 full displacement 
The affinities were determined by Dr. Janina Cramer. 
 
In spite of significant changes in the structure of the lipid chain, the azide-functionalized 
analog APO-GPP bound FTase with an affinity comparable to that of the native isoprenoid 
FPP (2.8 nM). The other azide-functionalized AAA-GPP, which is shortened by one carbon 
atom and lacks one double bond, bound FTase about 9 times less tighly than did FPP. 
Compared to the native substrates FPP and GGPP, it is striking that the isoprenoid HOM-
GPP is much closer to GGPP in its length than to FPP. Yet this analog still displayed an 
affinity of 16.4 nM for FTase, which is about three times stronger than GGPP. The reason for 
this might be found in the diene group, which may cause an increased hydrophobicity of the 
isoprenoid and compensate for the longer chain. The biotin-functionalized analog contains the 
same core structure as AAA-GPP from postions 1-11 in the linear chain, but is then 
augmented by three additional carbon atoms and the terminal biotin group. While the length 
of BGPP is much closer to that of GGPP than to FPP it binds to FTase with an affinity 
comparable to that of AAA-GPP (32 nM). 
HOM-GPP and BGPP showed full displacement of NBD-FPP out of the complex; this 
suggests that these analogs share the binding site with FTase. In contrast, the azide-
functionalized analogs displayed only partial displacement, which hints at a different binding 
mode.  
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3.1.3 The isoprenoid analogs as efficient lipid donors for the prenylation 
reaction catalyzed by FTase 
Transferrability of the analogs onto CAAX-tagged peptides. Since tight binding of the lipid 
substrate to FTase does not necessarily correlate with efficient catalysis, the next step was to 
evaluate whether the functionalized isoprenoids could serve as native lipid donors in the 
prenylation reaction catalyzed by FTase.  
Using the fluorescence assay developed by Pompliano and colleagues (Figure 3-2 A), the 
prenylation reaction was monitored by the increase in fluorescence of dansyl-GCVLS upon 
prenylation. The reaction was initiated by mixing the fluorescently labeled peptide with 
catalytic amount of FTase and excess of either FPP (Figure 3-2 B, black line) or the 
isoprenoid analog APO-GPP (red), HOM-GPP (blue), and AAA-GPP (green). All four 
isoprenoids showed a significant fluorescence increase upon addition of the prenylation 
machinery, which strongly suggests that these analogs serve as lipid substrates for FTase.  
Two major differences between the functionalized isoprenoids were observed. First, the 
relative fluorescence increase varied from 4.6-fold (FPP) and 4.2-fold (APO-GPP and HOM-
GPP) to 3.3-fold (AAA-GPP). Since this assay is sensitive to hydrophobicity changes in the 
environment of the dansyl fluorophore, these observations most probably resulted from 
different hydrophobicities of the analogs. As expected, the more hydrophobic HOM-GPP and 
APO-GPP, which comprise a diene group and an aliphatic azide, respectively, showed a 
higher fluorescence increase than AAA-GPP which contains the azide moiety next to an 
amide functionality.  
 
 
 
Figure 3-2 Fluorescence increase of dansyl-GCVLS upon prenylation. A Schematic representation of the 
fluorescence assay. B Relative fluorescence increase upon addition of FPP (black), APO-GPP (red), HOM-GPP 
(blue), and AAA-GPP (green). 
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Addition of BGPP to the reaction mixture had no impact on the fluorescence, indicating that 
this analog was either no lipid donor for FTase or that its incorporation into dansyl-GCVLS did 
not cause a hydrophobicity change affecting the fluorescent group. To examine these two 
possibilities, all prenylation reaction mixtures were analyzed by ESI-MS. In accordance with 
the fluorescence assay, the prenylation reactions using APO-GPP, HOM-GPP, and AAA-GPP 
as lipid donors showed full conversion of dansyl-GCVLS into the prenylated species, whereas 
no product was detected for BGPP. Hence, despite nanomolar affinity, the biotin-
functionalized analog does not serve as an efficient FTase substrate; this can be explained by 
its overall length, hydrophilicity, and/or its bulky biotin group.  
While the importance of the hydrophobicity of the farnesyl group for Ras function and 
processing in biological systems is well established293, 294, Spielmann and co-workers 
demonstrated that hydrophobicity is not the primary determinant for lipid transferability by 
FTase295, 296. By utilizing a number of isoprenoid analogs that differ in size, shape, and 
hydrophobicity, these studies revealed that the shape and the size of the functionalized lipids 
are more important for FTase-catalyzed transfer.  
As mentioned in section 1.2.1, there are two prevailing hypotheses that explain the lipid 
substrate specificity of FTase. In the molecular ruler hypothesis, the depth of the lipid binding 
pocket of the enzyme is a simple length-discriminating molecular ruler34. Isoprenoids larger 
and/or bulkier than FPP such as BGPP fail to be transferred because the pyrophosphate and 
the C1 of the isoprene chain are misaligned for efficient catalysis. Considering the tight 
binding between BGPP and FTase, it is unlikely that the C1 carbon and the pyrophosphate in 
BGPP are mispositioned, given that numerous mutagenesis and computational modeling 
studies have suggested that pyrophosphate binding is the primary energy source of lipid 
binding297, 298. Several studies on lipid analogs that are longer than FPP suggest that the 
conformation of the bound lipid rather than simply the length of the lipid determines whether it 
is transferred by FTase or not. For example, Gibbs and co-workers found that 2Z-GGPP was 
in fact a substrate for FTase, in contrast to the native all-trans GGPP. Distefano and co-
workers solved the structure of the benzophenone-derivatized analog 3 and GGPP in 
complex with FTase, which revealed that the pyrophosphate group and the C1 atom of the 
isoprenoids were correctly located (Figure 1-5)38. Instead, the conformation was perturbed in 
both cases which interfered with the CAAX peptide binding site or prevented the conversion 
into product, respectively. 
Thus, the most plausible explanation for BGPP´s failure not to serve as a FTase substrate is 
its conformation due to the overall length and/or bulkiness of the biotin group, as postulated 
by the second site-exclusion model. However, the crystal structure of FTase in complex with 
BGPP should clarify this matter (section 3.2.4).   
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Kinetics of FTase-mediated transfer of the analogs onto CAAX-tagged peptides. Key to 
a universal chemical derivatization tool is the efficiency of labeling, since long labeling times 
and excess enzyme or substrate concentrations are undesirable. Substitutions in the lipid 
chain have been shown to potentially affect the rates of FTase catalysis229. Therefore, the 
fluorescence assay described above was employed to study the kinetics of the FTase-
catalyzed reaction with the isoprenoid analogs as lipid donors. The initial velocities of the 
prenylation reactions were measured at various isoprenoid concentrations to calculate the 
kinetic constants. To directly correlate fluorescence units to actual product concentrations, the 
completion of the reaction was verified by adding excess FTase to the prenylation mixture 
when the fluorescence had reached its maximum. Since this did not lead to any further 
fluorescence change, the total fluorescence increase was subsequently correlated to the 
peptide concentration to give the Michaelis-Menten curves shown in Figure 3-3.    
 
 
Figure 3-3 Michaelis-Menten kinetics of dansyl-GVLS prenylation. Kinetics of prenylation of dansyl-GVLS using  
FPP (A), AAA-GPP (B), APO-GPP (C), and HOM-GPP (D). The kinetic parameters are indicated in the 
corresponding panels. 
 
The KM values obtained for the three analogs were in the low (APO-GPP and HOM-GPP) and 
in the high nanomolar range (HOM-GPP, Figure 3-3). Notably, substrate binding and product 
release are rate-limiting for steady-state catalysis under conditions of subsaturating and 
saturating substrate concentrations for mammalian FTase, respectively39, 52. Therefore, the KM 
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for lipid substrates does not simply reflect the KD when peptide concentration is saturating, 
assuming that FTase follows an ordered binding mechanism. The KM may reflect the binding 
of the lipid to the E*product complex to accelerate product dissociation52, 291. Spielmann and 
co-workers postulate that KM is reciprocally dependent on the hydrophobicity ( 1/KM) and on 
the lipid binding geometry291. In accord with their findings, the rather hydrophobic APO-GPP 
and HOM-GPP display lower KM values than the hydrophilic AAA-GPP.  
∝
Since the ratio between kcat and KM provides a measure of catalytic efficiency of enzymatic 
reactions, the transfer efficiencies of the prenylation reactions with the respective analogs 
were judged by kcat/KM. APO-GPP was an excellent alternative substrate for the enzyme, with 
a 3.5-fold enhancement in catalytic efficiency over the natural substrate FPP. It appears that 
the linear carbon chain in APO-GPP with a terminal azide moiety is a good mimic for the 
ω-prenyl unit in FPP, which is in accord with the observation by Spielmann and co-workers 
for compound 23 (Table 3-2)285. The catalytic efficiency of HOM-GPP, in contrast, was 2-fold 
lower than FPP. This could be due to the overall length of the analog, which is elongated by 
three atoms compared to the native substrate and may result in a suboptimal accommodation 
of lipid and peptide substrate in the FTase active site. AAA-GPP represented the poorest 
analog and was transferred 36 times less efficiently than FPP. This result is rather surprising 
since its overall length is very similar to FPP.  
The study of Spielmann and co-workers mentioned before also investigated the influence of 
hydrophobicity, size, shape, overall length, and conformational flexibility of the substituted 
isoprenoid analogs on the catalytic efficiency of the FTase-mediated prenylation reaction. 
Their findings suggest that there is no correlation between transfer efficiency and 
hydrophobicity 295, 296. Instead, there is a compromise between the conformation of the ternary 
complex best suited for catalysis and the optimal interaction of the lipid with the FTase-
product complex to accelerate product dissociation 291, 297. In particular, using 
benzyloxyisoprenyl pyrophosphates of various lengths, Spielmann and co-workers 
demonstrated that conformational flexibility plays an important role in the kinetics of the 
prenylation reaction291, 297. They suggest that by incorporating a linker chain with flexible 
methylene units a large number of available conformations is created. Therefore, the analogs 
may be less organized and, once bound to the lipid binding site, have to find the optimal 
geometric fit, leading to a decreased overall transfer rate. In contrast, the isoprene units of 
FPP may preorganize the molecule to fit into the isoprenoid binding site and thereby reduce 
the number of conformations needed to place the lipid pyrophosphate into the active site. In 
thermodynamic terms, this would mean that a more flexible chain creates an entropic 
disadvantage. Therefore, Spielmann and colleagues postulate that an ideal accommodation 
of the lipid donor in the FTase lipid binding pocket involves an optimal interplay between 
flexibility and conformational rigidity of the lipid. While the overall length of AAA-GPP may be 
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optimal for a good fit in the FTase lipid binding pocket, it is possible that the rotational 
flexibility of the amide group of AAA-GPP may create various conformations that could lead to 
such a dramatic decrease in the overall catalytic efficiency.  
Taken together, compared to other reported azide- or alkyne-functionalized FPP analogs 
used for selective chemical reactions involving azides, APO-GPP represents the azide-
tagged analog with the highest catalytic efficiency reported to date (Table 3-2). HOM-GPP is 
as efficient as other commonly used azide- or alkyne-containing analogs, while AAA-GPP 
represents a rather poor substrate.  
 
Table 3-2 Comparison of the kinetic parameters of the functionalized isoprenoids in comparison to 
other reported azide- or alkyne-tagged FPP analogs.  
Structure KM / nM kcat / s-1 kcat/KM / s-1 
here: 370.3 0.66 1.78 
 40-1710
53, 241, 285 0.07-2.3 0.77-2.25 
 
2120285 0.45 0.21 
 
670285 1.1 1.64 
 
1050285 0.35 0.33 
4230285 0.48 0.11 
 
1900285 1.06 0.55 
APO-GPP 68.4 0.42 6.14 
AAA-GPP 397.6 0.02 0.05 
HOM-GPP 88.6 0.08 0.90 
 
Transferrability of the analogs onto CAAX-tagged proteins. Next, the ability of FTase to 
transfer the developed isoprenoid analogs onto proteins that contain a genetically encoded 
CAAX box was tested. As hydrophilic, easily detectable model protein substrates, Cyan 
Fluorescent Protein (CFP) and its red variant (Cherry) were chosen. The yeast Rab protein 
Ypt7 was included into the test group to represent an average protein that is not as robust as 
a fluorescent protein under non-native conditions. For reasons discussed earlier, the proteins 
were expressed in E.coli with the C-terminal motif TKCVIM, derived from a mammalian 
K-Ras4B protein242. Incubation of CFP-CAAX and Ypt7-CAAX with equimolar enzyme and 
excess of the respective isoprenoid analog led to full conversion of the proteins, which was 
confirmed by ESI-MS.  
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The reaction conditions of the prenylation reaction were optimized to compromise between 
(i) the amount of reagents used, since the preparation of FTase and particularly the 
isoprenoids is laborious, and (ii) labeling time, which should be as short as possible to 
prevent protein denaturation. AAA-GPP was chosen as a model isoprenoid since it displayed 
the slowest kinetics (Figure 3-3).  
In this experiment, 60 µM of CFP-CAAX was premixed with 1-20 eq of AAA-GPP. The 
reaction was initiated by addition of 4.6 µM FTase, stopped with 6 M GdmHCl at the indicated 
time intervals, and analyzed by ESI-MS. Conversion of CFP-CAAX into the prenylated 
product was estimated by the height of the mass peaks. Except for a 1:1 equimolar 
composition of protein and AAA-GPP, the reaction was found to be completed with only two 
equivalents of lipid substrate following an incubation for 12 h at room temperature (Figure 3-4 
A, B). A similar situation pertained for the other two analogs led to the same result, which was 
confirmed by ESI-MS (Figure 3-4 C, D). 
 
 
Figure 3-4 Incoproration of AAA-G, APO-G, and HOM-G into CFP-CAAX as evidenced by ESI-MS. A Monitoring 
of prenylation of CFP-CAAX by ESI-MS using different amounts of AAA-GPP. B-D ESI-MS of prenylated CFP-
CAAX for AAA-GPP (B, expected: 29982 Da; found: 29983 Da), APO-GPP (C, expected: 29983 Da; found: 29980 
Da), and HOM-GPP (D, expected main peak: 29980 Da; found: 29978 Da). The mass spectrum of unprenylated 
CFP-CAAX (experimentally determined mass: 29747 Da) was included in black in all spectra. All spectra showed a 
minor peak of [M-131]+ that reflected the removal of the N-terminal translation initiator Met by methionine 
aminopeptidase. Additionally, D showed a fragmentation peak of [M-80]+ typically corresponding to the loss of the 
hexadienyl group during ionization266, 299. 
 
48 
Exploiting the substrate tolerance of FTase for site-specific protein labeling 
To verify that the performed ESI-MS analysis gave a quantitative assessment of the sample 
and that the flight efficiencies of unprenylated and prenylated sample were comparable, 
equimolar amounts of CFP-CAAX and CFP-CAAX-F were premixed and analyzed by ESI-
MS, which revealed that their flight efficiencies were similar. These results suggest that 
efficient protein labeling with FTase can be achieved using catalytic amounts of enzyme and 
two equivalents of lipid donor.  
 
3.1.4 Biochemical features of proteins derivatized with the isoprenoid analogs 
As mentioned earlier, it is desirable that the envisaged protein derivatization strategy should 
not change the physical, biochemical, or functional properties of the target protein. To fulfill 
these requirements, three aspects have to be examined.  
 
(1) First, the native folding of the target protein should not be influenced under the reaction 
conditions used. In spite of the extended reaction time no protein degradation was observed 
(Figure 3-5 A).  
 
 
Figure 3-5 Biochemical characterization of the prenylated proteins. A Investigation of potential protein degradation 
after prenylation under the established prenylation conditions by SDS-PAGE. B Determination of the affinity of 
NBD-geranylated Ypt7-CAAX for MRS6 by fluorescence spectroscopy.    
 
To examine the compatibility of the established labeling time of 12 h at room temperature with 
protein folding, a binding interaction of Ypt7-CAAX with one of its known binding partners was 
utilized. Ypt7 is a yeast GTPase of the Rab family, which is known to bind many of its 
regulators, including MRS6, the yeast equivalent of mammalian REP. Since the functionalized 
analogs do not contain any reporter group that can be used to quantify the binding interaction, 
Ypt7-CAAX was prenylated with NBD-GPP under the developed prenylation conditions 
instead. Excess lipid substrate was removed by a NAP-5 column, and the binding interaction 
between Ypt7-CAAX and MRS6 was monitored by fluorescence spectroscopy using 100 nM 
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Ypt7-CAAX-NBD-G and increasing amounts of MRS6. This resulted in a large and saturable 
increase in NBD fluorescence, which reflected hydrophobicity changes in the fluorophore 
environment. The obtained data could be fitted to a KD value of 275.4 ± 19.8 nM (Figure 3-5 
B); this is very close to that determined earlier242. The data strongly suggests that the 
established prenylation conditions are mild enough to preserve the native protein fold.   
 
(2) A further stringent criterion for a generic protein labeling method is the hydrophobicity of 
the protein derivative produced. When increased, hydrophobicity tends to reduce protein 
solubility and is often associated with protein aggregation and/or precipitation. Isoprene lipids 
normally render proteins more hydrophobic, given their native function to mediate association 
of the prenylated substrates with membranes. However, reduction of chain length or 
substitution of parts of the structure with non-isoprenyl moieties can reduce the 
hydrophobicity of the isoprenoid242.  
In search of a technique that provides information about the hydrophobicity of biomolecules, 
reversed-phase High Performance Liquid Chromatography (rp-HPLC) was chosen. To 
investigate the influence of the functionalities incorporated into prenylated CFP-CAAX, the 
retention times of the various conjugated analogs and farnesyl were determined under 
identical conditions on a C4 reversed-phase column. The retention times of the derivatives 
including the three analogs were shorter compared to that of CFP-CAAX, which eluted at 
11.85 min prior to and at 12.35 min upon addition of the farnesyl group (Table 3-3).  
 
Table 3-3  Retention times of CFP-CAAX on a C4 HPLC column upon prenylation 
prenylated CFP-CAAX Retention Time / min 
no prenylation 11.85 
FPP 12.35 
HOM-GPP 12.20 
AAA-GPP 11.90 
APO-GPP 12.08 
The prenylated proteins were eluted with a linear gradient of 20-70 % buffer B (0.1 % formic 
acid in ACN) in buffer A (0.1 % formic acid in water) over 10 min. 
 
CFP-CAAX-AAA-G showed no significant change in retention time relative to unprenylated 
CFP-CAAX (11.90 min), while CFP-CAAX-APO-G and CFP-CAAX-HOM-G eluted at 12.08 
min and 12.20 min, respectively. These results are consistent with the increase in 
fluorescence obtained in the fluorescent prenylation assay, suggesting that prenylation with 
the isoprenoid analogs influences the hydrophobicity of the target proteins to a lesser extent 
than FPP. In particular, AAA-GPP appears not to influence the hydrophobicity of the tested 
proteins at all.  
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(3) Third, key to a successful derivatization of the incorporated diene and azide functionalities 
by a chemical reaction is the accessibility of the reactive groups to the solvent. The oligomeric 
state of the protein and its association to FTase upon prenylation have to be investigated 
since studies on FTase prenylation have indicated that (i) farnesylated proteins remain in 
complex with FTase without excess isoprenoid and/or protein substrate52 and that 
(ii) farnesylated proteins oligomerize in the absence of detergents. Gel filtration analysis was 
chosen for this purpose as a technique that provides information on the oligomerization state 
of biomolecules.  
CFP-CAAX and Ypt7-CAAX were prenylated under the optimized reaction conditions using 
60 µM protein, 0.08 eq FTase, and 2 eq FPP, AAA-GPP, APO-GPP, or HOM-GPP. After 
completion, the reaction mixtures were separated on a 10/30 Sephadex-200 column in 
prenylation buffer without detergent and analyzed by SDS-PAGE. As shown in Figure 3-6, the 
elution profiles for the prenylated CFP-CAAX and Ypt7-CAAX proteins were highly similar for 
the respective isoprenoid, which suggests that the nature of the lipid defines the oligomeric 
state of the proteins to a large extent.  
As anticipated, farnesylated Ypt7-CAAX (Figure 3-6 A) and CFP-CAAX (Figure 3-6 E) eluted 
as oligomers and partly in complex with FTase owing to increased protein hydrophobicity and 
lack of excess lipid and/or protein substrate for product release, respectively. In accordance 
with the HPLC-based experiments, Ypt7-CAAX-AAA-G (B) and CFP-CAAX-AAA-G (F) were 
completely soluble and eluted exclusively in monomeric form. Ypt7-CAAX-APO-G (C) and 
CFP-CAAX-APO-G (G) were almost completely monomeric, while the most hydrophobic 
Ypt7-CAAX-HOM-G (D) and CFP-CAAX-HOM-G (H) existed partly in monomeric and partly in 
dimeric, trimeric, and oligomeric form.  
The proteins that had eluted as monomers were confirmed to be fully prenylated by ESI-MS, 
as shown for CFP-CAAX (red: CFP-CAAX-AAA-G, blue: CFP-CAAX-APO-G, green: CFP-
CAAX-HOM-G, Figure 3-6 I).  
From these data, it appears that the proteins modified with the more hydrophilic isoprenoids 
AAA-GPP and APO-GPP are readily released by FTase and stay in the monomeric form even 
in the absence of detergent and excess substrates.   
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Figure 3-6 Gel filtration analysis of prenylation mixtures of CFP-CAAX and Ypt7-CAAX upon prenylation with FPP, 
AAA-GPP, APO-GPP, and HOM-GPP followed by analysis of the fractions by SDS-PAGE. The molecular weight 
of each peak was determined by comparison with protein standards of known molecular weight (1–670 kDa, 2–
158 kDa, 3–44 kDa, 4–17 kDa, 5–1.3 kDa, shown as arrow heads). For further details, see text.  
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3.1.5 Further chemoselective derivatization of the prenylated proteins by 
Staudinger ligation and Diels-Alder cycloaddition 
The incorporated azide and diene groups on the prenylated proteins were tested for their 
ability to be modified by a chemoselective reaction (Scheme 3-1). 
 
 
Scheme  3-1 Schematic representation of the two-step labeling approach involving prenylation with the azide- and 
diene-tagged analogs and subsequent Staudinger ligation with phosphine 27 or Diels-Alder cycloaddition with 
maleimide 28. 
 
Staudinger ligation. Farnesylated proteins and peptides containing azide tags can be 
derivatized either by the “Click reaction”, Staudinger ligation, or strain-promoted cycloaddition, 
as described in section 1.5. Staudinger ligation was selected as the reaction of choice since 
(i) it does not require catalysts such as Cu2+ or the use of a triazolyl ligand necessary for click 
chemistry, which in many cases results in protein denaturation during the course of the 
reaction300; (ii) the synthetic effort to prepare the cyclooctyne compound is quite high; and 
(iii) much knowledge about protein derivatization by Staudinger ligation has accumulated in 
the research group of Prof. Waldmann301, 302. We chose the variation of the Staudinger 
ligation developed by Bertozzi and co-workers, since the reaction proceeds in a very specific 
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manner between an azide and a phosphine group. The latter can be provided in the form of 
an aryl phosphine that is relatively stable in aqueous solution274, 303.  
 
 
Figure 3-7 Chemoselective derivatization of the incorporated azides by Staudinger ligation. A-D ESI-MS spectra 
of CFP-CAAX-AAA-G (unligated protein: 29975 Da, expected ligated protein: 30298 Da) and CFP-CAAX-APO-G 
(unligated protein: 29976 Da, expected ligated protein: 30299 Da) upon incubation with DMSO A, C or phosphine 
27 B, D. The minor additional peaks in the control reactions represent contaminations from the positive samples. 
Each spectrum showed a minor peak of [M-131]+ that reflected the removal of the N-terminal translation initiator 
Met by methionine aminopeptidase. E Chemical structure of the alkoxyimidate side product as reported by 
Distefano and co-workers282. F Mechanism of the Staudinger ligation as proposed by Bertozzi and colleagues304. 
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In initial ligations, 50 µM CFP-CAAX prenylated either with AAA-GPP or with APO-GPP was 
reacted with 250 µM phosphine 27 in 25 mM HEPES, pH 7.2, 40 mM NaCl, 2 m, MgCl2 in the 
presence or absence of 0.05 (v/v) % Tween-20 and/or 2 mM DTE for 8 h at 25 °C. 
Conventional separation methods such as HPLC or SDS-PAGE could not be used since the 
ligated and unligated proteins had similar hydrophobicities and masses (<< 1 kDa). 
Therefore, the reaction yields were estimated by mass spectrometry. While the control 
reaction with CFP-CAAX-F showed no protein modification, the reaction mixtures containing 
CFP-CAAX-AAA-G or CFP-CAAX-APO-G resulted in complete ligation in the absence or 
presence of DTE or Tween-20 (Figure 3-7 B, D), suggesting that both reagents were 
compatible with the Staudinger ligation.  
Importantly, the control reactions with CFP-CAAX-AAA-G and CFP-CAAX-APO-G without the 
addition of phosphine 27 showed that the stability of the azides was not affected inspite of the 
presence of DTE as a reducing reagent, which stands in contrast to previous reports on azide 
reduction to amines by thiols (Figure 3-7 A, C)305.  
In addition to the major (desired) amide-linked product of the Staudinger reaction between 
phosphine 27 and an azide (Figure 3-7 F)304, several groups have reported on an alternative 
alkyoxyimidate product (Figure 3-7 E)282. Mass spectrometric analysis of a reaction mixture 
containing CFP-CAAX-AAA-G and CFP-CAAX-APO-G and phosphine 27 showed a peak with 
the expected mass of the amide-linked reaction product (Figure 3-7 B, D) but no evidence for 
either the alkoxyimidate compound or the starting material.  
In the case of CFP-CAAX-APO-G, an additional peak at 29952 Da was observed. This 
corresponded to the mass of unreacted CFP-CAAX-APO-G with an amine instead of an 
azide. Since this could not be due to a reduction of the azide as evidenced by the control 
sample, additional phosphine conjugations to Cherry-CAAX-APO-G and Ypt7-CAAX-APO-G 
were performed to establish that this phenomenon was not CFP-CAAX-specific. Both cases 
also yielded two reaction products. The origin of the side-product is still unknown, and further 
experiments are required to clarify this matter. 
It is widely established that the Staudinger ligation displays significantly slower reaction 
kinetics than the click reaction243. To monitor the Staudinger ligation in a time-resolved 
manner the reaction was allowed to proceed under the conditions described and stopped at 
the indicated time intervals by passing it over a spin gel filtration column to remove the 
phosphine from the reaction mixture. Estimated by ESI-MS analysis, the reaction yields of 
either CFP-CAAX-AAA-G or CFP-CAAX-APO-G were plotted against reaction times (Figure 
3-8), which revealed that the reaction kinetics were quite different for the two analogs. 
Ligation of CFP-CAAX-AAA-G was complete after 1.5 h while that of CFP-CAAX-APO-G 
afforded more than 4 h. This can be explained from the perspective that the analogs vary in 
the electrophilicities of their azide groups. The azide moiety in AAA-GPP is more electrophilic 
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than that in APO-GPP owing to the presence of the amide functionality. The azide in APO-
GPP has aliphatic carbon atoms as neighbors, which make it less electrophilic. While the 
attack of the lone pair of the phosphorus of the triaryl phosphine on the azide might be 
enhanced in AAA-G in the initial formation of the phosphazide, the real cause is still unknown, 
given that mechanistic investigations of the Staudinger ligation indicate that intramolecular 
amide bond formation rather than phosphazide formation is the rate-determining step of the 
reaction (Figure 3-7 F)304, 306.  
The results demonstrate that the Staudinger ligation is fully chemoselective, is tolerant to 
detergents and reducing agents, and proceeds rapidly in aqueous media in the presence of a 
relatively small excess of phosphine (5 eq).  
 
 
Figure 3-8. Time course of the Staudinger ligation monitored by ESI-MS for CFP-CAAX-AAA-G (left) and CFP-
CAAX-APO-G (right). 50 µM CFP-CAAX-AAA-G or CFP-CAAX-APO-G was reacted with 250 µM phosphine 27 for 
the indicated time periods at room temperature.  
 
Diels-Alder cycloaddition. The Diels-Alder reaction is known to be a selective cycloaddition 
between a diene and a dienophile that can proceed in aqueous media with a higher velocity 
and selectivity than in organic solvents307-309. Its compatibility with biomolecules has been 
explored in the bioconjugation and immobilization of oligonucleotides310, 311 and other 
biomolecules312 as well as in microarray applications313-315. Recently, the applicability of the 
Diels-Alder cycloaddition on the functionalization and immobilization of proteins has been 
demonstrated in the group of Prof. Waldmann266, 299. 
As shown in Scheme 3-1, dienophile 28 was chosen as a model substrate. Since it is a 
substrate of a Michael addition reaction with thiols as well, all cysteines in the reaction 
mixture had to be protected. This was necessary to prevent (i) either unspecific protein 
labeling, if solvent-accessible cysteines were present on the protein surface (in the case of 
CFP-CAAX there were no solvent-exposed cysteines other than that in the CAAX motif) or (ii) 
the decrease of free substrate concentration due to multiple cysteines present in FTase that 
would be labeled with the maleimide (Figure 3-9). A reaction mixture containing CFP-CAAX-
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HOM-G was first treated with Ellman´s reagent (5,5´-dithiobis(2-nitrobenzoic acid), DTNB) to 
block all accessible cysteines of FTase and then subjected to Diels-Alder cycloaddition using 
50 µM protein and 40-fold excess of dienophile at 25 °C. In contrast to the reaction conditions 
previously used to couple a bodipy-functionalized maleimide to a diene-tagged Rab7 protein 
266, 299, conditions were chosen that did not affect protein folding and induce protein 
precipitation. Therefore, the reaction was allowed to proceed for 15 h at 25 °C. 
 
 
Figure 3-9 Michael addition of intrinsic solvent-exposed cysteine or lysine residues to maleimide 28 and chemical 
structure of Ellman´s reagent 
 
To evaluate the chemoselectivity of the reaction, control reactions were carried out in which 
CFP-CAAX-HOM-G was substituted by CFP-CAAX-F. As in the case of the Staudinger 
ligation, the reaction could not be monitored by SDS-PAGE or HPLC. Therefore, it was 
judged by ESI-MS. CFP-CAAX-HOM-G reacted with one molecule of dienophile both at pH 
6.0 and pH 7.2 (Figure 3-10 A, B). At pH 7.2, however, the control sample prenylated with 
FPP, which cannot undergo Diels-Alder cycloaddition, clearly showed a mass peak (30156 
Da, Figure 3-10 D). Corresponding to the addition of one molecule of dienophile 28 to CFP-
CAAX-F, the obtained result suggests that the Diels-Alder cycloaddition is not chemoselective 
at neutral pH, most likely owing to a Michael addition reaction of the lysines present in the 
protein structure to the maleimide. By lowering the pH, all lysines appear to be protonated, 
which inhibits the undesired side reaction, in agreement with earlier studies (Figure 3-10 C)266, 
299.  
With 40-fold excess of dienophile 28 and a reaction time of 15 h at 25 °C, the yield of the 
cycloaddition was only 30 %, significantly lower than in the previous report. That study utilized 
a Rab7 concentration of 40 µM in combination with a 40-100-fold excess of reagent and a 
reaction time of 24 h, which led to protein precipitation and yielded 50-90 % product. The 
significantly lower yield of 30 % in our case can be approached by (i) a shorter reaction time 
and (ii) the observation that CFP-CAAX-HOM-G partially exists in oligomeric forms (Figure 
3-6). Thus, the diene moiety may be buried within the protein core or between protein 
interfaces and not fully accessible to the reactive dienophile. 
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Figure 3-10 Ligation of CFP-CAAX-HOM-G with 6-maleimidohexanoic acid 28. A, B ESI-MS spectra of CFP-
CAAX-HOM-G reacted with 28 at pH 6.0 and 7.2, respectively (unligated protein: 29974 Da, expected ligated 
protein: 30185 Da). C, D ESI-MS spectra of control reactions of CFP-CAAX-F incubated with reagent 28 at pH 6.0 
and 7.2, respectively (unligated protein: 29945 Da, expected ligated protein: 30156 Da). All spectra showed a 
minor peak of [M-131]+ that reflected  the removal of the N-terminal translation initiator Met by methionine 
aminopeptidase. In addition, the spectrum of A and B showed a typical fragmentation peak of [M-80]+ 
corresponding to the loss of the hexadienyl group during ionization. 
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3.2 Towards the isolation and analysis of the cellular mammalian 
prenylome 
The aim of the second part of this work was to develop a technique that allows for (i) sensitive 
detection of prenylatable proteins, even in complex mixtures such as cell lysates or living 
cells, and (ii) simultaneous analysis of the activity of the three protein prenyltransferases in 
vivo. 
Initially, we anticipated that the strategy described in section 3.1 would be suitable for this 
purpose. During the course of the project, Zhao and co-workers published a study that 
followed an almost identical approach, designated as the “Tagging-via-substrate technology”, 
to label and identify FTase substrates in vivo288. After metabolically incorporating a related 
azide-tagged farnesyl pyrophosphate analog (compound 22, Table 3-2) into FTase substrates 
in cultivated cells, the azide moiety was further functionalized with a biotin-phosphine 
conjugate in the resulting lysate. This allowed for a moderately sensitive detection and 
identification of the prenylated proteins by means of streptavidin pulldown and mass 
spectrometry.  
This approach represented an important further development towards the direct read-out of 
biotin-tagged and enriched prenylated proteins. However, the methodology suffered from a 
limited detection sensitivity, which prevented the authors from identifying all known FTase 
substrates. This could be a result of the two-step labeling procedure that was dependent on 
the chemical step, the Staudinger ligation. This reaction, as mentioned earlier, displays rather 
slow reaction kinetics. Additionally, the approach was restricted to the labeling of FTase 
substrates and did not allow for the investigation of either the GGTase-I or the RabGGTase 
action.  
We conjectured that incorporating the biotin moiety directly into the isoprene chain, as in 
BGPP, may minimize signal loss and therefore increase the detection sensitivity. Ideally, the 
biotin-functionalized isoprenoid should be an efficient lipid donor for all three protein 
prenyltransferases to enable a proteome-wide analysis of prenylation.  
This chapter describes the use of biotin-geranyl pyrophosphate BGPP as an efficient 
substrate in the RabGGTase-mediated prenylation reaction, enabling the isolation and 
analysis of RabGTPases in vitro and in lysate. The strategies for engineering FTase and 
GGTase-I mutants capable of faithfully delivering BGPP to their cognate substrates by site-
directed mutagenesis will be described. Finally, the scope of applications of the developed 
strategy will be discussed.  
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3.2.1 BGPP as an efficient lipid donor for the RabGGTase-mediated 
prenylation reaction in vitro 
BGPP represents an extended, bulky, hydrophilic isoprenoid hybrid molecule that is not 
accepted as a lipid donor by FTase (section 3.1.3). Compared to the native substrates FPP 
and GGPP (Figure 3-11 A), the BGPP structure is much closer to GGPP in size than to FPP 
and thus may be tolerated as a substrate by GGTase-I and/or RabGGTase. 
 
 
Figure 3-11 BGPP and its interaction with protein prenyltransferases. A Chemical structure of BGPP in 
comparison with the natural substrates FPP and GGPP. B Titration of 50 nM of NBD-FPP GGTase-I. The changes 
of NBD-FPP fluorescence were followed at 25°C in 50 mM Hepes pH 7.2, 50 mM NaCl, and 5 mM DTT in a 
volume of 1 mL. The NBD fluorescence was excited at 487 nm and data were collected at 530 nm. The data was 
fitted to a quadratic equation. C, D Competitive titration in which 50 nM NBD-FPP was mixed with 50 nM GGPP C 
or 1 µM BGPP D and then titrated with GGTase-I. The data was fitted numerically using the program Scientist. E 
Titration of 200 nM of NBD-FPP with RabGGTase. The experiments were performed as in B, but the fluorescence 
data was collected at 550 nm. The data were fitted as in B. F-H Competitive titration in which 200 nM NBD-FPP 
was mixed with 200 nM GGPP F, 200 nM FPP G, or 4 µM BGPP H and then titrated with RabGGTase. The data 
was fitted as in C ,D. The KD values of the respective isoprenoids for GGTase-I or RabGGTase are shown in the 
corresponding panels. 
 
To analyze the interaction between BGPP and the enzymes, the affinity of BGPP for 
GGTase-I and RabGGTase was determined using competitive titration experiments as 
described in 3.1.2. While BGPP bound to GGTase-I as tightly as to FTase (45 nM, Figure 3-
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11 D), its affinity for RabGGTase was 49-fold lower (Figure 3-11 H). This result was quite 
surprising, since we had anticipated that the longer and bulkier BGPP would be better 
accommodated in the larger active site of RabGGTase. One of the reasons may be the 
rotational flexibility of the amide moiety within the lipid chain. 
 
 
Figure 3-12 Evaluation of the incorporation of synthetic isoprenoids by wild-type protein prenyltransferases into 
recombinant GTPases. A Schematic representation of the prenylation procedure for recombinant GTPases 
followed by subsequent Western blot analysis using a STR-HRP conjugate. B Prenylation of Ki-Ras (lane 1), RhoA 
(lane 2), and Rab7 (lane 3) by FTase, GGTase-I, or RabGGTase/REP-1, respectively, using BGPP as a lipid 
donor. The reaction products were detected by Western blot with STR-HRP. C as in B but using NBD-GPP (lane 
1) or NBD-FPP (lanes 2 and 3) as lipid donors. The reaction products in C were visualized by fluorescence 
scanning of the SDS-PAGE gel. 
 
The ability of BGPP to serve as a protein prenyltransferase substrate was examined using 
recombinant Ki-Ras, RhoA, and Rab7 in combination with FTase, GGTase-I, and 
RabGGTase, respectively. 2 µM of the respective recombinant protein was mixed with an 
equimolar amount of enzyme (and REP-1 for RabGGTase), and the reaction was initiated by 
the addition of excess BGPP. The efficiency of transfer was evaluated by loading 0.5 pmol of 
protein on an SDS-PAGE gel followed by Western blot developed with a streptavidin-
horseradish peroxidase (STR-HRP) conjugate (Figure 3-12 A). Western blot analysis showed 
that BGPP was efficiently transferred by RabGGTase (Figure 3-12 B, lane 3), whereas no or 
minimal transfer activity was detected for FTase and GGTase-I, respectively (lane 1 and 2). 
When this experiment was repeated with the fluorescent analogs NBD-GPP and NBD-FPP, 
all three protein substrates were lipidated to a similar extent (Figure 3-12 C, lanes 1-3). The 
results indicate that BGPP is only recognized as an efficient substrate by RabGGTase.  
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To confirm that the incorporation of biotin-geranyl was not specific to Rab7, the experiment 
was repeated using Rab27 as an alternative RabGTPase. In both cases, strong signals were 
detected, which were enzyme-dependent since omission of either RabGGTase (Figure 3-13 
A, lane 3 and 6) or REP-1 (lane 2 and 5) resulted in lack of a chemiluminescent signal. To 
assess the efficiency of the prenylation reaction and whether BG was transferred to one or 
two C-terminal cysteines of the Rab proteins, the reaction mixture was further analyzed by 
ESI-MS. Under the conditions employed, Rab7 and Rab27 were fully converted into the 
doubly prenylated species, as shown for Rab7 in Figure 3-13 B (black: before, red: after 
prenylation).  
 
 
Figure 3-13 Analysis of RabGGTase-catalyzed biotin-geranyl transfer onto recombinant RabGTPases. A Western 
blot analysis of Rab7 and Rab27 in vitro prenylated with BGPP. Proteins were incubated with equimolar amounts 
of RabGGTase and REP-1 as well as 5 eq of BGPP. The samples were resolved on SDS-PAGE and subjected to 
Western blotting with STR-HRP to detect the incorporation of biotin-geranyl into the proteins (lane 1 and 4 for 
Rab7 and Rab27, respectively). Omission of either BGPP or RabGGTase resulted in a lack of chemiluminescent 
signal (lane 2, 3 and 5, 6 for Rab7 and Rab27, respectively). B ESI-MS of unprenylated Rab7 (23713 Da, in black) 
and doubly-biotin-geranylated Rab7 (expected: 24468 Da, found: 24467 Da, in red). The mass spectra revealed 
the doubly prenylated species only, suggesting that the prenylation reaction had proceeded to completion. 
 
3.2.2 BGPP as an efficient lipid donor for the RabGGTase-mediated 
prenylation of endogenous RabGTPases in COS-7 lysate 
Subsequently, the sensitivity of the strategy was explored by labeling endogenous 
RabGTPases in mammalian lysates with BGPP. As a model cell strain for this study, COS-7 
cells, kidney cells derived from the green monkey, were utilized. The cells were grown in 
Dulbecco’s Modified Eagle’s medium supplemented with 10% fetal bovine serum, 1% 
penicillin, and 1% streptomycin. To increase the pool of unprenylated proteins in vivo, 20 µM 
compactin, an inhibitor of isoprenoid synthesis, was included in the medium, and the cells 
were grown overnight at 37 °C (Figure 3-14). After cell lysis, the resulting lysates were 
subjected to prenylation with 2 µM recombinant RabGGTase, REP-1, and 10 µM BGPP for 
typically 2-4 h at room temperature.  
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Analysis of the reaction mixture by Western blot revealed three prominent bands in the range 
of 25 kDa. These bands presumably represented the endogenous RabGTPases in COS-7 
cells retained in the unprenylated form owing to the lack of GGPP substrate due to compactin 
treatment (Figure 3-14).  
 
 
Figure 3-14 Incorporation of biotin-geranyl into endogeneous RabGTPases in COS-7 lysates. Schematically 
shown is the treatment of COS-7 cells with either DMSO (left) or compactin (right) followed by lysate preparation 
and in vitro prenylation with BGPP as a lipid substrate. At the bottom, the outcome of the experiment after Western 
blot analysis reveals that specific incorporation of biotin-geranyl was achieved when the RabGTPases had been 
rendered unprenylated upon compactin treatment, whereas only faint bands appeared without statin incubation. 
COMP: compactin. 
 
In contrast, when cells pretreated with only DMSO were in vitro prenylated with BGPP, only 
very faint bands in the same molecular range were detected. These bands were enzyme-
specific and disappeared when RabGGTase and/or REP-1 were omitted in the prenylation 
mixture. This suggested the existence of a minor pool of unprenylated RabGTPases, which 
may originate from either newly synthesized Rab proteins on their way to prenylation, a pool 
of RabGTPases that are not prenylated under physiological conditions, or a mixture of both.  
. 
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3.2.3 Enrichment of biotin-geranylated RabGTPases by means of streptavidin 
chromatography 
To investigate the origin of the detected bands, the biotin group on the transferred prenyl 
moiety was utilized to enrich the minor pool of unprenylated proteins by means of streptavidin 
pulldown (Figure 3-16 A).  
 
Establishing prenylation conditions for subsequent streptavidin pulldown. Before 
testing whether the endogenous RabGTPases in compactin-treated cells could be enriched 
on streptavidin beads, optimal prenylation conditions were elaborated to achieve a 
compromise between (i) sufficient BGPP concentration to drive the biotin-geranylation 
reaction to completion with sufficiently high reaction kinetics and (ii) a minimal required 
volume of beads ensuring a quantitative elution with SDS sample buffer. In vitro prenylation 
using 0.5 µM Rab7, RabGGTase, and REP-1 for 2 h at room temperature reached maximal 
prenylation efficiency using only a two-fold excess of BGPP. 
 
 
Figure 3-15 Juxtaposition of prenylation of recombinant (left) or endogenous RabGTPases in compactin-treated 
COS-7 cells (right). In a volume of 10 µL, 0.5 µM Rab7, RabGGTase, REP-1 was mixed with 1 µM BGPP. The 
reaction was allowed to proceed for 2 h at room temperature. Alternatively, 10 µL of compactin lysate was 
supplemented with the Rab prenylation machinery and 1 µM BGPP for 2 h at room temperature.   
 
Judging from the band intensities on the Western blot in comparison to biotinylated protein 
standards of known amount, the concentration of total endogenous RabGTPases in COS-7 
lysate was estimated to be 0.5 µM. Thus, the same experiment was repeated in compactin-
treated COS-7 lysate using 1 µM BGPP to test whether the prenylation kinetics were 
comparable or whether a higher amount of the lipid substrate was required. The latter is 
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theoretically possible if a partial dephosphorylation of BGPP in the lysate by endogenous 
phosphatases takes place.  
As shown in Figure 3-15, the transfer efficiencies were very similar, suggesting that a small 
excess of BGPP is enough to drive the prenylation of the RabGTPases to completion in a 
reasonable time both in vitro and in lysate.  
Having established the optimal prenylation conditions for subsequent streptavidin pulldown, 
we next wanted to test whether the biotin group(s) on the RabGTPases were accessible for 
streptavidin under non-denaturing conditions. The shielding of the biotin group may occur 
since the biotin-geranylated RabGTPases may stay in complex with REP-1 after prenylation. 
Indeed, gel filtration and subsequent SDS-PAGE/Western blot analysis of the reaction 
mixture revealed that Rab7 was only partially released from REP-1/RabGGTase upon 
prenylation with BGPP (Figure 3-16 B).  
 
 
Figure 3-16 Enrichment of biotin-geranylated RabGTPases by means of streptavidin pulldown. A Schematic 
representation of the strategy to enrich the minor pool of unprenylated RabGTPases in COS-7 lysate. B Gel 
Filtration analysis of recombinant Rab7 prenylated with RabGGTase, REP-1, and BGPP in vitro. Fractions were 
subjected to SDS-PAGE and the proteins were visualized by either Coomassie Blue staining or subjected to 
Western blot analysis. The molecular weight of each peak was determined by comparison with protein standards 
of known molecular weight (1–670 kDa, 2–158 kDa, 3–4 kDa, 4, 4–17 kDa, 5–1.3 kDa, shown as arrow heads). 
 
Nonetheless, even as part of the ternary complex, it is conveivable that only one of the two 
transferred biotin group might be buried in the lipid binding site. To test this possibility, 
compactin-treated lysate was prenylated under the optimized reaction conditions and 
subsequently incubated with magnetic streptavidin beads for 1 h at room temperature, 
washed three times with PBS, and eluted with 2x SDS sample buffer. Western blot analysis 
revealed that all biotin-geranylated proteins bound to the streptavidin beads. This suggests 
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that at least one biotin group on the RabGTPase was accessible to streptavidin, possibly 
located at the “exit groove” (section 1.2.2). Judging from the Western blot signals, the overall 
recovery was nearly quantitative (Figure 3-17 A, lanes 1 and 5).  
 
 
Figure 3-17 Enrichment of endogenous RabGTPases prenylated with biotin-geranyl using streptavidin affinity 
chromatography. A Recovery of biotin-prenylated Rabs in compactin-treated lysate after pulldown on streptavidin 
beads. The recovery of the prenylated Rabs was nearly quantitative as judged by visual inspection of Western 
blots. B Inhibition of isoprenoid and protein synthesis to elucidate the origin of the pool of unprenylated 
RabGTPases. COS-7 cells were treated with DMSO (lanes 4-6), cycloheximide (lanes 7-12; negative control 
without BGPP addition: lanes 10-12), or a combination of cycloheximide and compactin (lanes 1-3) overnight. The 
resulting lysates were prenylated with RabGGTase/REP-1 and BGPP as a lipid donor in vitro, incubated with 
magnetic streptavidin beads, washed with PBS, and eluted with 1x SDS sample buffer. Input lysate: lanes 1, 4, 7, 
and 10; flowthrough: lanes 2, 5, 8, 11; output lysate: lanes 3, 6, 9, and 12. C Enrichment of the pool of 
unprenylated proteins from the lysates of untreated mouse liver (left) or mouse brain (right). Strong signals in the 
high-molecular weight range represent endogenous biotinylated proteins. IP: input; FT: flow-through; W: wash; 
OP: output; CHX: cycloheximide; COMP: compactin; PD: pulldown. 
 
Detection of the minor pool of unprenylated RabGTPase in COS-7 cells and mouse 
tissue. After demonstrating that the biotin-geranylated proteins can be enriched in vitro and in 
compactin-treated lysate, the biotin-geranylated lysates from untreated COS-7 cells were 
subjected to a streptavidin pulldown. As can be seen in Figure 3-17 B, enrichment resulted in 
signal amplification of a dominant lower and faint upper bands around 25 kDa (lane 6), while 
a negative control, where BGPP had been omitted, showed no signal at all (lane 12).  
To test whether these bands resulted from newly synthesized Rab proteins on their way to be 
prenylated, protein synthesis in COS-7 cells was blocked with cycloheximide. The resulting 
lysate was biotin-geranylated with RabGGTase and enriched on streptavidin beads prior to 
Western blot analysis. If the observed bands originated from newly synthesized RabGTPases 
they should disappear upon inhibition of protein synthesis. Conversely, if they were a result of 
a pool of unprenylated proteins, they should remain unaffected. The pool of unprenylated 
proteins in COS-7 cells was reduced but not abolished by cycloheximide treatment (Figure 3-
17 B, lane 9). Several minor bands disappeared following the treatment, which suggests that 
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they may represent newly synthesized proteins on their way to be prenylated. The intensity of 
the most dominant lower band remained essentially unchanged, indicating that the 
RabGGTase substrate(s) is/are present in the cell in the unprenylated form for several hours. 
To verify this assumption, COS-7 cells were incubated with cycloheximide and compactin to 
simultaneously block isoprenoid and protein synthesis. This resulted in a mixture of 
endogeneously unprenylated proteins and of unprenylated newly synthesized RabGTPases, 
similar to the untreated case (Figure 3-17 B, lane 3). 
In order to test whether the unprenylated RabGTPase pool could also be detected directly in 
the tissues of living organisms, as shown for COS-7 cells, mouse brains and livers, provided 
by Oliver Leske (Prof. Heumann, Ruhr-Universität Bochum), were lysed, in vitro prenylated 
with recombinant RabGGTase/REP-1/BGPP, and enriched by streptavidin pulldown. 
Enzyme-independent high molecular weight bands were detected that most probably 
represented endogenous biotinylated proteins in mouse tissue (Figure 3-17 C).  
For the lysate derived from mouse liver, these endougenously biotinylated proteins dominated 
the Western blot. Only a minor band in the 25 kDa range was detected, which was absent in 
the control experiment where BGPP had been omitted. 
The abundance of RabGTPases in lysate derived from mouse brain was much higher and 
clearly visible (Figure 3-17 C). This finding is not surprising since Rab proteins were first 
identified as ras-related genes expressed in rat brains316. Thus, using BGPP as a protein 
prenyltransferase substrate even the minor pool of unprenylated RabGTPases in lysates 
derived directly from mouse tissue could be isolated.  
 
3.2.4 Engineering FTase and GGTase-I mutants capable of BGPP transfer 
The developed methodology allows for an efficient detection and isolation of RabGGTase 
substrates in mammalian cells and tissues. Compared to other methods (e.g. radioactive 
labeling; prenylation with derivatized isoprenoids such as the NBD-tagged isoprenoids 16, 17 
or the aniline-functionalized AGPP 13, which can be detected by specific antibodies317; or the 
use of anti-farnesyl/geranylgeranyl antibodies318, 319) the developed technology is less 
laborious, displays higher sensitivity, enabling a detection of as little as 10 fmol of prenylated 
protein, and is highly efficient in enriching the prenylation products. 
Using this approach, questions regarding RabGTPase biogenesis, e.g. expression profiles in 
different cell types, the rates of Rab expression and prenylation, and the effect of prenylation 
modulators (section 1.4), can be clarified. Given the importance of the prenylation substrates 
of the other two protein prenyltransferases for cellular biogenesis and disease, it would be of 
great value to expand this methodology to the other two enzymes. However, BGPP is an 
efficient lipid donor for RabGGTase only. The finding that the isoprenoid analog retains the 
67 
RESULTS AND DISCUSSION 
ability to bind to FTase with high affinity but fails to be transferred can be explained either by 
the molecular ruler hypothesis or the second site exclusion model, which was discussed in 
the introduction. The second model was favored since the diphosphate group of the lipid 
makes the largest contribution to the overall binding energy by interaction with the positively 
charged part of the active site (section 3.1.3).  
 
Structural analysis of the FTase:BGPP complex. In order to provide the experimental 
proof for this assumption, Dr. Zhong Guo (Prof. Roger S. Goody, Department of Physical 
Biochemistry, Max-Planck-Institut für molekulare Physiologie, Dortmund) crystallized wild-
type FTase in complex with BGPP and determined its structure by X-ray crystallography to 
2.8 Å resolution. Structural analysis revealed that BGPP binds to the active site of FTase in a 
bent conformation. As anticipated, the diphosphate and geranyl group of BGPP bind to the 
same site as FPP in the FTase:FPP:protein substrate complex (Figure 3-18 A, B).  
In contrast, the terminal part of the molecule is bent by 90°, pointing towards the opening of 
the active site due to the overall length and the bulkiness of the terminal biotin moiety. 
Superimposition of the FTase:BGPP and the FTase:FPP:protein substrate complexes 
provides an explanation for the failure of FTase to transfer BGPP. The distal part of the lipid 
cannot be optimally accommodated by the lipid binding pocket present in the FTase active 
site. Therefore, it protrudes into the peptide binding site of the enzyme and prevents the 
proper positioning of the protein substrate (Figure 3-18 C). Consistent with the arguments 
from the biochemical view point mentioned earlier (section 3.1.3), this strengthens the 
assumption that the failure of FTase to accept BGPP as a substrate can be explained by the 
second site exclusion model, as postulated by Distefano and co-workers38. 
Comparison of the recently solved high resolution structure of RabGGTase in complex with 
GGPP36 with the structures of CAAX prenyltransferases in complex with their respective lipid 
substrates provides insight into the possible structural differences between RabGGTase and 
the other protein prenyltransferases, which turns out to be coupled to their ability to transfer 
BGPP22, 36. At first glance, it seems likely that the size of BGPP in combination with the depth 
of the lipid binding pocket of the CAAX prenyltransferases is the origin of the inability of 
BGPP to serve as an efficient substrate. The length of BGPP, however, is unlikely to be the 
only explanation since GGTase-I, which possesses a sufficiently deep isoprenoid binding site 
to accommodate GGPP, is also inefficient in transferring BGPP. As shown in the next section 
(Figure 3-19 A-C), this is in accord with the finding that the mutants FTaseW102T_Y365F and 
FTaseW102T, which constitute mutations that have been shown to interconvert the FTase and 
GGTase-I lipid specificity20, 320, transferred biotin-geranyl onto CFP-CAAX very inefficiently 
and not at all, respectively.  
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Figure 3-18 Structural analysis of the BGPP:FTase complex. A Side view of the optically sliced active site of 
FTase in surface representation with bound BGPP. BGPP is shown in ball-and-stick representation, colored 
according to atom type. The FPP molecule colored in blue is placed for comparison into the active site based on 
the FPP analog:FTase:peptide complex structure (PDB:1D8D). B Worm representation of the active site of FTase 
complexed to BGPP. The aromatic residues of the beta subunit, W102β, Y154β, and Y205β, that form the bottom 
of the lipid binding site, are displayed in ball-and-stick representation. The isoprenoid molecules are labeled as in 
A. C Top view of the FTase active site in surface representation with bound BGPP displayed as in A. The peptide 
substrate displayed as a green worm is placed into the active site based on the FPP analog:FTase:peptide 
complex. The reactive cysteine is shown in ball-and-stick representation, while the catalytic Zn2+ ion is displayed 
as a magenta van der Waals sphere. D Superimposition of the critical amino acids at the bottom of the lipid 
binding pocket in complex with the respective lipid in the FTase:FPP (PDB:1D8D), GGTase-I:GGPP (PDB:1N4P), 
and the RabGGTase:GGPP (PDB:3DST) complex. E Optical slice through the active site of the RabGGTase: 
GGPP complex structure superimposed with structures of FPP:FTase:peptide and BGPP:FTase complexes. 
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Analysis of GGPP in complex with RabGGTase and GGTase-I showed that the coordination 
of the fourth isoprene unit of GGPP is substantially different in the two enzymes (Figure 3-18 
D, E). In GGTase-I, the terminal isoprenoid unit is directed towards T49β and F324β in the 
GGTase-I:GGPP complex. In RabGGTase, in contrast, the fourth isoprene unit points 
towards S48β and L99β (analogous to T49β and Y126β in GGTase-I), as revealed in the 
recently solved RabGGTase:GGPP complex36. Compared to the corresponding amino acids 
in FTase and GGTase-I, the leucine is replaced by a bulky tyrosine side chain in both FTase 
and GGTase-I (Y154β and Y126β, respectively). This may provide a mechanistic explanation 
for the ability of the bulky BGPP to penetrate more deeply into the lipid binding cavity of 
RabGGTase, which may not be possible in FTase and GGTase-I (Figure 3-18 D, E). This 
reasoning is in accordance with studies with cis and trans-isoprenylpyrophosphate synthases, 
which carry conserved amino acids in the active site. These bulky amino acid residues have 
been demonstrated to play essential roles in determining the product chain length by blocking 
further product elongation321, 322. 
 
 
Figure 3-19 First round of engineering of an FTase mutant capable of utilizing BGPP as a lipid donor. A Western 
blot analysis of CFP-CAAX (CFP-TKCVIM) in vitro biotin-geranylated with FTaseW102T (lane 1 and 2), 
FTaseW102T_Y365F (lane 3 and 4), and FTaseW102T_Y154T (lane 5 and 6). B-D ESI-MS analysis of CFP-CAAX in vitro 
biotin-geranylated by FTaseY154T B, FTaseW102T_Y365F C, or FTaseW102T_Y154T D (black: spectra of unprenylated CFP-
CAAX, red: mono-prenylated CFP-CAAX). For better illustration, the unprenylated spectrum was omitted for B. 
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Design of a BGPP-transferring FTase mutant. The structural differences in the depth and 
width of the active sites between FTase, GGTase-I, and RabGGTase provided guidance for 
the design of FTase and GGTase-I mutants that would be capable of utilizing BGPP as a 
substrate. Interestingly, a similar strategy has been employed to engineer trans-
isoprenylpyrophosphate synthases that can produce longer lipid polymers323, 324.  
To mimic the lipid binding site of RabGGTase, a double mutant FTaseW102T_Y154T was 
engineered by site-directed mutagenesis, which has threonines instead of the more bulky 
native groups at the bottom of the isoprenoid binding pocket. The mutant efficiently 
transferred biotin-geranyl onto recombinant Ki-Ras or other CAAX-tagged proteins such as 
CFP-CAAX in vitro, as confirmed by Western blot (Figure 3-19 A). ESI-MS analysis revealed 
that CFP-CAAX was entirely converted to the biotin-geranylated product (Figure 3-19 D).  
Compared to wild-type RabGGTase, however, the catalytic efficiency of the mutant enzyme 
was low. In order to elucidate the structural changes that occurred in the 
FTaseW102T_Y154T:BGPP complex compared to the wild-type enzyme and to find a solution to 
further improve the activity of the mutants, Dr. Zhong Guo solved the complex structure to 
2.75 Å resolution.  
Superimposition of the complexes of BGPP bound to wild-type FTase and FTaseW102T_Y154T 
revealed that the mutation to the less bulky amino acids resulted in an expansion of the active 
site, similar to that of RabGGTase. As a result, the terminal part of BGPP is inserted into the 
newly formed cavity in an almost completely extended conformation (Figure 3-20 A). The first 
15 carbon atoms of BGPP are located at positions nearly identical to the lipid chain of FPP 
and BGPP in the wild-type FTase:FPP and wild-type FTase:BGPP structures, respectively.  
As can be seen in Figure 3-20 B, however, the location of the oxygen group of the biotin 
moiety is still very close to the side chains of the CAAX peptide; this may result in sterical 
clashes between the two substrates and hence a lower catalytic efficiency (Figure 3-20 C, D). 
We anticipated that an additional mutation of the bulky tyrosine Y205β to a smaller amino 
acid would further expand the active site and improve the activity of the mutant enzyme. In 
vitro prenylation of recombinant Ki-Ras using wild-type FTase, FTaseW102T_Y154T, 
FTaseW102T_Y205T, or FTaseW102T_Y154T_Y205T (Figure 3-20 E, lanes 1-4, respectively) showed that 
the extent of prenylation at excess BGPP and equimolar concentrations of enzyme and 
protein substrate was similar after 4 h reaction time in vitro.  
However, when the same experiment was repeated in lysate of compactin-treated COS-7 
cells, the efficiencies of the mutants were different. Several prenylatable proteins were 
labeled by the FTase mutants (Figure 3-20 F, lanes 1-4). In all cases, the Western blots were 
dominated by high molecular weight species (~50-80 kDa), which are likely to represent 
nuclear lamins. The observation that the high molecular weight substrates were the most 
abundant ones among FTase substrates is in accord with earlier findings by Zhao and 
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Spielmann and co-workers288, 317. Additional intermediate (~ 40 kDa) and low molecular mass 
products (~ 25 kDa) could be detected even without an enrichment step. The 25 kDa signals 
probably represent small GTPases of the Ras family.  
Notably, the detection of the RasGTPases underscores the sensitivity of the developed 
methodology in comparison to other developed functionalized isoprenoid analogs.  
While being a good mimic of FPP, the incorporation of NBD-GPP into endogenous FTase 
substrates derived from compactin-treated COS-7 lysates does not result in detectable 
signals on SDS-PAGE gels (Dr. Christine Delon, unpublished results).  
Spielmann and co-workers metabolically incorporated the aniline-derivatized isoprenoid 
analog 13 into compactin-treated HEK-293 cells. After lysate preparation, visualization of 
protein substrates that had been labeled was achieved by using antibodies directed against 
the aniline moiety, which enabled them to detect substrates in the 45-66 kDa range317. 
However, endogenous RasGTPases could only be detected when overexpressed, probably 
because of the limited detection sensitivity of their system (Figure 3-20 G).  
Zhao and co-workers followed the same procedure to incorporate the azide-tagged lipid 
donor 22 into endogenous FTase substrates of COS-1 cells288. The prenylation pattern 
obtained in their experiments displayed numerous bands, in addition to the two prominent 
high molecular weight bands detected by Spielmann and co-workers. While some very faint 
bands were observed in a range corresponding to small RasGTPases and γ-subunits of 
trimeric G proteins, these bands were overlaid by background signals of the biotin-
functionalized phosphine reactant (Figure 3-20 H). Nevertheless, the overall pattern looks 
very similar to that obtained in our studies, suggesting that our engineering procedures 
retained the substrate specificity of the resulting FTase mutants. Thus, comparison of our 
strategy to existing methodologies underlines the further improvement in sensitivity and a 
minimized background labeling in our system.  
The prenylation pattern of the double and triple FTase mutants was similar, but the intensity 
of the bands, especially in the low and high molecular weight range, as mentioned earlier, 
was significantly different. While the double mutant displayed more intense bands in the low 
molecular weight range, the triple mutant showed a higher extent of prenylation of high 
molecular weight substrates. Since maximal biotin-geranylation of the unprenylated proteins 
is desirable, an equimolar mixture of FTaseW102T_Y154T and FTaseW102T_Y154T_Y205T was chosen 
for further work.  
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Figure 3-20 Second round of engineering of  FTase mutants capable of utilizing BGPP as a lipid donor. A Optical 
slice through the active site of the FTaseW102T_Y154T:BGPP complex superimposed with the structure of the wt 
FTase:BPP complex. The picture is drawn as in Figure 3-18 A, and the isoprenoid from the BGPP:FTase complex 
is shown in atomic colors while the BGPP in complex with the mutant is colored in blue. B Ball and stick 
representation of the active site of the wt FTase in complex with the FPP analog and peptide substrate 
superimposed with the BGPP from the BGPP:FTaseW102T_Y154T complex. C Worm representation of the active site 
of FTase complexed to BGPP. The aromatic residues of the β-subunit, W102β, Y154β, and Y205β, which form the 
bottom of the lipid binding site, are displayed in ball-and-stick representation. The isoprenoid molecules are 
labeled as in A. D as in B, and the residues W102β and Y154β of the wt FTase are displayed in ball and stick 
representation and colored in orange and pink, respectively. The residue Y205β which is mutated in the triple 
mutant is colored in red. E, F Comparison of the FTase mutants in their ability to prenylate the recombinant 
substrate Ki-Ras E or endogenous substrates in compactin-treated COS-7 lysate F. Lane 1- FTase wild-type, lane 
2- FTaseW102T_Y154T, lane 3- FTaseY154T_Y205T, lane 4- FTaseW102T_Y154T_Y205T. G, H Prenylation pattern of FTase 
prenylation in mammalian lysate reported by Spielmann and co-workers G317 and Zhao and co-workers H288. 
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Design of a BGPP-transferring GGTase-I mutant. We followed the same strategy for 
expanding the lipid binding pocket to engineer a variant of GGTase-I capable of accepting 
BGPP as an efficient substrate. Since the bulky amino acid W102β in FTase is already 
occupied by a Thr residue in the GGTase-I active site, a single mutation (Y126Tβ) was 
introduced to mimic the RabGGTase lipid binding pocket. An in vitro prenylation assay 
showed that the Y126Tβ mutant could catalyze the biotin-geranylation of recombinant GST-
RhoA (Figure 3-21 A). The efficiency of transfer was slightly enhanced compared to wild-type 
GGTase-I (Figure 3-21 B), but was still much lower than that of RabGGTase or the 
engineered double and triple FTase mutants. In addition, prenylation with BGPP never 
reached completion and could not be detected when using less than 20 pmol of recombinant 
protein on the Western blot. This result was surprising, since the active site of the GGTase-I 
mutant was expanded to a comparable extent to that of RabGGTase or FTaseW102T_Y154T. This 
suggests that there might be a second structural requirement for BGPP to function as an 
efficient protein prenyltransferase substrate, other than just an enlarged lipid binding cavity.  
 
 
Figure 3-21 First round of engineering of a GGTase-I mutant capable of utilizing BGPP. A Mutation of Y126Tβ in 
GGTase-I leads to a specific incorporation of biotin-geranyl into GST-RhoA. B Comparison of the prenylation 
efficiencies of GGTase-IY126T and the wild-type enzyme, which was analyzed by Western blot analysis. The band 
intensities were determined using the AIDA software. C Representation of the mutated amino acids as well as 
Y105β and W106β at the bottom of the lipid binding pocket of FTaseW102T_Y154T in complex with BGPP 
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Therefore, the structures of the three wild-type enzymes in complex with their respective 
isoprenoid substrates were re-analyzed, revealing the presence of two conserved residues, 
Y105β/W106β and Y51β/W52β, in wild-type FTase and RabGGTase, respectively, which are 
replaced by phenylalanine in wild-type GGTase-I (F52β and F53β). Interestingly, the benzyl 
ring of F53β and of the analogous amino acids in FTase and RabGGTase point into the 
isoprenoid binding pocket. This could hint at an important hydrogen bonding to the oxygen of 
the terminal carbonyl group of BGPP that might be important for catalysis, as shown in Figure 
3-21 C. Therefore, one could conjecture that a replacement of F53β by a tyrosine would 
enhance the catalytic efficiency of GGTase-I by positioning the biotin group in the active site 
for efficient catalysis. In contrast, the control mutation F52Yβ should not have such an effect, 
since the side chain of this amino acid does not point towards the bound BGPP in the active 
site (Figure 3-21 C).  
Comparison of the transfer efficiency of GGTase-IY126T, GGTase-IF52Y_Y126T, GGTase-
IF53Y_Y126T, and GGTase-IF52Y_F53Y_Y126T demonstrated that, as expected, mutation to tyrosine at 
position 53β led to a dramatic increase in the extent of prenylation of recombinant RhoA 
along with an enhanced catalytic activity, while a mutation at position 52β did not improve, but 
instead lowered the efficiency of BGPP transfer (Figure 3-22 A).  
Similar results were obtained when the same experiment was repeated in lysate derived from 
compactin-treated COS-7 cells (Figure 3-22 B). The extent of prenylation was highest for 
GGTase-IF53Y_Y126T and GGTase-IF52Y_F53Y_Y126T. We chose to further work with 
GGTase-IF53Y_Y126T, since the potency of this mutant was essentially the same as the triple 
mutant.  
 
 
Figure 3-22 Second round of engineering of a GGTase-I mutant capable of transferring BGPP. A, B Comparison 
of the prenylation efficiencies of the designed GGTase-I mutants using Western blot analysis of equal amounts of 
recombinant RhoA A or of the lysate of compactin-treated COS-7 cells B. Lane 1- wild-type GGTase-I, lane 2- 
GGTase-IY126T, lane 3- GGTase-IF52Y_Y126T, lane 4- GGTase-IF53Y_Y126T, and lane 5- GGTase-IF52Y_F53Y_Y126T. C To 
investigate the effect of NP-40 detergent on the biotin-geranylation of Ki-Ras and RhoA by mutants of FTase and 
GGTase-I, respectively, in vitro prenylation experiments were carried out as in A in the presence or absence of 0.5 
% NP-40, and the samples were analyzed by Western blot. The presence of detergent did not significantly affect 
the FTase-mediated prenylation but significantly inhibited the activity of GGTase-I. 
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The prenylation pattern of GGTase-IF53Y_Y126T in compactin-treated COS-7 lysate was 
substantially different from that of the FTase mutants. It was dominated by numerous signals 
that were exclusively in the 20-25 kDa range, most probably representing Rho/RacGTPases 
(Figure 3-22 B). The prenylation pattern was practically identical to that obtained with NBD-
FPP as a lipid donor in combination with wild-type GGTase-I; NBD-FPP constitutes the only 
GGPP analog equipped with a reporter group available so far that allows for the labeling of 
endogenous GGTase-I substrates in mammalian lysate (Dr. Christine Delon, unpublished). A 
major difference, however, is the sensitivity of BGPP, which is significantly higher compared 
to NBD-FPP. 
The protocol for lysate preparation had to be adapted to the conditions of prenylation using 
GGTase-I. Typically, 0.05 % NP-40 was utilized for cell lysis. This detergent, however, 
appeared to inhibit prenylation of GGTase-I at the concentration used (Figure 3-22 C). 
Therefore, cells were lysed by mechanical disruption using a 0.55 mm syringe needle. 
 
Investigation of peptide substrate specificity of the mutants. While the obtained 
prenylation patterns suggested that the FTase and GGTase-I mutants orthogonally deliver 
biotin-geranyl to their native protein substrates, previous studies have shown that either 
changes in the native isoprenoid structures or mutations in the active site of FTase and 
GGTase-I near the CAAX peptide binding sites may influence the substrate specificities of 
both enzymes295, 325, 326.  
As mentioned in section 1.2.2, Beese and co-workers mutated W102β and Y365β in the 
FTase active site and thereby interconverted the lipid substrate specificities of FTase and 
GGTase-I. Surprisingly, this retained the peptide preference for CVLS, a typical FTase CAAX 
motif, in comparison to CVLL, a typical GGTase-I CAAX motif.  
Following this line of experiment, Dr. Yao-Wen Wu (Prof. Roger S. Goody, Department of 
Physical Biochemistry, Max-Planck-Institut für molekulare Physiologie, Dortmund) 
investigated the substrate specificity of FTaseW102T_Y154T, FTaseW102T_Y154T_Y205T, GGTase-
IF53Y_Y126T, and GGTase-IF52Y_F53Y_Y126T using the described fluorescence assay with either 
dansyl-labeled GCVLS or GCVLL as a peptide substrate.  
Wild-type FTase was discriminatory towards the two CAAX boxes CVLS and CVLL in the 
farnesylation process (Figure 3-23 A). The fluorescence increase observed in the presence of 
the CVLL probably represents residual catalytic activity.  
In spite of significant changes in the active site, the triple GGTase-I mutant retained the native 
preference for CVLL compared to CVLS towards biotin-geranyl transfer (Figure 3-23 E).  
Unexpectedly, only a minimal fluorescence increase was observed when using all other 
mutants in combination with BGPP (exemplary spectra shown in Figure 3-23 B). This was 
most probably due to a lack of increase in hydrophobicity upon prenylation, since Western 
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blot analyses had confirmed that biotin-geranyl was indeed transferred onto recombinant or 
endogenous CAAX substrates (Figure 3-20 and 3-22). Therefore, GGPP was employed as a 
lipid substrate for the analysis of the other mutants.  
Both FTaseW102T_Y154T and FTaseW102T_Y154T_Y205T displayed an excellent substrate specificity 
toward CVLS using GGPP as a lipid donor (Figure 3-23 C, D), whereas GGTase-IF53Y_Y126T 
and GGTase-IF52Y_F53Y_Y126T preferred the native GGTase-I CAAX box CVLL over CVLS 
(Figure 3-23 F, G).  
 
 
Figure 3-23 Specificity of FTase and GGTase-I mutants towards dansyl-GCVLS and dansyl-GCVLL peptide 
substrates. Prenylation reaction of wild-type FTase with FPP A, FTaseW102T_Y154T with BGPP B or GGPP C, 
FTaseW102T_Y154T_Y205T with GGPP D, GGTase-IF52Y_F53Y_Y126T with BGPP E or GGPP G, or of GGTase-IF53Y_Y126T 
with GGPP F were performed as described in Materials and Methods. Equal amounts of substrates were used for 
each test pair. The fluorescence increase observed in C where FTaseW102T_Y154T was incubated with GGPP and 
the GGTase-I substrate was also observed in case of A and probably represented residual catalytic activity. The 
experiments were performed by Dr. Yao-Wen Wu. 
 
The analysis demonstrates that the peptide substrate specificity towards CVLL and CVLS 
was not significantly altered in all protein prenyltransferase mutants tested for GGPP 
prenylation. However, while the mutations did not eliminate the native peptide specificities of 
FTase and GGTase-I for CVLS and CVLL, the effects of the mutations on the overall 
recognition of the CAAX sequence require further investigation. 
Since BGPP prenylation in most cases did not result in a fluorescence change, it cannot be 
excluded that BGPP changes the substrate specificity for CVLL and CVLS of those mutants 
tested. Many studies have reported altered peptide specificities due to modifications in the 
isoprenoid chains325, 326. It is believed, however, that changes in the first geranyl unit affect the 
peptide specificity of FTase, whereas modifications adjacent to the first geranyl unit do not 
influence the peptide preference. Therefore, it is likely that BGPP will not change the peptide 
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specificities of the prenyltransferase mutants. However, additional experiments are necessary 
to confirm this reasoning. 
 
3.2.5 Analysis of the entire cellular prenylome 
The results obtained suggest that the developed strategy enables a selective labeling of the 
complete set of protein prenyltransferase substrates in complex mixtures such as cellular 
lysates. In an attempt to tag and detect all 
prenylatable proteins, i.e. the prenylome, 
simultaneously, compactin lysate was 
supplemented with 2 µM RabGGTase, 2 µM REP-
1, and 5 µM BGPP, and the reaction was allowed 
to proceed for 2 h at room temperature. 
Subsequently, 20 µM ZnCl2 as well as 1 µM 
FTaseW102T_Y154T, 1 µM FTaseW102T_Y154T_Y205T, 2 µM 
GGTaseF53Y_Y126T, and 5 µM BGPP were added 
and reacted for another 4-6 h at room 
temperature. The prenylation mixture was 
subjected to SDS-PAGE and Western blot 
analysis. When all three enzymes acted 
simultaneously, a prenylation pattern was obtained 
that represented an overlay of those of the 
individual protein prenyltransferases (Figure 3-24). This further demonstrates that the mutant 
prenyltransferases faithfully and orthogonally deliver biotin-geranyl to their cognate 
substrates, resulting in the first affinity-tagging and isolation of the entire cellular mammalian 
prenylome reported to date.  
 
Figure 3-24 Analysis of the cellular mammalian 
prenylome. Cell lysates were prenylated with 
different engineered protein prenyltransferases. 
Lane 1- lysates prenylated with 
FTaseW102T_Y154T_Y205T, lane 2- with GGTase-
IF53Y_Y126T, lane 3- with RabGGTase, lane 4- with 
all three protein prenyltransferases. 
 
3.2.6 Effect of protein prenyltransferase inhibitors on the prenylome 
Since the developed methodology enables the assessment of the status of all prenylatable 
proteins in the cell, it can be applied for monitoring the effect of prenylation-modulating drugs 
such as protein prenyltransferase inhibitors327. This is particularly important because some of 
the compounds that had been developed as specific inhibitors of a single protein 
prenyltransferase have reached clinical trials without full assessment of their cross-reactivity 
towards the other two enzymes, mainly owing to a lack of appropriate technologies, as 
described in section 1.4.  
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Figure 3-25 Evaluation of the in vivo activity of BMS3. A Schematic overview on inhibitor treatment of cells, lysate 
preparation, in vitro prenylation with BGPP, and Western blot analysis. B Chemical structure of BMS3. C Inhibition 
of protein prenylation in COS-7 cells treated with BMS3 for 18 h. The cell lysates were prenylated with the 
respective protein prenyltransferases (FTaseW102T_Y154T and FTaseW102T_Y154T_Y205T, GGTase-IF53Y_Y126T, or 
RabGGTase) and analyzed by Western blot. D Quantification of results shown in C and calculation of the Ki,app 
values for BMS3 and the respective protein prenyltransferase. 
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In order to demonstrate that a prenylome-wide analysis of such off-target effects can be 
performed using the developed technology, the benzodiazepine compound BMS3 (Figure 3-
25 B), synthesized by Dr. Robin S. Bon (Prof. Waldmann, Department of Chemical Biology, 
Max Planck Institute of Molecular Physiology, Dortmund), was chosen as a model inhibitor220.  
COS-7 cells were treated with increasing concentrations of BMS3 up to 500 µM for 18 h and 
analyzed for the presence of unprenylated proteins upon inhibition of the protein 
prenyltransferases by BMS3 (Figure 3-25 A). The cells were lysed, and the resulting lysate 
was prenylated with BGPP using either FTaseW102T_Y154T/ FTaseW102T_Y154T_Y205T, GGTase-
IF53Y_Y126T, or wild-type RabGGTase/REP-1. As references, compactin- and DMSO-treated 
cells were used as fully unprenylated or fully prenylated control, respectively.  
Western blot analysis of the prenylation mixtures revealed that BMS3 fully inhibited 
RabGGTase and FTase at the highest concentrations used, while prenylation of the 
GGTase-I substrates remained unaffected (Figure 3-25 C), in accordance with the in vitro 
data reported by Ross-MacDonald and co-workers220. Evaluation of the Western blot signal 
intensities using the AIDA software revealed Ki values of 50 and 7 nM for FTase and 
RabGGTase, respectively (Figure 3-25 D). These values cannot be regarded as IC50 values, 
since the reference representing the supposedly fully inhibited situation, the compactin-
treated COS-7 cells, showed less intense bands than the BMS3-treated cells. This hints at a 
salvage pathway for FPP synthesis other than that derived from mevalonate.  
These results provide the first quantitative in vivo protein prenyltransferase inhibition data, 
demonstrating that BMS3 is a potent dual specificity inhibitor of FTase and RabGGTase in 
vivo. Compared to the IC50s in vitro, the values are higher, most probably due to inefficient 
uptake inside the cell, chemical instability of the compound, and/or its metabolic degradation.  
To further corroborate the utility of the developed approach as a novel and powerful method 
for monitoring changes in protein prenylation in eukaryotic cells in response to therapeutic 
compounds, the in vivo effects of two established commercially available protein 
prenyltransferase inhibitors, FTase inhibitor B581 and GGTI-298, were investigated.  
COS-7 cells were treated with B581 at concentrations ranging from 2 to 100 µM328. In 
accordance with earlier studies, B581 is a selective peptomimic inhibitor of FTase329, 330. 
Surprisingly, however, it did not show complete inhibition of FTase even at a concentration of 
100 µM (Figure 3-26 A-C). The discrepancy to the literature reports may be explained that the 
inhibitory effect of B581 was investigated on Ras and lamin A prenylation, on its reverse 
transforming properties in Ras-transformed cells, and on the MAPK pathway controlled by 
Ras, wheras the overall FTase inhibition on all its substrates as well as the extent of the 
overall inhibition remained unclear. The failure of complete inhibition of FTase by B581 may 
result from a low affinity of the inhibitor for FTase, a complex inhibition mechanism, or cross-
prenylation of FTase substrates in the FTI-treated cells by GGTase-I.  
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In addition, the developed technology experimentally confirmed the lack of inhibitory activity 
of B581 towards RabGGTase (Figure 3-26 C), which had been unclear before. 
 
 
Figure 3-26 Inhibition of protein prenylation in COS-7 cells by FTI B581 and GGTI-298. The lysates of COS-7 cells 
were analyzed for the presence of unprenylated substrates upon inhibition of FTase A, E, GGTase-I B, D, and 
RabGGTase C, F. Cells were treated with the indicated concentrations of FTase inhibitor B581 A-C or GGTI-298 
D-F. Lysates were collected, in vitro prenylated with the respective wild-type or mutant protein prenyltransferase 
as in Figure 3-25, and processed for Western blot with STR-HRP. G Chemical structure of B581 (left) and GGTI-
298 (right). Cell treatment and lysate preparation were performed by Dr. Christine Delon. 
 
GGTI-298 is regarded as a specific inhibitor of GGTase-I without affecting the processing of 
H-Ras in vivo even at concentrations of up to 15 µM. While the outcome of its influence on 
important signal transduction pathways has been thoroughly studied331-335, its in vivo 
specificity towards the other two protein prenyltransferases is not established since the 
inhibitory effect of GGTI-298 has mainly been tested on H-Ras and lamin B prenylation only.  
COS-7 cells were treated with varying concentrations of GGTI-298 up to 15 µM. The resulting 
lysates were prenylated with BGPP using either FTase mutants, GGTase-I mutant, or wild-
type RabGGTase/REP-1. In accordance with the described studies, there was full in vivo 
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inhibition of GGTase-I at concentrations above 5 µM and no activity towards RabGGTase 
(Figure 3-26 D and F, respectively). Surprisingly, the compound also inhibited FTase at a 
concentration of 15 µM, since high molecular weight bands could be observed (Figure 3-26 
E). This experiment strongly suggests that GGTI-298 is less specific in vivo than previously 
believed.  
 
 
Figure 3-27 In vivo evaluation of pyrrolidine-derived protein prenyltransferase inhibitors. Cells were treated with 
5-50 µM P49-F6, P50-E11, and P23-D6 or 20 µM compactin or DMSO as positive or negative control, 
respectively. The resulting lysates were biotin-geranylated using FTase mutants A, GGTase-I mutant B, or wild-
type RabGGTase C. D Chemical structures of P49-F6, P50-E11, and P23-D6, which were synthesized by Dr. 
Céline Deraeve. Inhibitor treatment and lysate preparation was performed by Dr. Christine Delon. 
 
Further, the in vivo effect of three recently described pyrrolidine-based inhibitors of 
RabGGTase, P49-F6, P50-E11, and P23-D6, were analyzed (Figure 3-27 D)336. All three 
compounds were demonstrated to be specific micromolar RabGGTase inhibitors in vitro, and 
the published data also suggested that P49-F6 inhibits the prenylation of Rab5B and 
increases its cytoplasmic localization in vivo.  
COS-7 cells were treated with increasing amounts of P49-F6, P50-E11, and P23-D6, which 
were synthesized by Dr. Céline Deraeve (Prof. Waldmann, Department of Chemical Biology, 
Max-Planck-Institut für molekulare Physiologie, Dortmund). Subsequent biotin-geranylation of 
the resulting lysates demonstrated that none of the compounds showed in vivo inhibition of 
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protein prenylation at concentrations up to 50 µM and for up to 48 h (Figure 3-27 A-C). It 
therefore appears that the redistribution of endogenous Rab5B from the membrane to the 
cytosol in response to P49-F6 treatment, as described in the publication, was not a result of 
RabGGTase inhibition336.  
 
3.2.7 Quantitative analysis of the mammalian prenylome 
A potential biomedical application of the developed technology is the proteome-wide analysis 
of protein prenyltransferase action and their protein substrates. Thus, a direct tissue- and 
organ-specific profiling of protein prenyltransferase substrate expression and the effect of 
prenylation-affecting drugs on the status of the prenylome should be achievable. A premise 
for such an approach is the ability to separate the protein prenyltransferase substrates into 
single proteins. Similar molecular weights of many prenylation substrates, in particular those 
of GGTase-I and RabGGTase, complicate their analysis by 1D SDS-PAGE.  
 
 
 
Figure 3-28 2D SDS PAGE analysis and Western blot analysis of compactin-treated COS-7 cell lysate prenylated 
with BGPP using engineered protein prenyltransferases A-C. The prenylation was carried out using 
FTaseW102T_Y154T A, GGTase-IY126T B, or RabGGTase C and visualized by Western blotting with STR-HRP. 
 
In an attempt to improve the separation of the products, lysates derived from compactin-
treated COS-7 cells were biotin-geranylated with FTaseW102T_Y154T, GGTase-IY126T, and wild-
type RabGGTase and analyzed on 2D SDS-PAGE with Western blotting. Thereby, the 
signals were separated into a pattern of dozens of single spots or groups of spots, which 
showed an enzyme-specific distribution (Figure 3-28 A-C).  
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However, even in 2D configuration, a reliable separation of single protein prenyltransferase 
substrates could not be accomplished. Coupling the quantitative isolation of biotin-labeled 
proteins from complex lysate samples to mass spectrometry may provide a potential route for 
their identification and quantification. Multidimensional Protein Identification Technology 
(MudPIT) has proven to be suitable for such purposes. It is based on the proteolytic digestion 
of complex protein mixtures and multi-dimensional chromatography, followed by their 
separation by tandem mass spectrometry and matching of the spectra with sequence 
databases337.  
Lysate derived from either compactin- or DMSO-treated treated COS-7 cells were biotin-
geranylated with 1 µM RabGGTase/REP-1/BGPP for 4-6 h at room temperature, enriched on 
magnetic streptavidin beads, and washed with 4M GdmHCl/PBS, 4 M urea/PBS, and 50 mM 
NH4HCO3, pH 8.0, three times each. To digest all associated proteins, the beads were treated 
with trypsin and chymotrypsin. The resulting peptides were analyzed by MudPIT, which was 
performed by Benjamin Fränzel and Dr. Dirk Wolters (Proteincenter, Ruhr-Universität 
Bochum). 42 RabGTPases were found by database search of the obtained peptide 
sequences; these proteins were absent in the DMSO-treated negative control (Figure 3-29 A). 
The lack of some known RabGTPases, such as Rab17, could be explained by their cell-type 
specific expression338.  
In addition to providing information about the identity of proteins in lysate mixtures, MudPIT 
analysis also gives a measure of protein abundance based on sequence coverage339, 340; this 
is the percentage of a protein´s amino acid sequence covered by the identified peptides. A 
comparison among different Rabs is feasible since RabGTPases have similar molecular 
weights and are expected to show a similar behavior in the mass-spectrometric experiments. 
In order to obtain an absolute quantification of the data, a known amount of recombinant 
[15N]-labeled Rab22A was spiked into the samples prior to tryptic digestion. The experiment 
revealed that protein abundances were substantially different among the Rab proteins, with 
Rab1A/B, Rab5C, Rab14, and Rab11B being the most dominant proteins, with an abundance 
of more than 1.5 pmol per mL lysate. Since 3 mL lysate corresponded to approximately 10 
million cells, 1.5 pmol per mL lysate is equal to roughly 270,000 molecules per cell. 
In contrast, Rab4A/B, Rab6C, Rab15, Rab27A/B, Rab30, Rab33B, Rab34, Rab37, Rab 
39A/B, Rab41 and Rab43 were found at an abundance of less than 0.3 pmol per mL lysate 
each (Figure 3-29 A).  
To confirm that the abundance data obtained using mass-spectrometry was reliable, we 
performed quantitative Western blotting of the COS-7 lysates using specific antibodies for 
Rab1A, Rab6A, and Rab7. Compactin-treated lysate was prenylated with RabGGTase/ 
REP-1/BGPP, and the prenylation mixtures along with known amounts of recombinant GST-
Rab1, Rab6A, or Rab7 were subjected to 1D SDS-PAGE. After transfer onto a nitrocellulose 
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membrane, the membrane was incubated with either anti-Rab1A, anti-Rab6A, or anti-Rab7 
antibodies followed by anti-mouse or anti-rabbit antibody, depending on the source of the 
polyclonal antibodies.  
 
 
Figure 3-29 Identification and quantification of RabGTPases from compactin- and BMS3- treated COS-7 lysates. 
A Abundance of RabGTPases from compactin-treated (blue, green, red, and black bars) and BMS3-treated (gray 
bars) COS-7 cells using the MudPIT technology. The protein abundance is given in pmol per mL COS-7 lysate, 
and individual Rab proteins are colored according to their function: blue- Rabs controlling the biosynthetic 
pathways; green- Rabs controlling secretion; orange- Rabs controlling endocytosis; black – all other RabGTPases. 
B Lysate of COS-7 cells was resolved on SDS-PAGE gel together with the indicated amounts of recombinant 
GST-Rab1A (top), Rab6A (middle), or Rab7 (bottom). The gels were subjected to Western blotting with specific 
anti-Rab1A, anti-Rab7, or anti-Rab6A antibodies, and the antibody binding was detected using the 
chemiluminescent method. 
 
The band intensities on the Western blot were judged by visual inspection, which revealed ca. 
125 fmol of Rab1A (2.1 pmol per mL lysate or ~ 380,000 Rab1A molecules per cell), 25-50 
fmol of Rab6A (~ 75,000-150,000 molecules per cell), and 50-125 fmol of Rab7 (~150,000-
375,000 molecules per cell, Table 3-4). In good agreement with the MudPIT data, Rab1A was 
significantly more abundant in COS-7 cells than Rab7 and Rab6A (Figure 3-29 B). The 
observed abundance differences among the Rabs were larger than observed using the mass 
spectrometric approach. This is likely to be a result of a non-linear relationship between 
amounts of the proteins on the blot and the chemiluminescence capture by the photo-film. 
Having confirmed that the quantitative information on the Rab abundances obtained by 
MudPIT was reliable, we considered the abundance of unprenylated RabGTPases found by 
MudPIT in the compactin-treated cells as the total abundance of expressed RabGTPases in 
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COS-7 cells. Analysis of this data shows that the expression of the most abundant 
RabGTPases found forms three clusters. The first group is formed by GTPases that control 
the early steps of endocytosis (Rab5A,B,C, Rab7, Rab9, Rab21 and Rab22, Figure 3-29 A in 
orange), the second by GTPases that control secretion (Rab3A,B,C,D, Rab10, Rab11A,B, 
and Rab18, Figure 3-29 A in green), and the third by RabGTPases that control the traffic in 
and to the Golgi apparatus (Rab1A,B, Rab2A,B, Rab6A,B,C, and Rab14, Figure 3-29 A in 
blue).  
The obtained results suggest that the more highly abundant RabGTPases are associated with 
the main hubs of endocytic and biosynthetic routes, which probably reflects the number of 
individual fusion events in these compartments. In contrast, the less abundant proteins can 
be attributed to GTPases that regulate specialized trafficking processes.  
 
Table 3-4 RabGTPase abundances in COS-7 lysate obtained by MudPIT and specific antibodies. 
 MudPIT Specific antibodies 
 pmol per mL lysate molecules per cell pmol per mL lysate molecules per cell 
Rab1A 1.7 310,000 2.1 380,000 
Rab6A 0.8 140,000 0.4-0.8 75,000-150,000 
Rab7 1.7 310,000 0.8-2 150,000-375,000 
 
By coupling enrichment of biotin-geranylated RabGTPases to their specific mass spectro-
metric identification and quantification, the BMS3-treated COS-7 lysates were reanalyzed. 
The aim was to determine whether BMS3-mediated inhibition of RabGGTase affected all 
RabGTPases to a similar extent or whether the prenylation of some proteins were inhibited 
more strongly than others. The latter is theoretically possible owing to (i) the very diverse 
structures of Rab C-terminal prenylation motifs and (ii) the lack of information on the mode of 
BMS3-mediated inhibition, which may result in different inhibition patterns of the single Rabs.  
MudPIT analysis of the samples revealed no significant changes in the relative abundance of 
unprenylated Rab proteins in BMS3-treated cell lysates compared with cells that were treated 
with compactin (which can be regarded as the total abundance of expressed RabGTPases). 
The data suggests that BMS3-mediated inhibition is non-discriminatory with respect to the 
RabGTPases (Figure 3-29 in gray).  
The results obtained demonstrate that coupling the enrichment of biotin-geranylated protein 
prenyltransferase substrates with the mass-spectrometric MudPIT technology provides a 
useful tool to identify and quantify unprenylated proteins in vivo. 
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4 SUMMARY AND OUTLOOK 
Protein prenylation is one of the most extensively studied posttranslational modifications; it 
plays a central part in the regulation of diverse cellular processes and also underlies various 
pathologies, particularly cancer. 
The present study was aimed at the investigation of the enzymatic protein prenylation 
reactions as potential tools for generic protein derivatization and for selective labeling of all 
protein prenyltransferase substrates in mammalian cells.  
The first part of this work examined whether the PTM reaction catalyzed by FTase can serve 
as a universal protein labeling strategy. Three azide- and diene-functionalized isoprenoid 
analogs were designed, all of which were transferred by FTase to peptides and proteins 
equipped with the C-terminal CAAX sequence derived from mammalian K-Ras4B, albeit with 
different kinetics.  
APO-GPP displayed a catalytic efficiency that was 3.5-fold enhanced compared to the native 
substrate FPP, whereas the kcat/KM values for HOM-GPP and AAA-GPP were 2- and 36-fold 
lower, respectively. Nevertheless, catalytic amounts of FTase and a small excess of either 
isoprenoid analog were sufficient to quantitatively convert the protein into the prenylated 
species following incubation for 12 h at room temperature.  
The established reaction conditions were mild enough to preserve the native structure of the 
protein substrates. With regard to the biochemical properties of the prenylated proteins, APO-
GPP and particularly AAA-GPP appear to represent the least invasive analogs, since the 
apparent hydrophobicity and the oligomerization state of the target proteins did not change 
upon prenylation.  
We showed that the azide functionalities in APO-GPP and AAA-GPP were suitable for 
subsequent Staudinger ligation with a triaryl phosphine. In contrast to Diels-Alder 
cycloaddition, the Staudinger ligation was fully chemoselective and proceeded with rapid 
reaction kinetics. In particular, the azide in AAA-G was most suitable for the Staudinger 
ligation, since its reaction required only 1.5 h and exclusively yielded the desired product. In 
contrast, the azide in APO-G displayed a 3-fold decrease in reaction kinetics and also left 
20 % of the target protein unligated.  
In summary, AAA-GPP is the analog of choice for a two-step labeling strategy based on 
FTase-catalyzed prenylation of CAAX-tagged proteins and subsequent Staudinger ligation.  
Compared to other labeling strategies, the FTase-mediated prenylation reaction displays the 
shortest peptide recognition sequence reported to date without suffering from a loss in 
efficiency. To compete with other technologies, especially those that can be applied in vivo, 
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several improvements have to be implemented♣. For instance, the CAAX sequence CVIM 
fused to the C-terminus of the target protein is only one of many protein substrates that will be 
recognized as a substrate in vivo. Engineering FTase mutants that specifically recognize a 
non-native CAAX sequence would therefore be an invaluable tool to broaden the applicability 
of the approach.  
One of the methods suitable for targeted protein engineering is directed evolution. By creating 
a randomized library of FTase mutants with altered active sites one could identify an FTase 
enzyme that specifically recognizes non-native CAAX motifs. In addition, it may also be 
possible to move the recognition sequence from the C- to the N-terminus. This would allow 
for more flexibility with regard to the location of the CAAX sequence within the target protein. 
Furthermore, the substrate promiscuity of wild-type FTase towards the lipid donor is limited. 
As a result, the incorporation of substantial modifications into the lipid chain is restricted. It 
may be possible to replace the lipid moiety by fully non-isoprene moieties, which could help to 
increase the solubility of the prenylated target protein. Ongoing work in our group suggests 
that the β-subunit of FTase on its own may be sufficient for catalysis (Alexandrov et al., 
unpublished). This is an important finding with regard to the implementation of screening and 
selection systems to evolve FTase since the evolution of the more complex dimeric enzyme 
would require a co-expression of both subunits.   
The second part of this work describes the development of a generic strategy to selectively 
label the prenylome of mammalian cells. The investigation was triggered by the observation 
that the biotin-functionalized isoprenoid analog BGPP functions as an efficient lipid donor for 
RabGGTase. This probe was used for the affinity-labeling of RabGTPases in vitro and in 
cellular lysates. Due to the extraordinarily high sensitivity of the assay, a stable pool of non-
prenylated RabGTPases could be detected in untreated COS-7 lysate and mouse tissue. 
Based on the crystal structure of BGPP in complex with wild-type FTase, FTase and 
GGTase-I mutants capable of selectively labeling their cognate protein substrates were 
generated by site-directed mutagenesis. These mutants displayed no change in their native 
CAAX peptide specificity. Together with wild-type RabGGTase, the set of engineered protein 
prenyltransferases enabled the isolation and analysis of the entire cellular prenylome. 
Separation into single RabGTPases was achieved by coupling an enrichment of the biotin-
geranylated proteins by means of streptavidin pulldown to mass spectrometry, which provided 
                                                                  
 
♣ During the course of the PhD thesis, several strategies for the enzymatic incorporation of functional 
groups into proteins equipped with peptide tags of different sizes have been reported. In these studies, 
existing enzymes were re-engineered to decrease the size of the peptide label including biotin ligase 
(15 AA)341 and phosphopantetheinyl transferase (8-12 AA)342, 343. Alternatively, the suitability of new 
enzymes were explored such as transglutaminase (7 AA)344, sortase (~ 20 AA)345, formylglycine 
generating enzyme (6-13 AA)346, 347, N-Myristoyl transferase (15 AA)348, 349, and lipoic acid ligase (22 
AA)350. 
90  
SUMMARY AND OUTLOOK 
91 
information on the abundances of the individual RabGTPases in the cell. The data suggests 
that the main hubs of vesicular transport feature more RabGTPases than specialized 
intracellular trafficking routes. The applicability of the methodology was demonstrated by the 
analysis of the in vivo effects of several protein prenyltransferase inhibitors including BMS3- a 
candidate anti-cancer therapeutic. These inhibitor studies revealed that BMS3 is a dual 
specificity inhibitor of RabGGTase and FTase in vivo. The investigation of several other 
commercially available inhibitors indicated that some of the inhibitors displayed the expected 
activities in vivo, whereas others either did not or targeted a broader spectrum of protein 
prenyltransferases than previously believed. 
There are a few unique features of the described technology that set it apart from existing 
methodologies. The procedure (i) is simple compared to other techniques such as metabolic 
labeling; (ii) displays the best detection sensitivity reported to date; and (iii) allows for the 
isolation and analysis of the entire cellular prenylome. In combination, this enables an 
unbiased, proteome-wide detection of protein prenyltransferase substrates. This particularly 
applies to RabGTPases which cannot be predicted on the basis of a short peptide recognition 
sequence. We conclude that the strength of this method is its ability to detect femtomolar 
quantities of unprenylated proteins in cell culture, specific organs, and in whole organisms. 
Detection of unprenylated proteins in specific organs should be possible since we could 
detect a minor pool of unprenylated RabGTPases in mouse liver and brain. This is particularly 
important with regard to the drug distribution and efficacy of prenylation-modulating drugs 
such as protein prenyltransferase inhibitors or statins.  
In future applications, the strategy developed for selective labeling and analysis of the 
mammalian prenylome is likely to serve as an important tool for providing insights into the 
coordination of GTPase expression and prenylation and their function in the regulation of 
intracellular signaling pathways as well as for elucidating their role in degenerative and 
infectious diseases.  
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SUMMARY AND OUTLOOK (german) 
Die Prenylierung von Proteinen ist eine der meist untersuchtesten posttranslationalen 
Modifikationen. Sie nimmt in der Regulierung unterschiedlicher zellulärer Prozesse eine 
zentrale Rolle ein.  
Ziel der vorliegenden Arbeit war die Untersuchung der enzymatischen Protein-
Prenylierungsreaktionen, die potentiell für eine allgemein anwendbare Proteinderivatisierung 
sowie für die selektive Markierung von den gesamten Proteinprenyltransferase-Substraten in 
eukaryotischen Zellen ausgenutzt werden können.  
Der erste Teil der vorliegenden Arbeit befasst sich mit der Fragestellung, ob die von FTase 
katalysierte posttranslationale Modifikationsreaktion für eine allgemein anwendbare 
Proteinlabeling-Strategie geeignet ist. Drei Azid- und Dien-funktionalisierte Isoprenoid-
Analoga wurden entwickelt, die mit Hilfe von FTase mit unterschiedlicher Reaktionskinetik auf 
Peptide und Proteine, welche mit der C-terminalen CAAX-Sequenz von K-Ras4B 
ausgestattet wurden, übertragen werden konnten. Verglichen mit dem nativen Substrat FPP 
war die katalytische Effizienz von APO-GPP um 3.5-fach erhöht, die von HOM-GPP und 
AAA-GPP hingegen um 2- bzw. 36-fach erniedrigt. Dennoch war eine katalytische Menge an 
FTase und ein leichter Überschuss des jeweiligen Isoprenoid-Analogs bei einer Inkubation 
von 12 h bei Raumtemperatur ausreichend, um die Proteine quantitativ mit den Isoprenoid-
Analogen zu prenylieren. Unter den etablierten milden Reaktionsbedingungen konnte die 
native Struktur des Proteinsubstrates bewahrt werden. Die Verwendung von APO-GPP und 
insbesondere AAA-GPP beeinflusste die biochemischen Eigenschaften der prenylierten 
Proteine nur gering: Sowohl die apparente Hydrophobizität als auch der 
Oligomerisationszustand der Proteine wurde durch die Prenylierung nicht nachteilig 
verändert.  
Es konnte gezeigt werden, dass die Azidfunktionalitäten von AAA-GPP und APO-GPP durch 
die Staudinger-Ligationsreaktion mit einem Triarylphosphin modifiziert wurden. Im Gegensatz 
zu der Diels-Alder-Zykloaddition verlief die Staudinger-Ligation vollständig chemoselektiv und 
mit hoher Reaktionskinetik. Die Azidgruppe von AAA-G war insbesondere geeignet für die 
Staudinger-Ligation, da die Reaktion nur 1.5 h benötigte und ausschließlich das gewünschte 
Produkt erzielte. Die Azidgruppe in APO-G dagegen zeigte eine 3-fach langsamere 
Reaktionskinetik mit lediglich 80%-igem Umsatz.  
Diese Ergebnisse empfehlen AAA-GPP im Vergleich zu APO-GPP für eine 2-stufige 
Labeling-Strategie von CAAX-modifizierten Proteinen mittels der FTase-katalysierten 
Prenylierung und anschließender Staudinger-Ligation.  
Verglichen mit anderen Labeling-Strategien zeigt die FTase-vermittelte Prenylierungsreaktion 
die bisher kürzeste bekannte Peptid-Erkennungssequenz. Um sich gegen andere 
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Technologien behaupten zu können, insbesondere denjenigen, die in vivo anwendbar sind, 
müssen zur generellen Anwendbarkeit einige Verbesserungen implementiert werden♣. Die 
genetisch kodierte CAAX-Sequenz CVIM am C-Terminus des Zielproteins wäre nur eine von 
vielen Proteinsubstraten, die als Substrat in vivo erkannt werden würden. Aus diesem Grunde 
würde das Engineering von FTase-Mutanten, die spezifisch nicht-native CAAX-Sequenzen 
erkennen würden, ein wertvolles Werkzeug darstellen, um die Anwendbarkeit der Methode 
für in vivo-Zwecke zu erweitern.  
Ein geeigneter Ansatz für ein gezieltes Protein-Engineering ist die gerichtete Evolution. Durch 
die Erstellung einer randomisierten Bibliothek an FTase-Mutanten mit veränderten aktiven 
Zentren könnte ein Enzym identifiziert werden, das spezifisch nicht-native CAAX-Motive 
erkennt. Eine solche Strategie könnte auch die Verschiebung der Erkennungssequenz vom 
C- zum N-Terminus ermöglichen, um eine größere Flexibilität bei der Positionierung der 
CAAX-Sequenz zu gewährleisten. Desweiteren ist die wünschenswerte Substratpromiskuität 
von Wildtyp-FTase gegenüber des Lipiddonors beschränkt, so dass die Inkorporation von 
beträchtlichen Modifikationen innerhalb der Lipidkette limitiert ist. Es bietet sich auch die 
Möglichkeit, die Lipidgruppen durch nicht-Isopren-Funktionalitäten zu ersetzen. Dieses hätte 
den zusätzlichen Vorteil, die Löslichkeit des prenylierten Zielproteins zu erhöhen. Die 
Beobachtung, dass die β-Untereinheit der FTase ausreichend katalytisch kompetent ist 
(Alexandrov et al., unveröffentlicht), stellt eine erhebliche Vereinfachung für eine zukünftige 
Etablierung von Screening- und Selektionssystemen zur FTase-Evolution dar, da die 
Evolution des komplexeren Dimers eine Ko-Expression beider Untereinheiten erfordern 
würde. 
Der zweite Teil dieser Arbeit befasst sich mit der Entwicklung einer allgemein anwendbaren 
Strategie zur selektiven und vollständigen Markierung des Prenyloms eukaryotischer Zellen. 
Ausgangspunkt der Untersuchung war die Beobachtung, dass die RabGGTase das Biotin-
funktionalisierte Isoprenoidanalog BGPP als Lipiddonor akzeptiert. BGPP konnte dadurch zur 
gezielten Markierung von Rab-Proteinen in vitro und in Zelllysaten ausgenutzt werden. 
Aufgrund der außerordentlich hohen Sensitivität des Assays konnte ein Pool an nicht-
prenylierten Rab-Proteinen in COS-7-Zelllysaten und in Geweben von Mäusen detektiert 
werden.  
                                                                  
 
♣ Im Laufe der Doktorarbeit wurde über einige Strategien zur enzymatischen Inkorporation von 
funktionellen Gruppen in Proteine, die mit Peptid-Tags verschiedener Größe ausgestattet wurden, 
berichtet. In diesen Studien wurden existierende Enzyme weiterentwickelt, um die Größe des 
Peptidlabels zu verringern; darunter waren Biotin-Ligase (15 AA)341 und Phosphopantetheinyl-
transferase (8-12 AA)342, 343. Alternativ wurde die Anwendbarkeit neuer Enzyme getestet wie z. B. 
Transglutaminase (7 AA)344, Sortase (~ 20 AA)345, Formylglycine-generierende Enzyme (6-13 AA)346, 
347, N-Myristoyl-transferase (15 AA)348, 349, sowie lipoic acid ligase (22 AA)350. 
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Basierend auf der Kristallstruktur von BGPP im Komplex mit Wildtyp-FTase wurden durch 
zielgerichtete Mutagenese FTase- und GGTase-I-Varianten generiert, in denen die Spezifität 
für das CAAX-Peptidsubstrat unverändert blieb und die ihre Proteinsubstrate selektiv mit 
Biotin-geranyl modifizierten. Durch diese Mutanten konnte zusammen mit Wildtyp-
RabGGTase die Isolierung und Analyse des gesamten zellulären Prenyloms erreicht werden. 
Die Auftrennung in einzelne Rab-Proteine gelang durch die Kopplung eines Streptavidin-
Pulldowns der Biotin-geranylierten Proteine mit der massenspektrometrischen MudPIT-
Methodik. Durch die zelluläre Quantifizierung spezifischer Rab-Proteine konnte die 
Vermutung bestätigt werden, dass die zentralen Prozesse des vesikulären Transports mehr 
Rab-Proteine aufweisen als die spezialisierten intrazellulären Transportwege.  
Die Anwendung der Methode konnte anhand der Analyse von den in vivo-Effekten einiger 
Proteinprenyltransferase-Inhibitoren wie z. B. BMS3, einem potentiellen Wirkstoff in der Anti-
Krebstherapie, veranschaulicht werden. Die Inhibitorstudien deuten darauf hin, dass BMS3 
ein dual-spezifischer Inhibitor von RabGGTase und FTase in vivo ist. Weitere 
Untersuchungen anderer kommerziell erhältlicher Inhibitoren zeigten, dass einige davon die 
erwarteten Aktivitäten in vivo aufwiesen, andere dagegen entweder eine breiteres Spektrum 
an Proteinprenyltransferasen beeinflussten oder gar keine Aktivität zeigten.  
Die Methode der Proteinderivatisierung mittels BGPP zeichnet sich durch zahlreiche Vorzüge 
gegenüber anderen existierenden Technologien aus: Die Strategie (i) ist im Vergleich zu 
anderen Techniken wie z. B. der metabolischen Markierung leicht durchführbar, (ii) zeigt die 
empfindlichste bisher bekannte Detektionssensitivität und (iii) ermöglicht die Isolierung und 
die Analyse des gesamten zellulären Prenyloms. Dadurch kann eine unverfälschte, Proteom-
weite Detektion von Proteinprenyltransferasesubstraten erzielt werden, vor allem von Rab-
Proteinen, die nicht direkt aufgrund einer kurzen Peptid-Erkennungssequenz vorausgesagt 
werden können. Die Stärke der hier etablierten Methode liegt in der Fähigkeit, femtomolare 
Mengen an unprenylierten Proteinen in der Zellkultur, spezifischen Organen und in ganzen 
Organismen zu bestimmen. Die Detektion von unprenylierten Proteinen in spezifischen 
Organen kann erwartet werden, da in dieser Arbeit ein kleiner Pool an unprenylierten Rab-
Proteinen in Mäuseleber und -gehirn nachgewiesen werden konnte. Dies ist eine wichtige 
Erkenntnis im Hinblick auf die Verteilung und Wirksamkeit von Verbindungen, die die 
Prenylierung modulieren, wie z. B. Proteinprenyltransferase-Inhibitoren oder Statine.  
Die etablierte Methodik zur selektiven Markierung und Analyse des eukaryotischen 
Prenyloms kann in Zukunft als wertvolles Werkzeug in der Analyse der Koordination von 
Expression und Prenylierung kleiner GTPasen sowie ihrer Rolle in der Regulation von 
intrazellulären Signalwegen und in den ensprechenden degenerativen und infektiösen 
Krankheiten dienen.  
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5 MATERIALS AND METHODS 
5.1 Materials 
5.1.1 General Materials 
Table 5-1 Chemical compounds used in this study. 
Supplier Material 
Applichem (Darmstadt, DE) Acrylamide/Bisacrylamide (37.5:1, 30% w/v), Ammonium sulfate, 
Guadinium hydrochloride (GdmHCl), Methanol  
Gerbu (Gaiberg, DE) Dithioerythritol (DTE), Dithiothreitol (DTT), Ethylenediamine-
tetraacetic acid (EDTA), Glycerol, Imidazol, 4-(2-Hydroxyethyl)-
piperazine-1-ethanesulfonic acid (HEPES), Isopropyl-β-D-thiogalac-
topyroanoside (IPTG), Sodium dodecylsulfate (SDS) 
JT Baker (Deventer, NL) Acetonitrile, Acetone, Dichloromethane, Disodium hydrogen-
phosphate, Ethanol, Hydrochloric acid, Isopropanol, Magnesium 
chloride, Potassium dihydrogenphosphate, Potassium hydroxide, 
Sodium dihydrogenphosphate, Urea  
Merck (Darmstadt, DE) 
 
Acetic acid, Ammonium persulfate (APS), Chloramphenicol (Cam), 
Imidazol 
Riedel-de-Haën (Seelze, DE) Ammonium carbonate, Nickel chloride 
Serva (Heidelberg, DE) 
 
Ampicillin (Amp), Bromphenol blue, Coomassie Brilliant Blue 
G250+R250, β-Mercaptoethanol, Triton X-100, Zinc chloride 
Sigma (Taufkirchen, DE)  
 
Agerose, Bovine serum albumine (BSA), Ethidium bromide, Farnesyl 
pyrophosphate (FPP), Geranylgeranyl pyrophosphate (GGPP), 
Phenylmethylsulfonylfluoride (PMSF), Sinapinic acid, Sodium 2-mer-
captoethanesulfonate (MESNA) 
Bio-Rad (München, DE) Bradford reagent, Electroporation cuvettes 
EMD Biosciences (San Diego, USA) Dansyl-GCVLL, Dansyl-GCVLS, FTI B581, GGTI-298 
Fluka (Steinheim, DE) Dimethylsulfoxide (DMSO), Ethanthiol, Sodium chloride, Trichloro-
acetic acid (TCA), Trifluoroacetic acid (TFA) 
Roth (Karlsruhe, DE) Glycine, N,N,N´,N´-tetramethylethylendiamine (TEMED), Trihydroxy-
methylaminomethane (TRIS) 
GE Healthcare (Uppsala, SE) Glutathione Sepharose, Hyperfilm ECL, ECL solution  
Invitrogen (Carlsbad, USA) IPG gel redrydration buffer, carrier ampholytes, IPG strips, NuPage 
LDS sample buffer, NuPage Novex Bis-Tris gels, NuPage running 
buffer, Dubecco´s modified Eagle´s medium, Fetal bovine serum, 
streptomycin 
Amersham Biosciences (Uppsala, SE) Low molecular weight marker, NAP-5 desalting column, PD-10 desal-
ting column 
New England Biolabs (Ipswich, USA) Magnetic Streptavidin Beads, 6-Tube Magnetic Separation Rack, 
anti-Rab7 antibody 
Schleicher&Schuell (Dassel, DE) Nitrocellulose paper, Whatman FP 30/0.2, 0.4 µM cellulose filter 
Qiagen GmbH (Hilden, DE) DyeEx 2.0 Spin Kit 
Biotrend (Köln, DE). Streptavidin-horseradish peroxidase conjugate 
Eppendorf (Hamburg, DE) Eppendorf tube (0.5, 1.5, and 2.0 mL),  
Falcon GmbH (Gräfeling-Locham, DE) Falcon Tube (15 and 50 mL) 
Pharmacia Biotech (Uppsala, SE) Superdex 75/200 Gel Filtration 
ILMVAC GmbH (Ilmenau, DE) Vacuum-membrane pump 
Nalgene (Rochester, USA) ZapCap filter 
Millipore (Billerica, USA) Amicon Ultra-4, 15 (10K, 30K) Concentrator 
Phenomenex (Aschaffenburg, DE) BioSep-SEC-2000 gel filtration, Jupiter 5 µM C4 300A reverse phase 
column 
Spectrum Lab Inc. (Racho Dominguez, 
USA) 
Dialysis membrane tubing (MWCO: 12-14 kDa, 5-8 kDa) 
Hellma Optik GmbH (Jena, DE) Quartz cuvette (1cm) 
Pharma Waldhof (Düsseldorf, DE) Guanosine diphosphate (GDP) 
Abcam (Cambridge, UK) anti-Rab1A antibody 
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5.1.2 Other chemicals from contributing people 
The isoprenoid analogs AAA-GPP, APO-GPP, HOM-GPP, and BGPP were synthesized by 
Dr. Joaquín Gomis (Prof. Waldmann, Department of Chemical Biology, Max-Planck-Institut 
für molekulare Physiologie, Dortmund). NBD-FPP and NBD-GPP were synthesized by Dr. 
Reinhard Reents and Dr. Kui-Thong Tan (Prof. Waldmann, Department of Chemical Biology, 
Max-Planck-Institut für molekulare Physiologie, Dortmund). The small molecules for the 
inhibitor studies were synthesized by Dr. Céline Deraeve and Dr. Robin S. Bon (Prof. 
Waldmann, Department of Chemical Biology, Max-Planck-Institut für molekulare Physiologie, 
Dortmund) according to literature procedures. Table 5-2 summarizes a selection of isoprenoid 
analogs that were coupled to C-terminal cysteines of protein prenyltransferase substrates, 
and protein prenyltransferase inhibitors. Synthetic procedures and analytical data can be 
found in the indicated references. The isoprenoids were stored at -20 °C under an 
atmosphere of argon or dissolved as 5.5-23.8 mM solutions in 25 mM (NH4)2CO3. The 
Rab6A-specific antibody was kindly provided by Prof. A. Barnekow, Universität zu Münster.  
Mouse brains and livers were kindly provided by Oliver Leske (Prof. R. Heumann, Ruhr-
Universität Bochum). 
 
Table 5-2 Chemical compounds from collaborators. 
Compound Collaborator 
AAA-GPP290 
APO-GPP290 
HOM-GPP290 
BGPP290 
Dr. Joaquín Gomis 
NBD-GPP227 
NBD-FPP227 
Dr. Reinhard Reents 
Dr. Kui-Thong Tan 
BMS3351 Dr. Robin S. Bon 
P49-F6336 
P50-E11336 
P23-D6336 
Dr. Celine Deraeve 
 
 
5.1.3 Plasmids 
All molecular clonings were kindly performed and provided by Melina Terbeck, Tina 
Rogowsky, and Sandra Thuns.  
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5.1.4 General instrumentation 
 
Table 5-3 General instrumentation.  
Supplier Instrument 
Pharmacia Biotech (Uppsala, SE) Äkta prime system with REC112 recorder 
Applied Biosystems (Weiterstadt, DE) Biorad PE 9700 thermocycler 
Beckman Coulter (Palo Alto, USA) Centrifuge Allegra X-22R, Centrifuge Avanti J20-XP, 
Centrifuge Optima L-70K Ultracentrifuge, UV-visible 
Spectrometer DU 640  
Eppendorf (Hamburg, DE) Centrifuge Eppendorf 5415C/D benchtop, Thermomixer 5436 
(1.5 mL) 
Bio-Rad (München, DE) Electroporation device E.coli pulser, Gel electrophoresis 
system 
Millipore (Eschborn, DE) Deionized water apparatus  
Fujifilm (JP) FLA-5000 (Fluorescence Image Reader) 
Thermo BioAnalysis (Santa Fe, USA) Fluoroskan Ascent FI type 374 
Waters (Eschborn, DE) High pressure liquid chromatography (HPLC) 
Agilent Technologies (Böblingen, DE) HPLC-ESI-MS, MALDI-TOF-MS 
Microfluidics (Newton, USA) Microfluidizer 
Calimatic Knick (Berlin, DE) pH-Meter 761 
Hoefer Scientific Instruments (Hollisten, USA) Semi-Phor semi-dry blot apparatus 
Jobin Yvon Horiba Group (Edison, USA)  Spex Fluoromax-3 Specrofluorometer 
Infors (Bottmingen, CH) Shaker 
Branson (Danbury, USA) Ultrasonic cell disrupter 
Fermentas (St. Leon-Rot, DE) Prestained molecular weight marker 
Invitrogen (Carlsbad, USA) ZOOM IPG-Runner System 
Falcon GmbH (Gräfeling-Locham, DE) Falcon Tube (15 and 50 mL) 
Pharmacia Biotech (Uppsala, SE) Superdex 75/200 Gel Filtration 
ILMVAC GmbH (Ilmenau, DE) Vacuum-membrane pump 
Nalgene (Rochester, USA) ZapCap filter 
Millipore (Billerica, USA) Amicon Ultra-4, 15 (10K, 30K) Concentrator 
Phenomenex (Aschaffenburg, DE) BioSep-SEC-2000 gel filtration, Jupiter 5 µM C4 300A reverse 
phase column 
Spectrum Lab Inc. (Racho Dominguez, USA) Dialysis membrane tubing (MWCO: 12-14 kDa, 5-8 kDa) 
Hellma Optik GmbH (Jena, DE) Quartz cuvette (1cm) 
Pharma Waldhof (Düsseldorf, DE) Guanosine diphosphate (GDP) 
 
Representations of crystal structures were created with the program Molsoft-ICM (Molsoft 
LLC, La Jolla, USA). Band intensities on SDS gels and Western blot were quantified using the 
software AIDA. 
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5.1.5 Frequently used buffers and growth media 
 
Table 5-4 Frequently used buffers and growth media. 
Antibiotics Buffer A 
125 mg/L Ampicillin 50 mM NaH2PO4, pH 8.0 
34 mg/mL Chloramphenicol 0.3 M NaCl 
59 mg/mL Kanamycin 2 mM β-mercaptoethanol 
Buffer B Breaking Buffer 
50 mM NaH2PO4, pH 8.0 50 mM NaH2PO4, pH 7.5 
0.3 M NaCl 0.3 M NaCl 
2 mM β-mercaptoethanol 2 mM MgCl2 
0.5 M Imidazole 10 µM GDP 
Bug Buffer Coomassie staining solution 
50 mM NaH2PO4, pH 8.0 10 % (v/v) acetic acid 
0.3 M NaCl 40 % (v/v) ethanol 
  0.1 % (w/v) Coomassie Brilliant Blue R250 
Destaining solution DNA loading buffer (5x) 
10 % (v/v) acetic acid 30 % (w/v) sucrose 
  20 % (v/v) glycerol 
  0.2 % (w/v) orange G 
LB agar plates LB medium 
15 g/L Bacto agar 5 g/L yeast extract 
50 mg/L Ampicillin 19 g/L tryptone 
  10 g/L NaCl 
PBS (20x) PBST (20x) 
160 g/L NaCl 160 g/L NaCl 
4 g/L KCl 4 g/L KCl 
28.8 g/L Na2HPO4·2H2O 28.8 g/L Na2HPO4·2H2O 
4.8 g/L KH2HPO4 4.8 g/L KH2HPO4 
  1 % Tween-20 
Prenylation buffer Lysate prenylation buffer 
25 mM HEPES, pH 7.2 25 mM HEPES, pH 7.2 
40 mM NaCl 40 mM NaCl 
2 mM MgCl2 2 mM MgCl2 
20 µM 
GDP (omitted for CAAX-
tagged proteins other 
than GTPases) 
20 µM GDP 
2 mM DTE 2 mM DTE 
20 µM 20 µM ZnCl2 (omitted for RabGGTase prenylation) 
 
ZnCl2 (omitted for 
RabGGTase prenylation) 0.5 mM PMSF 
  1/100 CLAP 
SDS-PAGE loading buffer (2x) SDS-PAGE resolving buffer 
62.3 mM Tris-HCl, pH 6.8 1.5  M Tris-HCl, pH 8.8 
2 % /w/v) SDS 0.4 % (w/v) SDS 
10 % (v/v) glycerol   
5 % (v/v) β-mercaptoethanol   
0.001 % (w/v) bromphenol blue   
SDS-PAGE running buffer (10x) SDS-PAGE stacking gel buffer (4x) 
0.25 M Tris-HCl 0.5 M Tris-HCl, pH 6.8 
2 M glycine 0.4 (w/v) SDS 
1 % (w/v) SDS   
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5.2 Protein expression and purification methods 
5.2.1 Expression and purification of CFP-CAAX 
The construct CFP-CAAX (CFP-TKCVIM) was purified from E.coli BL21 (DE3) Codon Plus 
RIL cells expressing the hexahistidine-tagged fluorescent protein bearing the 6AA Ki-Ras C-
terminal peptide. In brief, after cell growth, induction, and lysis of the cells, CFP-CAAX was 
purified from crude homogenate using Ni-NTA Sepharose columns (Pharmacia). The 
fractions containing the desired protein were identified using SDS-PAGE, concentrated to ~10 
mg/mL, aliquotted, shock-frozen in liquid nitrogen, and stored at -80 °C.  
 
5.2.2 Expression and purification of FTasewt, GGTase-Iwt and their respective 
mutants, RabGGTasewt, REP-1, MRS6p, and the small GTPases 
All proteins were kindly prepared and provided by Nataliya Lupilova, Melina Terbeck, and 
Astrid Sander. The expression and purification was reported earlier. Mutations of the β-
subunits of FTase and GGTase-I were generated using the Quikchange mutagenesis kit 
(Strategene) according to the manufacturer´s instructions352. 
 
5.2.3 Expression and purification of [15N]-labelled Rab22A 
[15N]-labeled human hexahistidine-tagged Rab22A protein was recombinantly expressed 
using a pOPINE-Rab22A vector in 1 L culture using M9 minimal medium with added glucose 
(10 mg/mL), [15N]H4Cl (1 mg/mL) as the isotope source, 100 μg/mL ampicillin, and trace 
elements. The culture was inoculated with an aliquot of an overnight culture to an OD600 of 
~0.1 and grown at 37°C on a shaker at 100 rpm to an OD600 of ~0.8. Recombinant expression 
was induced by the addition of 0.6 mM IPTG, and the culture was further grown overnight 
(12-15 h) at 21°C and 130 rpm. The protein was purified by a combination of affinity 
chromatography on a 5 mL Ni-NTA column (GE Healtcare) and gel filtration on a Superdex 75 
16/60 (GE Healtcare). 
5.3 Analytical methods 
5.3.1 LC-ESI-MS 
Liquid-Chromatography-Electrospray-Ionization-Mass-Spectrometry (LC-ESI-MS) analysis 
was performed on an Agilent 1100 series chromatography system (Hewlett Packard) 
equipped with an LCQ-ESI mass spectrometer (Finnigan, San José, USA) with Jupiter C4 
columns (5 µm, 15 x 0.46 cm, 400 Å pore size, Phenomenex, Aschaffenburg, DE). For 
separation by liquid chromatography, a gradient of buffer B (0.1 % formic acid in ACN) in 
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buffer A (0.1 % formic acid in water) was employed with a constant flow-rate of 1mL/min. 
Upon sample injection, a ratio of 20 % buffer B was kept constant for 5 min. Elution was 
achieved with a linear gradient of 20-70 % over 10 min followed by a steep gradient with 70-
90 % buffer B for 2 min. The column was extensively flushed for at least 10 min with 95 % 
buffer B. Under these conditions, the small GTPases as well as the fluorescent proteins 
typically eluted at a retention time of 12-13 min. Mass spectra data evaluation and 
deconvolution was carried out using the Xcalibur software package. The accuracy of the 
method for proteins within the molecular range of 20 kDa is about 1-2 Da.  
 
5.3.2 MALDI-TOF mass spectrometry 
Matrix-Assisted-Laser-Desorbtion-Ionization-Time-Of-Flight (MALDI-TOF) spectra were 
recorded on a Voyager-DE Pro Biospectrometry work station from Applied Biosystems 
(Weiterstadt, DE). Desalting of protein samples 
was achieved using small GF spin columns 
(DyeEx 2.0 Spin Kit, Qiagen, Hilden, DE) and 
mixed with an equal volum of matrix (saturated 
sinapinic acid solution in 0.3 % TFA/ACN 2:1 
(v/v)). The mixture was quickly spotted onto a MALDI sample plate, and subsequently air- or 
fan-dried. The spectra were measured as shown in Table 5-5. In order to obtain optimal 
signal-to-noise ratios, the laser intensity was manually adjusted during the measurements. 
Spectra recording and data evaluation was performed using the supplied Voyager software 
package. The accuracy of the method for proteins within the molecular weight range of 20-30 
kDa is about 20 Da.  
Table 5-5 Instrument settings. 
acceleration voltage 25 kV 
grid voltage 93 % 
extraction delay time 750 nm 
guide wire 0.3 % 
 
5.3.3 Gel filtration chromatography (GF) 
Gel Filtration chromatography was performed on a Waters 600 chromatography instrument 
equipped with a Waters 2487 absorbance detector and a Waters 2475 fluorescence detector 
(Waters, Milford, USA). Using a Superdex 75 HR 10/30 column (separation range: 3-70 kDa) 
or a Superdex 200 HR 10/30 column (separation range: 10-600 kDa, Pharmacia, Uppsala, 
SE), GF chromatography was carried out in running buffer (25 mM HEPES, pH 7.2, 40 mM 
NaCl, 2 mM MgCl2, 2 mM DTE, and optionally 20 µM GDP) at a flow rate of 0.5 mL/min.  For 
analytical gel filtration of the prenylation reactions, the crude prenylation mixtures were 
loaded onto a Superdex 200 10/30 gel filtration column (GE Healthcare) driven by an FPLC 
system. The column was pre-equilibrated with 25 mM Hepes, pH 7.2, 40 mM NaCl, 2 mM 
MgCl2 and, in the case of Ypt7-CAAX, 10 µM GDP. The flow rate was 1 mL/min, and the 
absorbance of the eluent was monitored at 280 nm. Fractions of 1 mL were collected and 
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analyzed by SDS-PAGE (see section 5.3.4). Selected fractions were subjected to ESI-MS 
and/or MALDI-MS.  
 
5.3.4 Denaturing SDS-PAGE (1D and 2D) 
1-dimensional SDS-PAGE. 15 % SDS-PAGE 
gels were used for the analysis of small 
GTPases or fluorescent proteins (molecular 
weight range from 20-30 kDa). The 
corresponding volumes of the individual 
components were mixed as indicated in Table 5-
6. The mixed solution was poured into a Biorad 
Multi-casting apparatus for 9 gels. After polymerization of the resolving gel, a stacking gel 
mixture was cast on top of the resolving gel. The protein samples were prepared by adding 
an equal volume of SDS-PAGE sample buffer (2x) and heated for 5-10 min at 95 °C. Gels 
were run at 50 mA per gel until the bromphenol blue front entered the buffer solution. 
Fluorescently labeled proteins were visualized by exposing the unstained gel to UV light or 
the FLA-5000 Fluorescence Image Reader (Fujifilm, JP). The proteins were subsequently 
stained in a solution of Coomassie brilliant blue or further processed for Western blot 
analysis.  
Table 5-6 SDS-PAGE gel components. 
 Lower buffer Upper buffer 
Acrylamide 25 mL 5 mL 
4 x buffer 12.5 mL 7.5 mL 
H2O 12.5 mL 17.5 mL 
APS 250 µL 240 µL 
TEMED 25 µL 30 µL 
 
2-dimensional SDS-PAGE. 2D gel electrophoresis was carried out using the ZOOM IPG-
Runner System (Invitrogen) according to the manufacturer´s instructions. Briefly, 5-10 µL of 
samples was dissolved in IPG gel rehydration buffer containing 8 M urea, 2 % w/v 3-[(3-
cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS), 0.5 % v/v carrier 
ampholytes, pH range 3-10, and 0.002 % bromphenol blue. The IPG strips (pH 3-10) were 
incubated in this solution overnight at room temperature. Separation of the proteins in the first 
dimension was achieved through isoelectric focusing, followed by incubating the IPG strip in 
NuPage LDS sample buffer (Invitrogen) containing reducing agent or iodoacetamide for 
alkylation for 15 min each. The proteins were separated by SDS-PAGE using NuPAGE 
Novex Bis-Tris gels (4-12% acrylamide gradient, Invitrogen). Bio-Rad standards were used as 
molecular weight markers. Western blot analysis was carried out as described in the following 
chapter. 
 
5.3.5 Western blot analysis 
The unstained SDS-PAGE gel was sandwiched between a nitrocellulose membrane and two 
gel-blotting Whatman filter papers each (Schleicher&Schuell, Dassel, DE) of the same size. 
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The order of the sandwich was as follows: cathode - 2 sheets of cathode buffer-wetted sheets 
- gel - anode buffer-wetted nitrocellulose membrane - 2 sheets of anode buffer-wetted sheets 
- anode. The transfer was carried out for 1 h at a current of 80 mA per gel in a Semi-Phor 
semi-dry blot apparatus (Hoefer Scientific Instruments, San Francisco, USA). The efficiency 
of transfer was judged by the transfer of the prestained molecular weight marker. The 
membrane was cut out and blocked with 20 mL of blocking solution (5 % non-fat dry milk in 
0.05 % PBST) for at least 30 min. Subsequently, the streptavidin-horseradish peroxidase 
conjugate (Biotrend, Köln, DE) at a concentration of 1 µg/mL in PBS containing 0.05 % 
Tween-20 (PBST) was added. The membrane was allowed to incubate for 2 h at room 
temperature. The membrane was washed three times with PBST. The horseradish 
peroxidase conjugates were detected using the ECL kit (Amersham, UK) and a Hyperfilm 
ECL (GE Healthcare).  
Alternatively, the blots were incubated with specific RabGTPase antibodies (see section 
5.4.5). Band intensities were judged either by visual inspection or quantified using the AIDA 
software. 
5.4 Biochemical methods 
5.4.1 In vitro protein prenylation 
Prenylation with AAA-GPP, APO-GPP, and HOM-GPP. All protein prenylation reactions 
were performed in prenylation buffer (25 mM Hepes, pH 7.2, 40 mM NaCl, 2 mM MgCl2), and 
in the case of Ypt7-CAAX 10 µM GDP. In a volume of 10 µL, 60 µM protein and 120 µM 
isoprenoid were preincubated for 5 min at room temperature. The prenylation reaction was 
initiated by the addition of 4.6 µM FTase and reacted for up to 12 h at room temperature to 
reach completion. Identification of the prenylated sample was performed by LC-ESI mass 
spectrometry. To remove excess isoprenoid, the samples were rebuffered on a NAP5 column 
(GE Healthcare), concentrated in a Vivaspin 500 (Vivascience) to a total protein concentration 
of ~ 5 mg/mL, shock-frozen and stored at -80 °C.  
 
Prenylation with BGPP, NBD-GPP, and NBD-FPP. 2 µM protein substrate (Rab7, RhoA or 
GST-RhoA, Ki-Ras or CFP-CAAX) was incubated with 2 µM of the appropriate protein 
prenyltransferase (RabGGTase, GGTase-I, or FTase, respectively) and 10 µM BGPP or 
NBD-GPP (FTase) or NBD-FPP (GGTase-I and RabGGTase) in prenylation buffer (25 mM 
Hepes pH 7.2, 40 mM NaCl, 2 mM DTE, 2 mM MgCl2, 20 µM GDP) in a final volume of 10 µL. 
When Rab proteins were used as protein substrate, REP-1 was also added to the mixture to 
a final concentration of 2 µM. For CAAX prenyltransferases, 20 µM ZnCl2 was included in the 
reaction mixture. The mixtures were incubated for > 2 h at room temperature and then 
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quenched by addition of 10 µL of 2x SDS-PAGE sample buffer. The samples were heated at 
95°C for 5 min, and 0.5 pmol (for subsequent Western blot of the biotin-conjugated proteins) 
or 20 pmol (for subsequent fluorescence scanning of the NBD-conjugated proteins) was 
loaded onto a 15 % SDS polyacrylamide gel. The biotin-labeled samples were transferred 
onto a nitrocellulose membrane and blotted with the STR-conjugate. Alternatively, NBD 
fluorescence was recorded using a fluorescence scanner with an excitation filter of 473 nm 
and an emission filter of 510 nm. LC-ESI mass analysis of prenylated samples was performed 
as described. 
 
5.4.2 Streptavidin pulldown 
Streptavidin pulldown and subsequent elution was successfully performed with magnetic 
streptavidin purchased from New England Biolabs. The amount of beads was used according 
to the manufacturer´s indicated binding capacity of 1.25 nmol per mL bead suspension. The 
prenylation mixture was incubated with the beads for 1 h on an end-to-end rotor at room 
temperature. In the case of in vitro prenylation, the beads were thoroughly washed with PBS 
using a magnetic separator rack (New England Biolabs), and the biotinylated proteins were 
eluted by boiling the beads with 50 µl 2x SDS PAGE sample buffer at 90 °C for 10 min 
followed by sample concentration. For subsequent MudPIT analysis, harsher washing 
conditions with three washes each with PBS/4 M GdmHCl, PBS/4 M urea, and with 50 mM 
NH4HCO3, pH 8, were used. 
 
5.4.3 In lysate protein prenylation 
Prenylation reactions of compactin-, DMSO, or inhibitor-treated COS-7 lysates was performed 
essentially as for in vitro prenylation in 10-30 µL of the respective lysate using a mixture of 1 
µM of both FTaseW102T_Y154T_Y205T and FTaseW102T_Y154T, 2 µM GGTaseF53Y_Y126T, or 2 µM wild-
type RabGGTase/REP-1 for typically 4-6 h at room temperature. When using frozen lysate 
stock, 20 µM GDP and 2 mM DTE, and in the case of CAAX prenyltransferases 20 µM ZnCl2, 
were added freshly prior to the reaction. If necessary, the samples were concentrated before 
loading onto the gel. For the reaction of all three protein prenyltransferases in one sample, 25 
µL of compactin-treated lysate was supplemented with 2 µM RabGGTase and REP-1 as well 
as 5 µM BGPP. After reaction for 2 h at room temperature, 1 µM of each FTase mutant and 2 
µM GGTase-IF53Y_Y126T mutant along with 5 µM BGPP and 20 µM ZnCl2 was added. The 
reaction was allowed to proceed for another 4-6 h. The reaction was stopped by SDS sample 
buffer. For the detection of the pool of unprenylated Rab proteins in DMSO- or cycloheximide-
treated lysate, 450 µL lysate was supplemented with 1 µM of RabGGTase, REP-1, and 
BGPP for 6 h at room temperature. The reaction was then subjected to magnetic streptavidin-
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agarose beads (New England Biolabs) and incubated for 1h on an end-to-end rocker at room 
temperature. After thorough washing with PBS, the biotinylated proteins were eluted by 
boiling the beads with 60 µl 1x SDS PAGE sample buffer at 90 °C for 10 min followed by 
sample concentration. For large-scale prenylation of RabGGTase, FTase, and GGTase-I 
mutants in compactin-treated cells for 2D SDS-PAGE, 2 µM of the respective enzyme (and 
REP-1) as well as 1 µM BGPP were added to 500, 2000, or 1000 µL of lysate, respectively, 
for 6 h at room temperature, and the samples were processed as described for the detection 
of the pool of unprenylated Rabs. For subsequent mass spectrometric analysis, 1 mL of 
compactin-, DMSO-, or BMS3-treated lysate was prenylated with 2 µM RabGGTase, REP-1, 
and 1 µM BGPP for 6 h at room temperature. After thorough washing (see section 5.4.2), on 
bead digestion and MudPIT analysis was performed by Benjamin Fränzel and Dr. Dirk 
Wolters352. 
 
5.4.4 Quantification of RabGTPase abundance in COS-7 lysate 
A volume of 60 µL of lysate derived from compactin-treated COS-7 cells was supplemented 
with 2 µM RabGGTase, REP-1, and excess BGPP and reacted for 4 h at room temperature. 
The reaction was stopped by the addition of 60 µL 1 x SDS sample buffer. After 
concentration, the samples along with varying amounts of recombinant GST-Rab1A, Rab6A, 
or Rab7 were loaded on a SDS-PAGE gel. After separation, the proteins were transferred 
onto a nitrocellulose membrane, which was subsequently incubated with 2 µg/mL anti-Rab1A, 
1:1000 dilution of anti-Rab6A provided by our collaborator, or 1:1000 dilution of anti-Rab7 in 3 
% milk/PBST for 2 h at room temperature followed by incubation with either anti-goat-HRP or 
anti-rabbit-HRP conjugates. Further processing was performed essentially as described in 
section 5.3.5. The abundance of the individual RabGTPases in the lysate was judged by 
visual inspection of the Western blots by comparing the band intensities with the recombinant 
proteins of known amount. 
 
5.4.5 Chemoselective modification of the prenylated proteins  
Staudinger ligation. 50 µM CFP-CAAX prenylated with either AAA-GPP or APO-GPP was 
incubated with 5 eq phosphine 27 (stock solution: 5 mM in DMSO) in 25 mM Hepes, pH 7.2, 
40 mM NaCl and 2 mM MgCl2 for 2 h at 25 °C. As controls, 50 µM CFP-CAAX-F and 50 µM 
CFP-CAAX-AAA/APO-G were supplemented with 5 eq phosphine 27 and 5 (v/v) % DMSO 
alone, respectively. In a screen for reaction conditions, samples were incubated with or 
without 0.05 (v/v) % Tween-20 and/or 2 mM DTE. To investigate the time course of the 
reaction, CFP-CAAX-AAA/APO-G were subjected to the Staudinger ligation under the 
described conditions with 2 mM DTE and 0.05 (v/v) % Tween-20. At the indicated time points, 
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the samples were quenched by passing the reaction mixtures through a spin gel filtration 
column (Qiagen), and the progression of the reaction was estimated by the intensity of the 
mass peaks by ESI-MS. 
 
Diels-Alder cycloaddition. The accessible cysteines in the CFP-CAAX-HOM-G-FTase 
mixture were blocked using Ellmann´s reagent (5,5´-dithiobis(2-nitrobenzoic acid), DTNB) as 
described earlier266, 299. The proteins were then rebuffered against either 25 mM Hepes, pH 
7.2, 40 mM NaCl, 2 mM MgCl2 or 50 mM Na2HPO4, pH 6.0, 40 mM NaCl, 2 mM MgCl2. 50 µM 
CFP-CAAX-HOM-G at pH 7.2 or 6.0 was incubated with 40 eq 6-maleimidohexanoic acid 28 
(stock: 20 mM in DMSO) 25 °C for up to 15 h. As controls, 50 µM CFP-CAAX-F and 50 µM 
CFP-CAAX-HOM-G were incubated with 40 eq maleimide 28 and 5 vol.-% DMSO alone, 
respectively. Excess dienophile 28 was removed by passing the reaction mixture through a 
DyeEx spin gel filtration column (Qiagen). The reaction yields were estimated by the intensity 
of the mass peaks by ESI-MS. 
5.5 Biophysical methods 
5.5.1 Fluorescence titrations- determination of KD 
Fluorescence measurements were performed on a Spex Fluoromax-3 spectrofluoro-meter 
(Jobin Yvon, Edison, USA). Measurements were carried out in 1 mL Quartz cuvettes (Hellma) 
with continuous stirring and thermostated at 25 °C unless otherwise indicated. All buffers 
used in these experiments were filtered through a 0.2 µm membrane filter (Whatman) and 
degassed on a vacuum-membrane pump (ILMVAC GmbH, Ilmenau, DE) by stirring for 1 h at 
room temperature. Fluorescence titrations were performed in titration buffer (50 mM HEPES, 
pH 7.2, 50 mM NaCl, and 5 mM DTE). The NBD fluorescence was excited at 487 nm, and 
data were collected at 530 nm for the interaction with FTase/GGTase-I or at 550 nm for the 
interaction with RabGGTase. NBD-GPP or NBD-FPP (A) was added to 1 mL buffer in a 
quartz cuvette and stirred until the fluorescence signal was stable. Small aliquots of the 
respective protein prenyltransferase (B) were added stepwise to the cuvette until the signal 
change reached saturation. The fluorescence signals were corrected for light scattering as 
well as dilution and plotted as a function of the reactant concentration. The data was fitted to 
the following equation using GraFit 5.0 (Erithacus Software, Surrey, UK):  [ ]
B
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where F is the fluorescence intensity (in arbitrary units), Fmin is the fluorescence intensity at 
the beginning of the titration, Fmax is the intensity of the complex, B is the total titrant 
concentration, A is the concentration of the fluorescent reactant, and Kd is the dissociation 
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constant to be determined for the interaction. In the fit to this equation, Fmin, Fmin, B, and Kd 
were allowed to vary in the program Grafit (Erithacus Software).  
For the competitive titration of FTase with AAA-GPP, APO-GPP, HOM-GPP, and BGPP, a 
pre-formed complex of 160 nM NBD-FPP and 210 nM FTase was titrated with the isoprenoid 
derivatives. The experimental data were fitted with the program Scientist (Micromath) using a 
model file which allows simulation and fitting to a set of three equations describing the two 
equilibria and the generation of the fluorescence signal. The Kd for the FTase:NBD-FPP 
interaction was held constant at the value determined from the direct titration.  
For the competitive titration of GGTase-I and RabGGTase, a pre-formed complex of 50 or 
200 nM NBD-FPP and 50 or 200 nM FPP or GGPP was titrated with the respective enzyme. 
In the case of BGPP, a higher concentration was used. The experimental data were fitted with 
the program Scientist as described above. 
 
5.5.2 Continuous fluorometric assay for FTase and GGTase-I prenylation 
To compare the enzymatic incorporation of the analogs by fluorescence spectroscopy, an 
established fluorescence-based assay was employed225. First, 2.2 µM N-dansyl-GCVLS 
(EMB Bioscience) and a saturating concentration of 20 µM of the respective isoprenoid were 
preincubated using the buffer reported by Poulter and colleagues, and the reaction was 
initiated by the addition of 50 nM FTase. Changes of dansyl fluorescence (λex/λem = 340 nm 
/505 nm) were monitored for 8000 s. At the saturation point, addition of excess FTase did not 
result in further increase in fluorescence, indicating that the peptide was completely 
prenylated. The total increase in fluorescence was linearly correlated to the initial peptide 
substrate concentration. In order to determine the kinetic parameters the initial rates of the 
prenylation reaction were measured from the linear region at different isoprenoid 
concentrations using 1-20 nM FTase. Conversion of vi and kcat into units of µM/s and 1/s, 
respectively, were performed as described above. The data were fitted using the Michaelis-
Menten model: 
(2) 
[ ]
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where Vmax is the maximal velocity, [S] the concentration of the isoprenoid substrate and KM 
the Michaelis-Menten constant. 
Examination of the specificity of the enzymatic incorporation of isoprenoids for dansyl-GCVLS 
and dansyl-GCVLL was performed in essentially the same manner352. First, N-dansyl-
GCVLS/L (6 µM, EMD Bioscience) and 107-140 nM of enzyme were preincubated in a buffer 
containing 50 mM Hepes, pH 7.8, 5 mM MgCl2, and 2 mM DTT, and the reaction was initiated 
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by the addition of a saturating concentration (6-11.5 µM) of the appropriate isoprenoid. 
Changes in dansyl fluorescence (λex/λem=340 nm/505 nm) were monitored for up to 4000 s. 
5.6 COS-7 cells general maintenance and lysate preparation 
COS-7 cells were grown in Dulbecco’s Modified Eagle’s medium (DMEM, Invitrogen), 
supplemented with 10% fetal bovine serum (Invitrogen) as well as 1 % penicillin and 
streptomycin (Invitrogen). Cells were incubated in a humidified atmosphere at 37°C in 5 % 
CO2 and passaged every 2–3 days. COS-7 cells were grown to 70 % confluence in either 6 
well or 15 cm dishes and fed with 0.5 % DMSO, 20 µg/mL cycloheximide, 20 µM compactin, 
0.5 µM BMS3, or the indicated concentration of inhibitor. Cells were incubated for a further 
12-18 h and then harvested to produce cell lysate. Cells were washed in phosphate buffered 
saline (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, and 1.4 mM KH2PO4) and incubated at 
4°C for 15 min in prenylation buffer (50 mM Hepes pH 7.2, 50 mM NaCl, 2 mM MgCl2, 2 mM 
DTT, 100 μM GDP, 10 μg/ml CLAP, 0.6 mM PMSF), either with or without 0.5 (v/v) % NP-40. 
Cells were then scraped and transferred to a reaction tube for centrifugation at 16,100 × g at 
4°C for 10 min. If detergent was omitted, the cells were disrupted by pushing them 5 times 
through a 0.55 mm syringe needle prior to centrifugation.  
Mouse brain or liver was homogenized using a Dounce homogenizer in prenylation buffer and 
further processed as described for COS-7 lysate preparation.  
5.7 Crystallization and structure solution of the BGPP:FTase and the 
BGPP: FTaseW102T_Y154T complexes 
These procedures are described in352.  
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